Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

EBMT Code (CIC):

Hospital:

Unit (check only one)

Adult Pediatric

CIBMTR Research ID:  (CRID)

Recipient Data Questions: 1 - 10

Date of birth:1 __ __ __ __ - __ __- __ __

Sex

male female

2

Ethnicity3

Hispanic or Latino

Not Hispanic or Latino

Not applicable (not a resident of the USA)

Unknown

Race (1) Questions: 4 - 4

Race4

Zip or postal code for place of recipient’s residence: (USA recipients only)5

Is the recipient participating in a clinical trial?

yes no

6

Clinical Trials (1) Questions: 7 - 10

Study Sponsor7

Specify other sponsor:8

Study ID Number9

Subject ID:10

Hematopoietic Cellular Transplant (HCT) Questions: 11 - 28

Date of this HCT:11 __ __ __ __ - __ __- __ __

Was this the first HCT for this recipient?

yes no

12

Is a subsequent HCT planned as part of the overall treatment protocol (not as a reaction to post-HCT disease assessment)? (For autologous HCTs only)

yes no

13

Specify subsequent HCT planned

Autologous Allogeneic

14

Specify the number of prior HCTs:15

Autologous

yes no

16

Allogeneic, unrelated

yes no

17

Allogeneic, related

yes no

18

Syngeneic

yes no

19

Date of the last HCT: (just before current HCT)20 __ __ __ __ - __ __- __ __

Was the last HCT performed at a different institution?

yes no

21

Name:22

City:

State:

Country:

What was the HSC source for the last HCT?23

Autologous

Allogeneic, unrelated donor

Allogeneic, related donor

Reason for current HCT24

Date of graft failure / rejection:25 __ __ __ __ - __ __- __ __

Date of relapse:26 __ __ __ __ - __ __- __ __

Date of secondary malignancy:27 __ __ __ __ - __ __- __ __

Specify other reason:28

Donor Information Questions: 29 - 63

Multiple donors?

yes no

29

Specify number of donors:30

Donor Information for this HCT (1) Questions: 31 - 63

Specify donor31

NMDP cord blood unit ID:32

NMDP donor ID:33

Non-NMDP unrelated donor ID: (not applicable for related donors)34

Non-NMDP cord blood unit ID: (include related and autologous CBUs)35

Is the CBU ID also the ISBT DIN number?

yes no

36

Specify the ISBT DIN number:37

Registry or UCB Bank ID38

Specify other Registry or UCB Bank:39

Specify the related donor type40

Syngeneic (monozygotic twin)

HLA-identical sibling (may include non-monozygotic twin)

HLA-matched other relative

HLA-mismatched relative

Date of birth (donor / infant)

Known Unknown

41

Date of birth: (donor / infant)42 __ __ __ __ - __ __- __ __

Age (donor / infant)

Known Unknown

43

Age: (donor / infant)44 Months (use only if less than 1 year old)

years

Sex (donor / infant)

male female

45

Bone marrow

yes no

46

PBSC

yes no

47

Single cord blood unit

yes no

48

Other product

yes no

49

Specify other product type:50

Specify number of products infused from this donor:51

Specify the number of these products intended to achieve hematopoietic engraftment:52

Did the recipient have more than one mobilization event to acquire cells for HCT?

yes no

53

Specify the total number of mobilization events performed for this HCT: (regardless of the number of collections or which collections were
used for this HCT)

54

G-CSF

yes no

55

GM-CSF

yes no

56

Pegylated G-CSF

yes no

57

Plerixafor (Mozobil)

yes no

58

Other CXCR4 inhibitor

yes no

59

Combined with chemotherapy

yes no

60

Was this donor used for any prior HCTs?

yes no

61

Donor CMV-antibodies (IgG or Total) (Allogeneic HCTs only)62

Reactive

Non-reactive

Not done

Not applicable (cord blood unit)

Was plerixafor (Mozobil) given at any time prior to the preparative regimen? (Related HCTs only)

yes no Unknown

63

Consent Questions: 64 - 71

Has the recipient signed an IRB-approved consent form for submitting research data to the NMDP / CIBMTR?64

Yes (patient consented)

No (patient declined)

Not approached

Date form was signed:65 __ __ __ __ - __ __- __ __

Did the recipient give permission to be directly contacted for future research?66

Yes (patient provided permission)

No (patient declined)

Not approached

Date form was signed:67 __ __ __ __ - __ __- __ __

Has the recipient signed an IRB-approved consent form to donate research blood samples to the NMDP / CIBMTR?68

Yes (patient consented)

No (patient declined)

Not approached

Not applicable (center not participating)

Date form was signed:69 __ __ __ __ - __ __- __ __

Has the donor signed an IRB-approved consent form to donate research blood samples to the NMDP / CIBMTR? (Allogeneic donors only)70

Yes (donor consented)

No (donor declined)

Not approached

Not applicable (center not participating)

Date form was signed:71 __ __ __ __ - __ __- __ __

Product Processing / Manipulation Questions: 72 - 90

Was the product manipulated prior to infusion?

yes no

72

Specify portion manipulated

entire product portion of product

73

Washed

yes no

74

Diluted

yes no

75

Buffy coat enriched (buffy coat preparation)

yes no

76

B-cell reduced

yes no

77

CD8 reduced

yes no

78

Plasma reduced (removal)

yes no

79

RBC reduced

yes no

80

Cultured (ex-vivo expansion)

yes no

81

Genetic manipulation (gene transfer / transduction)

yes no

82

PUVA treated

yes no

83

CD34 enriched (CD34+ selection)

yes no

84

CD133 enriched

yes no

85

Monocyte enriched

yes no

86

Mononuclear cells enriched

yes no

87

T-cell depletion

yes no

88

Other cell manipulation

yes no

89

Specify other cell manipulation:90

Clinical Status of Recipient Prior to the Preparative Regimen (Conditioning) Questions: 91 - 94

What scale was used to determine the recipient’s functional status?91

Karnofsky (recipient age ≥ 16 years)

Lansky (recipient age < 16 years) 

Karnofsky Scale (recipient age ≥ 16 years)92

Lansky Scale (recipient age < 16 years)93

Recipient CMV-antibodies (IgG or Total)

Reactive Non-reactive Not done

94

Comorbid Conditions Questions: 95 - 155

Is there a history of mechanical ventilation?

yes no

95

Is there a history of proven invasive fungal infection?

yes no

96

Were there clinically significant co-existing diseases or organ impairment at time of patient assessment prior to preparative regimen? Source: Blood, 2005 Oct 15;106(8):2912-2919

yes no

97

Arrhythmia - For example, any history of atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias requiring treatment

yes no Unknown

98

Cardiac - Any history of coronary artery disease (one or more vessel-coronary artery stenosis requiring medical treatment, stent, or bypass graft), congestive heart
failure, myocardial infarction, OR ejection fraction ≤ 50% on the most recent test

yes no Unknown

99

Cerebrovascular disease - Any history of transient ischemic attack, subarachnoid hemorrhage or cerebrovascular accident

yes no Unknown

100

Diabetes - Requiring treatment with insulin or oral hypoglycemics in the last 4 weeks but not diet alone

yes no Unknown

101

Heart valve disease - Except asymptomatic mitral valve prolapse

yes no Unknown

102

Hepatic, mild ­ Chronic hepatitis, bilirubin > upper limit of normal to 1.5 × upper limit of normal, or AST/ALT > upper limit of normal to 2.5 × upper limit of normal at the
time of transplant OR any history of hepatitis B or hepatitis C infection

yes no Unknown

103

Hepatic, moderate / severe ­ Liver cirrhosis, bilirubin > 1.5 × upper limit of normal, or AST/ALT > 2.5 × upper limit of normal

yes no Unknown

104

Infection - For example, documented infection, fever of unknown origin, or pulmonary nodules requiring continuation of antimicrobial treatment after day 0

yes no Unknown

105

Inflammatory bowel disease ­ Any history of Crohn’s disease or ulcerative colitis requiring treatment

yes no Unknown

106

Obesity - Patients with a body mass index > 35 kg/m2  prior to the start of conditioning

yes no Unknown

107

Peptic ulcer - Any history of peptic ulcer confirmed by endoscopy and requiring treatment

yes no Unknown

108

Psychiatric disturbance - For example, depression, anxiety, bipolar disorder or schizophrenia requiring psychiatric consult or treatment in the last 4 weeks

yes no Unknown

109

Pulmonary, moderate - Corrected diffusion capacity of carbon monoxide and/or FEV1 66-80% or dyspnea on slight activity at transplant

yes no Unknown

110

Pulmonary, severe - Corrected diffusion capacity of carbon monoxide and/or FEV1 ≤ 65% or dyspnea at rest or requiring oxygen at transplant

yes no Unknown

111

Renal, moderate / severe ­ Serum creatinine > 2 mg/dL or > 177 µmol/L or on dialysis at transplant, OR prior renal transplantation

yes no Unknown

112

Rheumatologic - For example, any history of systemic lupus erythmatosis, rheumatoid arthritis, polymyositis, mixed connective tissue disease, or polymyalgia
rheumatica requiring treatment (do NOT include degenerative joint disease, osteoarthritis)

yes no Unknown

113

Solid tumor, prior ­ Treated at any time point in the patient’s past history, excluding non­melanoma skin cancer, leukemia, lymphoma or multiple myeloma

yes no Unknown

114

Breast cancer

yes no

115

Year of diagnosis:116

Central nervous system (CNS) malignancy (glioblastoma, astrocytoma)

yes no

117

Year of diagnosis:118

Gastrointestinal malignancy (colon, rectum, stomach, pancreas, intestine)

yes no

119

Year of diagnosis:120

Genitourinary malignancy (kidney, bladder, ovary, testicle, genitalia, uterus, cervix)

yes no

121

Year of diagnosis:122

Lung cancer

yes no

123

Year of diagnosis:124

Melanoma

yes no

125

Year of diagnosis:126

Oropharyngeal cancer (tongue, buccal mucosa)

yes no

127

Year of diagnosis:128

Sarcoma

yes no

129

Year of diagnosis:130

Thyroid cancer

yes no

131

Year of diagnosis:132

Other co-morbid condition

yes no Unknown

133

Specify other co-morbid condition:134

Was there a history of malignancy (hematologic or non-melanoma skin cancer) other than the primary disease for which this HCT is being performed?

yes no

135

Acute myeloid leukemia (AML / ANLL)

yes no

136

Year of diagnosis:137

Other leukemia, including ALL

yes no

138

Year of diagnosis:139

Specify leukemia:140

Clonal cytogenetic abnormality without leukemia or MDS

yes no

141

Year of diagnosis:142

Hodgkin disease

yes no

143

Year of diagnosis:144

Lymphoma or lymphoproliferative disease

yes no

145

Year of diagnosis:146

Was the tumor EBV positive?

yes no

147

Other skin malignancy (basal cell, squamous)

yes no

148

Year of diagnosis:149

Specify other skin malignancy:150

Myelodysplasia (MDS) / myeloproliferative (MPN) disorder

yes no

151

Year of diagnosis:152

Other prior malignancy

yes no

153

Year of diagnosis:154

Specify other prior malignancy:155

Pre-HCT Preparative Regimen (Conditioning) Questions: 156 - 316

Height at initiation of pre-HCT preparative regimen:156 inches centimeters

Actual weight at initiation of pre-HCT preparative regimen:157 pounds kilograms

Was a pre-HCT preparative regimen prescribed?

yes no

158

Classify the recipient’s prescribed preparative regimen (Allogeneic HCTs only)159

Myeloablative

Non-myeloablative (NST)

Reduced intensity (RIC)

Date pre-HCT preparative regimen began: (irradiation or drugs)160 __ __ __ __ - __ __- __ __ (Use earliest date from question 164 radiation, or 169 - 316 chemotherapy)

Was irradiation planned as part of the pre-HCT preparative regimen?

yes no

161

What was the prescribed radiation field?162

Total body

Total body by intensity-modulated radiation therapy (IMRT)

Total lymphoid or nodal regions

Thoracoabdominal region

Total prescribed dose: (dose per fraction x total number of fractions) 163 Gy cGy

Date started:164 __ __ __ __ - __ __- __ __

Was the radiation fractionated?

yes no

165

Prescribed dose per fraction:166 Gy cGy

Number of days: (include "rest" days)167

Total number of fractions:168

ALG, ALS, ATG, ATS

yes no

169

Total prescribed dose:170 mg/kg

Date started:171 __ __ __ __ - __ __- __ __

Specify source172

ATGAM (horse)

ATG - Fresenius (rabbit)

Thymoglobulin (rabbit)

Other

Specify other source:173

Anthracycline

yes no

174

Daunorubicin

yes no

175

Total prescribed dose :176 mg/m2 mg/kg

Date started:177 __ __ __ __ - __ __- __ __

Doxorubicin (Adriamycin)

yes no

178

Total prescribed dose :179 mg/m2 mg/kg

Date started:180 __ __ __ __ - __ __- __ __

Idarubicin

yes no

181

Total prescribed dose :182 mg/m2 mg/kg

Date started:183 __ __ __ __ - __ __- __ __

Rubidazone

yes no

184

Total prescribed dose :185 mg/m2 mg/kg

Date started:186 __ __ __ __ - __ __- __ __

Other anthracycline

yes no

187

Total prescribed dose :188 mg/m2 mg/kg

Date started:189 __ __ __ __ - __ __- __ __

Specify other anthracycline:190

Bleomycin (BLM, Blenoxane)

yes no

191

Total prescribed dose :192 mg/m2 mg/kg

Date started:193 __ __ __ __ - __ __- __ __

Busulfan (Myleran)

yes no

194

Total prescribed dose :195 mg/m2

mg/kg

Target total AUC (µmol x min/L)

Date started:196 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

197

Carboplatin

yes no

198

Total prescribed dose :199 mg/m2 mg/kg

Date started:200 __ __ __ __ - __ __- __ __

Were pharmacokinetics performed to determine preparative regimen drug dosing?

yes no

201

Specify the target AUC:202 mg/mL/minute

Cisplatin (Platinol, CDDP)

yes no

203

Total prescribed dose :204 mg/m2 mg/kg

Date started:205 __ __ __ __ - __ __- __ __

Cladribine (2-CdA, Leustatin)

yes no

206

Total prescribed dose :207 mg/m2 mg/kg

Date started:208 __ __ __ __ - __ __- __ __

Corticosteroids (excluding anti-nausea medication)

yes no

209

Methylprednisolone (Solu-Medrol)

yes no

210

Total prescribed dose :211 mg/m2 mg/kg

Date started:212 __ __ __ __ - __ __- __ __

Prednisone

yes no

213

Total prescribed dose :214 mg/m2 mg/kg

Date started:215 __ __ __ __ - __ __- __ __

Dexamethasone

yes no

216

Total prescribed dose :217 mg/m2 mg/kg

Date started:218 __ __ __ __ - __ __- __ __

Other corticosteroid

yes no

219

Total prescribed dose :220 mg/m2 mg/kg

Date started:221 __ __ __ __ - __ __- __ __

Specify other corticosteroid:222

Cyclophosphamide (Cytoxan)

yes no

223

Total prescribed dose :224 mg/m2 mg/kg

Date started:225 __ __ __ __ - __ __- __ __

Cytarabine (Ara-C)

yes no

226

Total prescribed dose :227 mg/m2 mg/kg

Date started:228 __ __ __ __ - __ __- __ __

Etoposide (VP-16, VePesid)

yes no

229

Total prescribed dose :230 mg/m2 mg/kg

Date started:231 __ __ __ __ - __ __- __ __

Fludarabine

yes no

232

Total prescribed dose :233 mg/m2 mg/kg

Date started:234 __ __ __ __ - __ __- __ __

Ifosfamide

yes no

235

Total prescribed dose :236 mg/m2 mg/kg

Date started:237 __ __ __ __ - __ __- __ __

Intrathecal therapy (chemotherapy)

yes no

238

Intrathecal cytarabine (IT Ara-C)

yes no

239

Total prescribed dose :240 mg/m2 mg/kg

Date started:241 __ __ __ __ - __ __- __ __

Intrathecal methotrexate (IT MTX)

yes no

242

Total prescribed dose :243 mg/m2 mg/kg

Date started:244 __ __ __ __ - __ __- __ __

Intrathecal thiotepa

yes no

245

Total prescribed dose :246 mg/m2 mg/kg

Date started:247 __ __ __ __ - __ __- __ __

Other intrathecal drug

yes no

248

Total prescribed dose :249 mg/m2 mg/kg

Date started:250 __ __ __ __ - __ __- __ __

Specify other intrathecal drug:251

Melphalan (L-Pam)

yes no

252

Total prescribed dose :253 mg/m2 mg/kg

Date started:254 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

255

Mitoxantrone (Novantrone)

yes no

256

Total prescribed dose :257 mg/m2 mg/kg

Date started:258 __ __ __ __ - __ __- __ __

Monoclonal antibody

yes no

259

Radio labeled mAb

yes no

260

Total prescribed dose of radioactive component:261 mCi MBq

Date started:262 __ __ __ __ - __ __- __ __

Tositumomab (Bexxar)

yes no

263

Ibritumomab tiuxetan (Zevalin)

yes no

264

Other radio labeled mAb

yes no

265

Specify other radio labeled mAb:266

Alemtuzumab (Campath)

yes no

267

Total prescribed dose :268 mg/m2 mg/kg

Date started:269 __ __ __ __ - __ __- __ __

Rituximab (Rituxan, anti CD20)

yes no

270

Total prescribed dose :271 mg/m2 mg/kg

Date started:272 __ __ __ __ - __ __- __ __

Gemtuzumab (Mylotarg, anti CD33)

yes no

273

Total prescribed dose :274 mg/m2 mg/kg

Date started:275 __ __ __ __ - __ __- __ __

Other mAb

yes no

276

Total prescribed dose :277 mg/m2 mg/kg

Date started:278 __ __ __ __ - __ __- __ __

Specify other mAb:279

Nitrosourea

yes no

280

Carmustine (BCNU)

yes no

281

Total prescribed dose :282 mg/m2 mg/kg

Date started:283 __ __ __ __ - __ __- __ __

CCNU (Lomustine)

yes no

284

Total prescribed dose :285 mg/m2 mg/kg

Date started:286 __ __ __ __ - __ __- __ __

Other nitrosourea

yes no

287

Total prescribed dose :288 mg/m2 mg/kg

Date started:289 __ __ __ __ - __ __- __ __

Specify other nitrosourea:290

Paclitaxel (Taxol, Xyotax)

yes no

291

Total prescribed dose :292 mg/m2 mg/kg

Date started:293 __ __ __ __ - __ __- __ __

Teniposide (VM26)

yes no

294

Total prescribed dose :295 mg/m2 mg/kg

Date started:296 __ __ __ __ - __ __- __ __

Thiotepa

yes no

297

Total prescribed dose :298 mg/m2 mg/kg

Date started:299 __ __ __ __ - __ __- __ __

Treosulfan

yes no

300

Total prescribed dose :301 mg/m2 mg/kg

Date started:302 __ __ __ __ - __ __- __ __

Tyrosine kinase inhibitors

yes no

303

Dasatinib (Sprycel)

yes no

304

Total prescribed dose :305 mg/m2 mg/kg

Date started:306 __ __ __ __ - __ __- __ __

Imatinib mesylate (STI571, Gleevec)

yes no

307

Total prescribed dose :308 mg/m2 mg/kg

Date started:309 __ __ __ __ - __ __- __ __

Nilotinib

yes no

310

Total prescribed dose :311 mg/m2 mg/kg

Date started:312 __ __ __ __ - __ __- __ __

Other drug

yes no

313

Total prescribed dose :314 mg/m2 mg/kg

Date started:315 __ __ __ __ - __ __- __ __

Specify other drug:316

GVHD Prophylaxis Questions: 317 - 343

Was GVHD prophylaxis planned / given?

yes no

317

ALG, ALS, ATG, ATS

yes no

318

Total dose:319 mg/kg

Specify source320

ATGAM (horse)

ATG - Fresenius (rabbit)

Thymoglobulin (rabbit)

Other

Specify other source:321

Corticosteroids (systemic)

yes no

322

Cyclosporine (CSA, Neoral, Sandimmune)

yes no

323

Cyclophosphamide (Cytoxan)

yes no

324

Extra-corporeal photopheresis (ECP)

yes no

325

FK 506 (Tacrolimus, Prograf)

yes no

326

In vivo monoclonal antibody

yes no

327

Alemtuzumab (Campath)

yes no

328

Anti CD 25 (Zenapax, Daclizumab, AntiTAC)

yes no

329

Specify:330

Etanercept (Enbrel)

yes no

331

Infliximab (Remicade)

yes no

332

Other in vivo monoclonal antibody

yes no

333

Specify antibody:334

In vivo immunotoxin

yes no

335

Specify immunotoxin:336

Methotrexate (MTX) (Amethopterin)

yes no

337

Mycophenolate mofetil (MMF) (CellCept)

yes no

338

Sirolimus (Rapamycin, Rapamune)

yes no

339

Blinded randomized trial

yes no

340

Specify trial agent:341

Other agent

yes no

342

Specify other agent:343

Other Toxicity Modifying Regimen Questions: 344 - 344

Was KGF (palifermin, Kepivance) started or is there a plan to use it?

Yes No masked trial

344

Post-HCT Disease Therapy Planned as of Day 0 Questions: 345 - 357

Is this HCT part of a planned multiple (sequential) graft / HCT protocol?

yes no

345

Is additional post-HCT therapy planned?

yes no

346

Bortezomib (Velcade)

yes no

347

Cellular therapy (e.g. DCI, DLI)

yes no

348

Dexamethasone

yes no

349

Intrathecal therapy (chemotherapy)

yes no

350

Tyrosine kinase inhibitor (e.g. imatinib mesylate)

yes no

351

Lenalidomide (Revlimid)

yes no

352

Local radiotherapy

yes no

353

Rituximab (Rituxan, MabThera)

yes no

354

Thalidomide (Thalomid)

yes no

355

Other therapy

yes no

356

Specify other therapy:357

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

OMB No: 0915-0310

Expiration Date: 1/31/2020

Public Burden Statement:  An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control
number.  The OMB control number for this project is 0915-0310.  Public reporting burden for this collection of information is estimated to average 1.0 hours per response, including the
time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other
aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance Officer, 5600 Fishers Lane, Room 10-29, Rockville, Maryland, 20857.

Center Identification

Recipient Identification

Specify the HSC source(s) for all prior HCTs:

Specify the institution that performed the last HCT:

Specify product type: 

A series of collections should be considered a single product when they are all from the same donor and use the same collection method and technique (and mobilization, if
applicable), even if the collections are performed on different days.

Questions 53 – 60 are for autologous HCT recipients only.  If other than autologous skip to question 61

Specify all agents used in the mobilization events reported above:

Specify all methods used to manipulate the product:

Performance score prior to the preparative regimen:

Specify which malignancy(ies) occurred:

Indicate the total prescribed cumulative dose for the preparative regimen:

Specify radio labeled mAb:

This section is to be completed for allogeneic HCTs only; autologous HCTs continue with question 344.

Specify:

Specify in vivo monoclonal antibody:

Optional for non-U.S. Centers

Questions 347 – 357 are optional for non­U.S. centers

Center: CRID: 

Form 2400 R5.0: Pre-Transplant Essential Data

CIBMTR Form 2400 revision 5.0 last updated January 2017
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 1 / 12



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

EBMT Code (CIC):

Hospital:

Unit (check only one)

Adult Pediatric

CIBMTR Research ID:  (CRID)

Recipient Data Questions: 1 - 10

Date of birth:1 __ __ __ __ - __ __- __ __

Sex

male female

2

Ethnicity3

Hispanic or Latino

Not Hispanic or Latino

Not applicable (not a resident of the USA)

Unknown

Race (1) Questions: 4 - 4

Race4

Zip or postal code for place of recipient’s residence: (USA recipients only)5

Is the recipient participating in a clinical trial?

yes no

6

Clinical Trials (1) Questions: 7 - 10

Study Sponsor7

Specify other sponsor:8

Study ID Number9

Subject ID:10

Hematopoietic Cellular Transplant (HCT) Questions: 11 - 28

Date of this HCT:11 __ __ __ __ - __ __- __ __

Was this the first HCT for this recipient?

yes no

12

Is a subsequent HCT planned as part of the overall treatment protocol (not as a reaction to post-HCT disease assessment)? (For autologous HCTs only)

yes no

13

Specify subsequent HCT planned

Autologous Allogeneic

14

Specify the number of prior HCTs:15

Autologous

yes no

16

Allogeneic, unrelated

yes no

17

Allogeneic, related

yes no

18

Syngeneic

yes no

19

Date of the last HCT: (just before current HCT)20 __ __ __ __ - __ __- __ __

Was the last HCT performed at a different institution?

yes no

21

Name:22

City:

State:

Country:

What was the HSC source for the last HCT?23

Autologous

Allogeneic, unrelated donor

Allogeneic, related donor

Reason for current HCT24

Date of graft failure / rejection:25 __ __ __ __ - __ __- __ __

Date of relapse:26 __ __ __ __ - __ __- __ __

Date of secondary malignancy:27 __ __ __ __ - __ __- __ __

Specify other reason:28

Donor Information Questions: 29 - 63

Multiple donors?

yes no

29

Specify number of donors:30

Donor Information for this HCT (1) Questions: 31 - 63

Specify donor31

NMDP cord blood unit ID:32

NMDP donor ID:33

Non-NMDP unrelated donor ID: (not applicable for related donors)34

Non-NMDP cord blood unit ID: (include related and autologous CBUs)35

Is the CBU ID also the ISBT DIN number?

yes no

36

Specify the ISBT DIN number:37

Registry or UCB Bank ID38

Specify other Registry or UCB Bank:39

Specify the related donor type40

Syngeneic (monozygotic twin)

HLA-identical sibling (may include non-monozygotic twin)

HLA-matched other relative

HLA-mismatched relative

Date of birth (donor / infant)

Known Unknown

41

Date of birth: (donor / infant)42 __ __ __ __ - __ __- __ __

Age (donor / infant)

Known Unknown

43

Age: (donor / infant)44 Months (use only if less than 1 year old)

years

Sex (donor / infant)

male female

45

Bone marrow

yes no

46

PBSC

yes no

47

Single cord blood unit

yes no

48

Other product

yes no

49

Specify other product type:50

Specify number of products infused from this donor:51

Specify the number of these products intended to achieve hematopoietic engraftment:52

Did the recipient have more than one mobilization event to acquire cells for HCT?

yes no

53

Specify the total number of mobilization events performed for this HCT: (regardless of the number of collections or which collections were
used for this HCT)

54

G-CSF

yes no

55

GM-CSF

yes no

56

Pegylated G-CSF

yes no

57

Plerixafor (Mozobil)

yes no

58

Other CXCR4 inhibitor

yes no

59

Combined with chemotherapy

yes no

60

Was this donor used for any prior HCTs?

yes no

61

Donor CMV-antibodies (IgG or Total) (Allogeneic HCTs only)62

Reactive

Non-reactive

Not done

Not applicable (cord blood unit)

Was plerixafor (Mozobil) given at any time prior to the preparative regimen? (Related HCTs only)

yes no Unknown

63

Consent Questions: 64 - 71

Has the recipient signed an IRB-approved consent form for submitting research data to the NMDP / CIBMTR?64

Yes (patient consented)

No (patient declined)

Not approached

Date form was signed:65 __ __ __ __ - __ __- __ __

Did the recipient give permission to be directly contacted for future research?66

Yes (patient provided permission)

No (patient declined)

Not approached

Date form was signed:67 __ __ __ __ - __ __- __ __

Has the recipient signed an IRB-approved consent form to donate research blood samples to the NMDP / CIBMTR?68

Yes (patient consented)

No (patient declined)

Not approached

Not applicable (center not participating)

Date form was signed:69 __ __ __ __ - __ __- __ __

Has the donor signed an IRB-approved consent form to donate research blood samples to the NMDP / CIBMTR? (Allogeneic donors only)70

Yes (donor consented)

No (donor declined)

Not approached

Not applicable (center not participating)

Date form was signed:71 __ __ __ __ - __ __- __ __

Product Processing / Manipulation Questions: 72 - 90

Was the product manipulated prior to infusion?

yes no

72

Specify portion manipulated

entire product portion of product

73

Washed

yes no

74

Diluted

yes no

75

Buffy coat enriched (buffy coat preparation)

yes no

76

B-cell reduced

yes no

77

CD8 reduced

yes no

78

Plasma reduced (removal)

yes no

79

RBC reduced

yes no

80

Cultured (ex-vivo expansion)

yes no

81

Genetic manipulation (gene transfer / transduction)

yes no

82

PUVA treated

yes no

83

CD34 enriched (CD34+ selection)

yes no

84

CD133 enriched

yes no

85

Monocyte enriched

yes no

86

Mononuclear cells enriched

yes no

87

T-cell depletion

yes no

88

Other cell manipulation

yes no

89

Specify other cell manipulation:90

Clinical Status of Recipient Prior to the Preparative Regimen (Conditioning) Questions: 91 - 94

What scale was used to determine the recipient’s functional status?91

Karnofsky (recipient age ≥ 16 years)

Lansky (recipient age < 16 years) 

Karnofsky Scale (recipient age ≥ 16 years)92

Lansky Scale (recipient age < 16 years)93

Recipient CMV-antibodies (IgG or Total)

Reactive Non-reactive Not done

94

Comorbid Conditions Questions: 95 - 155

Is there a history of mechanical ventilation?

yes no

95

Is there a history of proven invasive fungal infection?

yes no

96

Were there clinically significant co-existing diseases or organ impairment at time of patient assessment prior to preparative regimen? Source: Blood, 2005 Oct 15;106(8):2912-2919

yes no

97

Arrhythmia - For example, any history of atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias requiring treatment

yes no Unknown

98

Cardiac - Any history of coronary artery disease (one or more vessel-coronary artery stenosis requiring medical treatment, stent, or bypass graft), congestive heart
failure, myocardial infarction, OR ejection fraction ≤ 50% on the most recent test

yes no Unknown

99

Cerebrovascular disease - Any history of transient ischemic attack, subarachnoid hemorrhage or cerebrovascular accident

yes no Unknown

100

Diabetes - Requiring treatment with insulin or oral hypoglycemics in the last 4 weeks but not diet alone

yes no Unknown

101

Heart valve disease - Except asymptomatic mitral valve prolapse

yes no Unknown

102

Hepatic, mild ­ Chronic hepatitis, bilirubin > upper limit of normal to 1.5 × upper limit of normal, or AST/ALT > upper limit of normal to 2.5 × upper limit of normal at the
time of transplant OR any history of hepatitis B or hepatitis C infection

yes no Unknown

103

Hepatic, moderate / severe ­ Liver cirrhosis, bilirubin > 1.5 × upper limit of normal, or AST/ALT > 2.5 × upper limit of normal

yes no Unknown

104

Infection - For example, documented infection, fever of unknown origin, or pulmonary nodules requiring continuation of antimicrobial treatment after day 0

yes no Unknown

105

Inflammatory bowel disease ­ Any history of Crohn’s disease or ulcerative colitis requiring treatment

yes no Unknown

106

Obesity - Patients with a body mass index > 35 kg/m2  prior to the start of conditioning

yes no Unknown

107

Peptic ulcer - Any history of peptic ulcer confirmed by endoscopy and requiring treatment

yes no Unknown

108

Psychiatric disturbance - For example, depression, anxiety, bipolar disorder or schizophrenia requiring psychiatric consult or treatment in the last 4 weeks

yes no Unknown

109

Pulmonary, moderate - Corrected diffusion capacity of carbon monoxide and/or FEV1 66-80% or dyspnea on slight activity at transplant

yes no Unknown

110

Pulmonary, severe - Corrected diffusion capacity of carbon monoxide and/or FEV1 ≤ 65% or dyspnea at rest or requiring oxygen at transplant

yes no Unknown

111

Renal, moderate / severe ­ Serum creatinine > 2 mg/dL or > 177 µmol/L or on dialysis at transplant, OR prior renal transplantation

yes no Unknown

112

Rheumatologic - For example, any history of systemic lupus erythmatosis, rheumatoid arthritis, polymyositis, mixed connective tissue disease, or polymyalgia
rheumatica requiring treatment (do NOT include degenerative joint disease, osteoarthritis)

yes no Unknown

113

Solid tumor, prior ­ Treated at any time point in the patient’s past history, excluding non­melanoma skin cancer, leukemia, lymphoma or multiple myeloma

yes no Unknown

114

Breast cancer

yes no

115

Year of diagnosis:116

Central nervous system (CNS) malignancy (glioblastoma, astrocytoma)

yes no

117

Year of diagnosis:118

Gastrointestinal malignancy (colon, rectum, stomach, pancreas, intestine)

yes no

119

Year of diagnosis:120

Genitourinary malignancy (kidney, bladder, ovary, testicle, genitalia, uterus, cervix)

yes no

121

Year of diagnosis:122

Lung cancer

yes no

123

Year of diagnosis:124

Melanoma

yes no

125

Year of diagnosis:126

Oropharyngeal cancer (tongue, buccal mucosa)

yes no

127

Year of diagnosis:128

Sarcoma

yes no

129

Year of diagnosis:130

Thyroid cancer

yes no

131

Year of diagnosis:132

Other co-morbid condition

yes no Unknown

133

Specify other co-morbid condition:134

Was there a history of malignancy (hematologic or non-melanoma skin cancer) other than the primary disease for which this HCT is being performed?

yes no

135

Acute myeloid leukemia (AML / ANLL)

yes no

136

Year of diagnosis:137

Other leukemia, including ALL

yes no

138

Year of diagnosis:139

Specify leukemia:140

Clonal cytogenetic abnormality without leukemia or MDS

yes no

141

Year of diagnosis:142

Hodgkin disease

yes no

143

Year of diagnosis:144

Lymphoma or lymphoproliferative disease

yes no

145

Year of diagnosis:146

Was the tumor EBV positive?

yes no

147

Other skin malignancy (basal cell, squamous)

yes no

148

Year of diagnosis:149

Specify other skin malignancy:150

Myelodysplasia (MDS) / myeloproliferative (MPN) disorder

yes no

151

Year of diagnosis:152

Other prior malignancy

yes no

153

Year of diagnosis:154

Specify other prior malignancy:155

Pre-HCT Preparative Regimen (Conditioning) Questions: 156 - 316

Height at initiation of pre-HCT preparative regimen:156 inches centimeters

Actual weight at initiation of pre-HCT preparative regimen:157 pounds kilograms

Was a pre-HCT preparative regimen prescribed?

yes no

158

Classify the recipient’s prescribed preparative regimen (Allogeneic HCTs only)159

Myeloablative

Non-myeloablative (NST)

Reduced intensity (RIC)

Date pre-HCT preparative regimen began: (irradiation or drugs)160 __ __ __ __ - __ __- __ __ (Use earliest date from question 164 radiation, or 169 - 316 chemotherapy)

Was irradiation planned as part of the pre-HCT preparative regimen?

yes no

161

What was the prescribed radiation field?162

Total body

Total body by intensity-modulated radiation therapy (IMRT)

Total lymphoid or nodal regions

Thoracoabdominal region

Total prescribed dose: (dose per fraction x total number of fractions) 163 Gy cGy

Date started:164 __ __ __ __ - __ __- __ __

Was the radiation fractionated?

yes no

165

Prescribed dose per fraction:166 Gy cGy

Number of days: (include "rest" days)167

Total number of fractions:168

ALG, ALS, ATG, ATS

yes no

169

Total prescribed dose:170 mg/kg

Date started:171 __ __ __ __ - __ __- __ __

Specify source172

ATGAM (horse)

ATG - Fresenius (rabbit)

Thymoglobulin (rabbit)

Other

Specify other source:173

Anthracycline

yes no

174

Daunorubicin

yes no

175

Total prescribed dose :176 mg/m2 mg/kg

Date started:177 __ __ __ __ - __ __- __ __

Doxorubicin (Adriamycin)

yes no

178

Total prescribed dose :179 mg/m2 mg/kg

Date started:180 __ __ __ __ - __ __- __ __

Idarubicin

yes no

181

Total prescribed dose :182 mg/m2 mg/kg

Date started:183 __ __ __ __ - __ __- __ __

Rubidazone

yes no

184

Total prescribed dose :185 mg/m2 mg/kg

Date started:186 __ __ __ __ - __ __- __ __

Other anthracycline

yes no

187

Total prescribed dose :188 mg/m2 mg/kg

Date started:189 __ __ __ __ - __ __- __ __

Specify other anthracycline:190

Bleomycin (BLM, Blenoxane)

yes no

191

Total prescribed dose :192 mg/m2 mg/kg

Date started:193 __ __ __ __ - __ __- __ __

Busulfan (Myleran)

yes no

194

Total prescribed dose :195 mg/m2

mg/kg

Target total AUC (µmol x min/L)

Date started:196 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

197

Carboplatin

yes no

198

Total prescribed dose :199 mg/m2 mg/kg

Date started:200 __ __ __ __ - __ __- __ __

Were pharmacokinetics performed to determine preparative regimen drug dosing?

yes no

201

Specify the target AUC:202 mg/mL/minute

Cisplatin (Platinol, CDDP)

yes no

203

Total prescribed dose :204 mg/m2 mg/kg

Date started:205 __ __ __ __ - __ __- __ __

Cladribine (2-CdA, Leustatin)

yes no

206

Total prescribed dose :207 mg/m2 mg/kg

Date started:208 __ __ __ __ - __ __- __ __

Corticosteroids (excluding anti-nausea medication)

yes no

209

Methylprednisolone (Solu-Medrol)

yes no

210

Total prescribed dose :211 mg/m2 mg/kg

Date started:212 __ __ __ __ - __ __- __ __

Prednisone

yes no

213

Total prescribed dose :214 mg/m2 mg/kg

Date started:215 __ __ __ __ - __ __- __ __

Dexamethasone

yes no

216

Total prescribed dose :217 mg/m2 mg/kg

Date started:218 __ __ __ __ - __ __- __ __

Other corticosteroid

yes no

219

Total prescribed dose :220 mg/m2 mg/kg

Date started:221 __ __ __ __ - __ __- __ __

Specify other corticosteroid:222

Cyclophosphamide (Cytoxan)

yes no

223

Total prescribed dose :224 mg/m2 mg/kg

Date started:225 __ __ __ __ - __ __- __ __

Cytarabine (Ara-C)

yes no

226

Total prescribed dose :227 mg/m2 mg/kg

Date started:228 __ __ __ __ - __ __- __ __

Etoposide (VP-16, VePesid)

yes no

229

Total prescribed dose :230 mg/m2 mg/kg

Date started:231 __ __ __ __ - __ __- __ __

Fludarabine

yes no

232

Total prescribed dose :233 mg/m2 mg/kg

Date started:234 __ __ __ __ - __ __- __ __

Ifosfamide

yes no

235

Total prescribed dose :236 mg/m2 mg/kg

Date started:237 __ __ __ __ - __ __- __ __

Intrathecal therapy (chemotherapy)

yes no

238

Intrathecal cytarabine (IT Ara-C)

yes no

239

Total prescribed dose :240 mg/m2 mg/kg

Date started:241 __ __ __ __ - __ __- __ __

Intrathecal methotrexate (IT MTX)

yes no

242

Total prescribed dose :243 mg/m2 mg/kg

Date started:244 __ __ __ __ - __ __- __ __

Intrathecal thiotepa

yes no

245

Total prescribed dose :246 mg/m2 mg/kg

Date started:247 __ __ __ __ - __ __- __ __

Other intrathecal drug

yes no

248

Total prescribed dose :249 mg/m2 mg/kg

Date started:250 __ __ __ __ - __ __- __ __

Specify other intrathecal drug:251

Melphalan (L-Pam)

yes no

252

Total prescribed dose :253 mg/m2 mg/kg

Date started:254 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

255

Mitoxantrone (Novantrone)

yes no

256

Total prescribed dose :257 mg/m2 mg/kg

Date started:258 __ __ __ __ - __ __- __ __

Monoclonal antibody

yes no

259

Radio labeled mAb

yes no

260

Total prescribed dose of radioactive component:261 mCi MBq

Date started:262 __ __ __ __ - __ __- __ __

Tositumomab (Bexxar)

yes no

263

Ibritumomab tiuxetan (Zevalin)

yes no

264

Other radio labeled mAb

yes no

265

Specify other radio labeled mAb:266

Alemtuzumab (Campath)

yes no

267

Total prescribed dose :268 mg/m2 mg/kg

Date started:269 __ __ __ __ - __ __- __ __

Rituximab (Rituxan, anti CD20)

yes no

270

Total prescribed dose :271 mg/m2 mg/kg

Date started:272 __ __ __ __ - __ __- __ __

Gemtuzumab (Mylotarg, anti CD33)

yes no

273

Total prescribed dose :274 mg/m2 mg/kg

Date started:275 __ __ __ __ - __ __- __ __

Other mAb

yes no

276

Total prescribed dose :277 mg/m2 mg/kg

Date started:278 __ __ __ __ - __ __- __ __

Specify other mAb:279

Nitrosourea

yes no

280

Carmustine (BCNU)

yes no

281

Total prescribed dose :282 mg/m2 mg/kg

Date started:283 __ __ __ __ - __ __- __ __

CCNU (Lomustine)

yes no

284

Total prescribed dose :285 mg/m2 mg/kg

Date started:286 __ __ __ __ - __ __- __ __

Other nitrosourea

yes no

287

Total prescribed dose :288 mg/m2 mg/kg

Date started:289 __ __ __ __ - __ __- __ __

Specify other nitrosourea:290

Paclitaxel (Taxol, Xyotax)

yes no

291

Total prescribed dose :292 mg/m2 mg/kg

Date started:293 __ __ __ __ - __ __- __ __

Teniposide (VM26)

yes no

294

Total prescribed dose :295 mg/m2 mg/kg

Date started:296 __ __ __ __ - __ __- __ __

Thiotepa

yes no

297

Total prescribed dose :298 mg/m2 mg/kg

Date started:299 __ __ __ __ - __ __- __ __

Treosulfan

yes no

300

Total prescribed dose :301 mg/m2 mg/kg

Date started:302 __ __ __ __ - __ __- __ __

Tyrosine kinase inhibitors

yes no

303

Dasatinib (Sprycel)

yes no

304

Total prescribed dose :305 mg/m2 mg/kg

Date started:306 __ __ __ __ - __ __- __ __

Imatinib mesylate (STI571, Gleevec)

yes no

307

Total prescribed dose :308 mg/m2 mg/kg

Date started:309 __ __ __ __ - __ __- __ __

Nilotinib

yes no

310

Total prescribed dose :311 mg/m2 mg/kg

Date started:312 __ __ __ __ - __ __- __ __

Other drug

yes no

313

Total prescribed dose :314 mg/m2 mg/kg

Date started:315 __ __ __ __ - __ __- __ __

Specify other drug:316

GVHD Prophylaxis Questions: 317 - 343

Was GVHD prophylaxis planned / given?

yes no

317

ALG, ALS, ATG, ATS

yes no

318

Total dose:319 mg/kg

Specify source320

ATGAM (horse)

ATG - Fresenius (rabbit)

Thymoglobulin (rabbit)

Other

Specify other source:321

Corticosteroids (systemic)

yes no

322

Cyclosporine (CSA, Neoral, Sandimmune)

yes no

323

Cyclophosphamide (Cytoxan)

yes no

324

Extra-corporeal photopheresis (ECP)

yes no

325

FK 506 (Tacrolimus, Prograf)

yes no

326

In vivo monoclonal antibody

yes no

327

Alemtuzumab (Campath)

yes no

328

Anti CD 25 (Zenapax, Daclizumab, AntiTAC)

yes no

329

Specify:330

Etanercept (Enbrel)

yes no

331

Infliximab (Remicade)

yes no

332

Other in vivo monoclonal antibody

yes no

333

Specify antibody:334

In vivo immunotoxin

yes no

335

Specify immunotoxin:336

Methotrexate (MTX) (Amethopterin)

yes no

337

Mycophenolate mofetil (MMF) (CellCept)

yes no

338

Sirolimus (Rapamycin, Rapamune)

yes no

339

Blinded randomized trial

yes no

340

Specify trial agent:341

Other agent

yes no

342

Specify other agent:343

Other Toxicity Modifying Regimen Questions: 344 - 344

Was KGF (palifermin, Kepivance) started or is there a plan to use it?

Yes No masked trial

344

Post-HCT Disease Therapy Planned as of Day 0 Questions: 345 - 357

Is this HCT part of a planned multiple (sequential) graft / HCT protocol?

yes no

345

Is additional post-HCT therapy planned?

yes no

346

Bortezomib (Velcade)

yes no

347

Cellular therapy (e.g. DCI, DLI)

yes no

348

Dexamethasone

yes no

349

Intrathecal therapy (chemotherapy)

yes no

350

Tyrosine kinase inhibitor (e.g. imatinib mesylate)

yes no

351

Lenalidomide (Revlimid)

yes no

352

Local radiotherapy

yes no

353

Rituximab (Rituxan, MabThera)

yes no

354

Thalidomide (Thalomid)

yes no

355

Other therapy

yes no

356

Specify other therapy:357

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

OMB No: 0915-0310

Expiration Date: 1/31/2020

Public Burden Statement:  An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control
number.  The OMB control number for this project is 0915-0310.  Public reporting burden for this collection of information is estimated to average 1.0 hours per response, including the
time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other
aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance Officer, 5600 Fishers Lane, Room 10-29, Rockville, Maryland, 20857.

Center Identification

Recipient Identification

Specify the HSC source(s) for all prior HCTs:

Specify the institution that performed the last HCT:

Specify product type: 

A series of collections should be considered a single product when they are all from the same donor and use the same collection method and technique (and mobilization, if
applicable), even if the collections are performed on different days.

Questions 53 – 60 are for autologous HCT recipients only.  If other than autologous skip to question 61

Specify all agents used in the mobilization events reported above:

Specify all methods used to manipulate the product:

Performance score prior to the preparative regimen:

Specify which malignancy(ies) occurred:

Indicate the total prescribed cumulative dose for the preparative regimen:

Specify radio labeled mAb:

This section is to be completed for allogeneic HCTs only; autologous HCTs continue with question 344.

Specify:

Specify in vivo monoclonal antibody:

Optional for non-U.S. Centers

Questions 347 – 357 are optional for non­U.S. centers

Center: CRID: 

Form 2400 R5.0: Pre-Transplant Essential Data

CIBMTR Form 2400 revision 5.0 last updated January 2017
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 2 / 12



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

EBMT Code (CIC):

Hospital:

Unit (check only one)

Adult Pediatric

CIBMTR Research ID:  (CRID)

Recipient Data Questions: 1 - 10

Date of birth:1 __ __ __ __ - __ __- __ __

Sex

male female

2

Ethnicity3

Hispanic or Latino

Not Hispanic or Latino

Not applicable (not a resident of the USA)

Unknown

Race (1) Questions: 4 - 4

Race4

Zip or postal code for place of recipient’s residence: (USA recipients only)5

Is the recipient participating in a clinical trial?

yes no

6

Clinical Trials (1) Questions: 7 - 10

Study Sponsor7

Specify other sponsor:8

Study ID Number9

Subject ID:10

Hematopoietic Cellular Transplant (HCT) Questions: 11 - 28

Date of this HCT:11 __ __ __ __ - __ __- __ __

Was this the first HCT for this recipient?

yes no

12

Is a subsequent HCT planned as part of the overall treatment protocol (not as a reaction to post-HCT disease assessment)? (For autologous HCTs only)

yes no

13

Specify subsequent HCT planned

Autologous Allogeneic

14

Specify the number of prior HCTs:15

Autologous

yes no

16

Allogeneic, unrelated

yes no

17

Allogeneic, related

yes no

18

Syngeneic

yes no

19

Date of the last HCT: (just before current HCT)20 __ __ __ __ - __ __- __ __

Was the last HCT performed at a different institution?

yes no

21

Name:22

City:

State:

Country:

What was the HSC source for the last HCT?23

Autologous

Allogeneic, unrelated donor

Allogeneic, related donor

Reason for current HCT24

Date of graft failure / rejection:25 __ __ __ __ - __ __- __ __

Date of relapse:26 __ __ __ __ - __ __- __ __

Date of secondary malignancy:27 __ __ __ __ - __ __- __ __

Specify other reason:28

Donor Information Questions: 29 - 63

Multiple donors?

yes no

29

Specify number of donors:30

Donor Information for this HCT (1) Questions: 31 - 63

Specify donor31

NMDP cord blood unit ID:32

NMDP donor ID:33

Non-NMDP unrelated donor ID: (not applicable for related donors)34

Non-NMDP cord blood unit ID: (include related and autologous CBUs)35

Is the CBU ID also the ISBT DIN number?

yes no

36

Specify the ISBT DIN number:37

Registry or UCB Bank ID38

Specify other Registry or UCB Bank:39

Specify the related donor type40

Syngeneic (monozygotic twin)

HLA-identical sibling (may include non-monozygotic twin)

HLA-matched other relative

HLA-mismatched relative

Date of birth (donor / infant)

Known Unknown

41

Date of birth: (donor / infant)42 __ __ __ __ - __ __- __ __

Age (donor / infant)

Known Unknown

43

Age: (donor / infant)44 Months (use only if less than 1 year old)

years

Sex (donor / infant)

male female

45

Bone marrow

yes no

46

PBSC

yes no

47

Single cord blood unit

yes no

48

Other product

yes no

49

Specify other product type:50

Specify number of products infused from this donor:51

Specify the number of these products intended to achieve hematopoietic engraftment:52

Did the recipient have more than one mobilization event to acquire cells for HCT?

yes no

53

Specify the total number of mobilization events performed for this HCT: (regardless of the number of collections or which collections were
used for this HCT)

54

G-CSF

yes no

55

GM-CSF

yes no

56

Pegylated G-CSF

yes no

57

Plerixafor (Mozobil)

yes no

58

Other CXCR4 inhibitor

yes no

59

Combined with chemotherapy

yes no

60

Was this donor used for any prior HCTs?

yes no

61

Donor CMV-antibodies (IgG or Total) (Allogeneic HCTs only)62

Reactive

Non-reactive

Not done

Not applicable (cord blood unit)

Was plerixafor (Mozobil) given at any time prior to the preparative regimen? (Related HCTs only)

yes no Unknown

63

Consent Questions: 64 - 71

Has the recipient signed an IRB-approved consent form for submitting research data to the NMDP / CIBMTR?64

Yes (patient consented)

No (patient declined)

Not approached

Date form was signed:65 __ __ __ __ - __ __- __ __

Did the recipient give permission to be directly contacted for future research?66

Yes (patient provided permission)

No (patient declined)

Not approached

Date form was signed:67 __ __ __ __ - __ __- __ __

Has the recipient signed an IRB-approved consent form to donate research blood samples to the NMDP / CIBMTR?68

Yes (patient consented)

No (patient declined)

Not approached

Not applicable (center not participating)

Date form was signed:69 __ __ __ __ - __ __- __ __

Has the donor signed an IRB-approved consent form to donate research blood samples to the NMDP / CIBMTR? (Allogeneic donors only)70

Yes (donor consented)

No (donor declined)

Not approached

Not applicable (center not participating)

Date form was signed:71 __ __ __ __ - __ __- __ __

Product Processing / Manipulation Questions: 72 - 90

Was the product manipulated prior to infusion?

yes no

72

Specify portion manipulated

entire product portion of product

73

Washed

yes no

74

Diluted

yes no

75

Buffy coat enriched (buffy coat preparation)

yes no

76

B-cell reduced

yes no

77

CD8 reduced

yes no

78

Plasma reduced (removal)

yes no

79

RBC reduced

yes no

80

Cultured (ex-vivo expansion)

yes no

81

Genetic manipulation (gene transfer / transduction)

yes no

82

PUVA treated

yes no

83

CD34 enriched (CD34+ selection)

yes no

84

CD133 enriched

yes no

85

Monocyte enriched

yes no

86

Mononuclear cells enriched

yes no

87

T-cell depletion

yes no

88

Other cell manipulation

yes no

89

Specify other cell manipulation:90

Clinical Status of Recipient Prior to the Preparative Regimen (Conditioning) Questions: 91 - 94

What scale was used to determine the recipient’s functional status?91

Karnofsky (recipient age ≥ 16 years)

Lansky (recipient age < 16 years) 

Karnofsky Scale (recipient age ≥ 16 years)92

Lansky Scale (recipient age < 16 years)93

Recipient CMV-antibodies (IgG or Total)

Reactive Non-reactive Not done

94

Comorbid Conditions Questions: 95 - 155

Is there a history of mechanical ventilation?

yes no

95

Is there a history of proven invasive fungal infection?

yes no

96

Were there clinically significant co-existing diseases or organ impairment at time of patient assessment prior to preparative regimen? Source: Blood, 2005 Oct 15;106(8):2912-2919

yes no

97

Arrhythmia - For example, any history of atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias requiring treatment

yes no Unknown

98

Cardiac - Any history of coronary artery disease (one or more vessel-coronary artery stenosis requiring medical treatment, stent, or bypass graft), congestive heart
failure, myocardial infarction, OR ejection fraction ≤ 50% on the most recent test

yes no Unknown

99

Cerebrovascular disease - Any history of transient ischemic attack, subarachnoid hemorrhage or cerebrovascular accident

yes no Unknown

100

Diabetes - Requiring treatment with insulin or oral hypoglycemics in the last 4 weeks but not diet alone

yes no Unknown

101

Heart valve disease - Except asymptomatic mitral valve prolapse

yes no Unknown

102

Hepatic, mild ­ Chronic hepatitis, bilirubin > upper limit of normal to 1.5 × upper limit of normal, or AST/ALT > upper limit of normal to 2.5 × upper limit of normal at the
time of transplant OR any history of hepatitis B or hepatitis C infection

yes no Unknown

103

Hepatic, moderate / severe ­ Liver cirrhosis, bilirubin > 1.5 × upper limit of normal, or AST/ALT > 2.5 × upper limit of normal

yes no Unknown

104

Infection - For example, documented infection, fever of unknown origin, or pulmonary nodules requiring continuation of antimicrobial treatment after day 0

yes no Unknown

105

Inflammatory bowel disease ­ Any history of Crohn’s disease or ulcerative colitis requiring treatment

yes no Unknown

106

Obesity - Patients with a body mass index > 35 kg/m2  prior to the start of conditioning

yes no Unknown

107

Peptic ulcer - Any history of peptic ulcer confirmed by endoscopy and requiring treatment

yes no Unknown

108

Psychiatric disturbance - For example, depression, anxiety, bipolar disorder or schizophrenia requiring psychiatric consult or treatment in the last 4 weeks

yes no Unknown

109

Pulmonary, moderate - Corrected diffusion capacity of carbon monoxide and/or FEV1 66-80% or dyspnea on slight activity at transplant

yes no Unknown

110

Pulmonary, severe - Corrected diffusion capacity of carbon monoxide and/or FEV1 ≤ 65% or dyspnea at rest or requiring oxygen at transplant

yes no Unknown

111

Renal, moderate / severe ­ Serum creatinine > 2 mg/dL or > 177 µmol/L or on dialysis at transplant, OR prior renal transplantation

yes no Unknown

112

Rheumatologic - For example, any history of systemic lupus erythmatosis, rheumatoid arthritis, polymyositis, mixed connective tissue disease, or polymyalgia
rheumatica requiring treatment (do NOT include degenerative joint disease, osteoarthritis)

yes no Unknown

113

Solid tumor, prior ­ Treated at any time point in the patient’s past history, excluding non­melanoma skin cancer, leukemia, lymphoma or multiple myeloma

yes no Unknown

114

Breast cancer

yes no

115

Year of diagnosis:116

Central nervous system (CNS) malignancy (glioblastoma, astrocytoma)

yes no

117

Year of diagnosis:118

Gastrointestinal malignancy (colon, rectum, stomach, pancreas, intestine)

yes no

119

Year of diagnosis:120

Genitourinary malignancy (kidney, bladder, ovary, testicle, genitalia, uterus, cervix)

yes no

121

Year of diagnosis:122

Lung cancer

yes no

123

Year of diagnosis:124

Melanoma

yes no

125

Year of diagnosis:126

Oropharyngeal cancer (tongue, buccal mucosa)

yes no

127

Year of diagnosis:128

Sarcoma

yes no

129

Year of diagnosis:130

Thyroid cancer

yes no

131

Year of diagnosis:132

Other co-morbid condition

yes no Unknown

133

Specify other co-morbid condition:134

Was there a history of malignancy (hematologic or non-melanoma skin cancer) other than the primary disease for which this HCT is being performed?

yes no

135

Acute myeloid leukemia (AML / ANLL)

yes no

136

Year of diagnosis:137

Other leukemia, including ALL

yes no

138

Year of diagnosis:139

Specify leukemia:140

Clonal cytogenetic abnormality without leukemia or MDS

yes no

141

Year of diagnosis:142

Hodgkin disease

yes no

143

Year of diagnosis:144

Lymphoma or lymphoproliferative disease

yes no

145

Year of diagnosis:146

Was the tumor EBV positive?

yes no

147

Other skin malignancy (basal cell, squamous)

yes no

148

Year of diagnosis:149

Specify other skin malignancy:150

Myelodysplasia (MDS) / myeloproliferative (MPN) disorder

yes no

151

Year of diagnosis:152

Other prior malignancy

yes no

153

Year of diagnosis:154

Specify other prior malignancy:155

Pre-HCT Preparative Regimen (Conditioning) Questions: 156 - 316

Height at initiation of pre-HCT preparative regimen:156 inches centimeters

Actual weight at initiation of pre-HCT preparative regimen:157 pounds kilograms

Was a pre-HCT preparative regimen prescribed?

yes no

158

Classify the recipient’s prescribed preparative regimen (Allogeneic HCTs only)159

Myeloablative

Non-myeloablative (NST)

Reduced intensity (RIC)

Date pre-HCT preparative regimen began: (irradiation or drugs)160 __ __ __ __ - __ __- __ __ (Use earliest date from question 164 radiation, or 169 - 316 chemotherapy)

Was irradiation planned as part of the pre-HCT preparative regimen?

yes no

161

What was the prescribed radiation field?162

Total body

Total body by intensity-modulated radiation therapy (IMRT)

Total lymphoid or nodal regions

Thoracoabdominal region

Total prescribed dose: (dose per fraction x total number of fractions) 163 Gy cGy

Date started:164 __ __ __ __ - __ __- __ __

Was the radiation fractionated?

yes no

165

Prescribed dose per fraction:166 Gy cGy

Number of days: (include "rest" days)167

Total number of fractions:168

ALG, ALS, ATG, ATS

yes no

169

Total prescribed dose:170 mg/kg

Date started:171 __ __ __ __ - __ __- __ __

Specify source172

ATGAM (horse)

ATG - Fresenius (rabbit)

Thymoglobulin (rabbit)

Other

Specify other source:173

Anthracycline

yes no

174

Daunorubicin

yes no

175

Total prescribed dose :176 mg/m2 mg/kg

Date started:177 __ __ __ __ - __ __- __ __

Doxorubicin (Adriamycin)

yes no

178

Total prescribed dose :179 mg/m2 mg/kg

Date started:180 __ __ __ __ - __ __- __ __

Idarubicin

yes no

181

Total prescribed dose :182 mg/m2 mg/kg

Date started:183 __ __ __ __ - __ __- __ __

Rubidazone

yes no

184

Total prescribed dose :185 mg/m2 mg/kg

Date started:186 __ __ __ __ - __ __- __ __

Other anthracycline

yes no

187

Total prescribed dose :188 mg/m2 mg/kg

Date started:189 __ __ __ __ - __ __- __ __

Specify other anthracycline:190

Bleomycin (BLM, Blenoxane)

yes no

191

Total prescribed dose :192 mg/m2 mg/kg

Date started:193 __ __ __ __ - __ __- __ __

Busulfan (Myleran)

yes no

194

Total prescribed dose :195 mg/m2

mg/kg

Target total AUC (µmol x min/L)

Date started:196 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

197

Carboplatin

yes no

198

Total prescribed dose :199 mg/m2 mg/kg

Date started:200 __ __ __ __ - __ __- __ __

Were pharmacokinetics performed to determine preparative regimen drug dosing?

yes no

201

Specify the target AUC:202 mg/mL/minute

Cisplatin (Platinol, CDDP)

yes no

203

Total prescribed dose :204 mg/m2 mg/kg

Date started:205 __ __ __ __ - __ __- __ __

Cladribine (2-CdA, Leustatin)

yes no

206

Total prescribed dose :207 mg/m2 mg/kg

Date started:208 __ __ __ __ - __ __- __ __

Corticosteroids (excluding anti-nausea medication)

yes no

209

Methylprednisolone (Solu-Medrol)

yes no

210

Total prescribed dose :211 mg/m2 mg/kg

Date started:212 __ __ __ __ - __ __- __ __

Prednisone

yes no

213

Total prescribed dose :214 mg/m2 mg/kg

Date started:215 __ __ __ __ - __ __- __ __

Dexamethasone

yes no

216

Total prescribed dose :217 mg/m2 mg/kg

Date started:218 __ __ __ __ - __ __- __ __

Other corticosteroid

yes no

219

Total prescribed dose :220 mg/m2 mg/kg

Date started:221 __ __ __ __ - __ __- __ __

Specify other corticosteroid:222

Cyclophosphamide (Cytoxan)

yes no

223

Total prescribed dose :224 mg/m2 mg/kg

Date started:225 __ __ __ __ - __ __- __ __

Cytarabine (Ara-C)

yes no

226

Total prescribed dose :227 mg/m2 mg/kg

Date started:228 __ __ __ __ - __ __- __ __

Etoposide (VP-16, VePesid)

yes no

229

Total prescribed dose :230 mg/m2 mg/kg

Date started:231 __ __ __ __ - __ __- __ __

Fludarabine

yes no

232

Total prescribed dose :233 mg/m2 mg/kg

Date started:234 __ __ __ __ - __ __- __ __

Ifosfamide

yes no

235

Total prescribed dose :236 mg/m2 mg/kg

Date started:237 __ __ __ __ - __ __- __ __

Intrathecal therapy (chemotherapy)

yes no

238

Intrathecal cytarabine (IT Ara-C)

yes no

239

Total prescribed dose :240 mg/m2 mg/kg

Date started:241 __ __ __ __ - __ __- __ __

Intrathecal methotrexate (IT MTX)

yes no

242

Total prescribed dose :243 mg/m2 mg/kg

Date started:244 __ __ __ __ - __ __- __ __

Intrathecal thiotepa

yes no

245

Total prescribed dose :246 mg/m2 mg/kg

Date started:247 __ __ __ __ - __ __- __ __

Other intrathecal drug

yes no

248

Total prescribed dose :249 mg/m2 mg/kg

Date started:250 __ __ __ __ - __ __- __ __

Specify other intrathecal drug:251

Melphalan (L-Pam)

yes no

252

Total prescribed dose :253 mg/m2 mg/kg

Date started:254 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

255

Mitoxantrone (Novantrone)

yes no

256

Total prescribed dose :257 mg/m2 mg/kg

Date started:258 __ __ __ __ - __ __- __ __

Monoclonal antibody

yes no

259

Radio labeled mAb

yes no

260

Total prescribed dose of radioactive component:261 mCi MBq

Date started:262 __ __ __ __ - __ __- __ __

Tositumomab (Bexxar)

yes no

263

Ibritumomab tiuxetan (Zevalin)

yes no

264

Other radio labeled mAb

yes no

265

Specify other radio labeled mAb:266

Alemtuzumab (Campath)

yes no

267

Total prescribed dose :268 mg/m2 mg/kg

Date started:269 __ __ __ __ - __ __- __ __

Rituximab (Rituxan, anti CD20)

yes no

270

Total prescribed dose :271 mg/m2 mg/kg

Date started:272 __ __ __ __ - __ __- __ __

Gemtuzumab (Mylotarg, anti CD33)

yes no

273

Total prescribed dose :274 mg/m2 mg/kg

Date started:275 __ __ __ __ - __ __- __ __

Other mAb

yes no

276

Total prescribed dose :277 mg/m2 mg/kg

Date started:278 __ __ __ __ - __ __- __ __

Specify other mAb:279

Nitrosourea

yes no

280

Carmustine (BCNU)

yes no

281

Total prescribed dose :282 mg/m2 mg/kg

Date started:283 __ __ __ __ - __ __- __ __

CCNU (Lomustine)

yes no

284

Total prescribed dose :285 mg/m2 mg/kg

Date started:286 __ __ __ __ - __ __- __ __

Other nitrosourea

yes no

287

Total prescribed dose :288 mg/m2 mg/kg

Date started:289 __ __ __ __ - __ __- __ __

Specify other nitrosourea:290

Paclitaxel (Taxol, Xyotax)

yes no

291

Total prescribed dose :292 mg/m2 mg/kg

Date started:293 __ __ __ __ - __ __- __ __

Teniposide (VM26)

yes no

294

Total prescribed dose :295 mg/m2 mg/kg

Date started:296 __ __ __ __ - __ __- __ __

Thiotepa

yes no

297

Total prescribed dose :298 mg/m2 mg/kg

Date started:299 __ __ __ __ - __ __- __ __

Treosulfan

yes no

300

Total prescribed dose :301 mg/m2 mg/kg

Date started:302 __ __ __ __ - __ __- __ __

Tyrosine kinase inhibitors

yes no

303

Dasatinib (Sprycel)

yes no

304

Total prescribed dose :305 mg/m2 mg/kg

Date started:306 __ __ __ __ - __ __- __ __

Imatinib mesylate (STI571, Gleevec)

yes no

307

Total prescribed dose :308 mg/m2 mg/kg

Date started:309 __ __ __ __ - __ __- __ __

Nilotinib

yes no

310

Total prescribed dose :311 mg/m2 mg/kg

Date started:312 __ __ __ __ - __ __- __ __

Other drug

yes no

313

Total prescribed dose :314 mg/m2 mg/kg

Date started:315 __ __ __ __ - __ __- __ __

Specify other drug:316

GVHD Prophylaxis Questions: 317 - 343

Was GVHD prophylaxis planned / given?

yes no

317

ALG, ALS, ATG, ATS

yes no

318

Total dose:319 mg/kg

Specify source320

ATGAM (horse)

ATG - Fresenius (rabbit)

Thymoglobulin (rabbit)

Other

Specify other source:321

Corticosteroids (systemic)

yes no

322

Cyclosporine (CSA, Neoral, Sandimmune)

yes no

323

Cyclophosphamide (Cytoxan)

yes no

324

Extra-corporeal photopheresis (ECP)

yes no

325

FK 506 (Tacrolimus, Prograf)

yes no

326

In vivo monoclonal antibody

yes no

327

Alemtuzumab (Campath)

yes no

328

Anti CD 25 (Zenapax, Daclizumab, AntiTAC)

yes no

329

Specify:330

Etanercept (Enbrel)

yes no

331

Infliximab (Remicade)

yes no

332

Other in vivo monoclonal antibody

yes no

333

Specify antibody:334

In vivo immunotoxin

yes no

335

Specify immunotoxin:336

Methotrexate (MTX) (Amethopterin)

yes no

337

Mycophenolate mofetil (MMF) (CellCept)

yes no

338

Sirolimus (Rapamycin, Rapamune)

yes no

339

Blinded randomized trial

yes no

340

Specify trial agent:341

Other agent

yes no

342

Specify other agent:343

Other Toxicity Modifying Regimen Questions: 344 - 344

Was KGF (palifermin, Kepivance) started or is there a plan to use it?

Yes No masked trial

344

Post-HCT Disease Therapy Planned as of Day 0 Questions: 345 - 357

Is this HCT part of a planned multiple (sequential) graft / HCT protocol?

yes no

345

Is additional post-HCT therapy planned?

yes no

346

Bortezomib (Velcade)

yes no

347

Cellular therapy (e.g. DCI, DLI)

yes no

348

Dexamethasone

yes no

349

Intrathecal therapy (chemotherapy)

yes no

350

Tyrosine kinase inhibitor (e.g. imatinib mesylate)

yes no

351

Lenalidomide (Revlimid)

yes no

352

Local radiotherapy

yes no

353

Rituximab (Rituxan, MabThera)

yes no

354

Thalidomide (Thalomid)

yes no

355

Other therapy

yes no

356

Specify other therapy:357

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

OMB No: 0915-0310

Expiration Date: 1/31/2020

Public Burden Statement:  An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control
number.  The OMB control number for this project is 0915-0310.  Public reporting burden for this collection of information is estimated to average 1.0 hours per response, including the
time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other
aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance Officer, 5600 Fishers Lane, Room 10-29, Rockville, Maryland, 20857.

Center Identification

Recipient Identification

Specify the HSC source(s) for all prior HCTs:

Specify the institution that performed the last HCT:

Specify product type: 

A series of collections should be considered a single product when they are all from the same donor and use the same collection method and technique (and mobilization, if
applicable), even if the collections are performed on different days.

Questions 53 – 60 are for autologous HCT recipients only.  If other than autologous skip to question 61

Specify all agents used in the mobilization events reported above:

Specify all methods used to manipulate the product:

Performance score prior to the preparative regimen:

Specify which malignancy(ies) occurred:

Indicate the total prescribed cumulative dose for the preparative regimen:

Specify radio labeled mAb:

This section is to be completed for allogeneic HCTs only; autologous HCTs continue with question 344.

Specify:

Specify in vivo monoclonal antibody:

Optional for non-U.S. Centers

Questions 347 – 357 are optional for non­U.S. centers

Center: CRID: 

Form 2400 R5.0: Pre-Transplant Essential Data

CIBMTR Form 2400 revision 5.0 last updated January 2017
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 3 / 12



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

EBMT Code (CIC):

Hospital:

Unit (check only one)

Adult Pediatric

CIBMTR Research ID:  (CRID)

Recipient Data Questions: 1 - 10

Date of birth:1 __ __ __ __ - __ __- __ __

Sex

male female

2

Ethnicity3

Hispanic or Latino

Not Hispanic or Latino

Not applicable (not a resident of the USA)

Unknown

Race (1) Questions: 4 - 4

Race4

Zip or postal code for place of recipient’s residence: (USA recipients only)5

Is the recipient participating in a clinical trial?

yes no

6

Clinical Trials (1) Questions: 7 - 10

Study Sponsor7

Specify other sponsor:8

Study ID Number9

Subject ID:10

Hematopoietic Cellular Transplant (HCT) Questions: 11 - 28

Date of this HCT:11 __ __ __ __ - __ __- __ __

Was this the first HCT for this recipient?

yes no

12

Is a subsequent HCT planned as part of the overall treatment protocol (not as a reaction to post-HCT disease assessment)? (For autologous HCTs only)

yes no

13

Specify subsequent HCT planned

Autologous Allogeneic

14

Specify the number of prior HCTs:15

Autologous

yes no

16

Allogeneic, unrelated

yes no

17

Allogeneic, related

yes no

18

Syngeneic

yes no

19

Date of the last HCT: (just before current HCT)20 __ __ __ __ - __ __- __ __

Was the last HCT performed at a different institution?

yes no

21

Name:22

City:

State:

Country:

What was the HSC source for the last HCT?23

Autologous

Allogeneic, unrelated donor

Allogeneic, related donor

Reason for current HCT24

Date of graft failure / rejection:25 __ __ __ __ - __ __- __ __

Date of relapse:26 __ __ __ __ - __ __- __ __

Date of secondary malignancy:27 __ __ __ __ - __ __- __ __

Specify other reason:28

Donor Information Questions: 29 - 63

Multiple donors?

yes no

29

Specify number of donors:30

Donor Information for this HCT (1) Questions: 31 - 63

Specify donor31

NMDP cord blood unit ID:32

NMDP donor ID:33

Non-NMDP unrelated donor ID: (not applicable for related donors)34

Non-NMDP cord blood unit ID: (include related and autologous CBUs)35

Is the CBU ID also the ISBT DIN number?

yes no

36

Specify the ISBT DIN number:37

Registry or UCB Bank ID38

Specify other Registry or UCB Bank:39

Specify the related donor type40

Syngeneic (monozygotic twin)

HLA-identical sibling (may include non-monozygotic twin)

HLA-matched other relative

HLA-mismatched relative

Date of birth (donor / infant)

Known Unknown

41

Date of birth: (donor / infant)42 __ __ __ __ - __ __- __ __

Age (donor / infant)

Known Unknown

43

Age: (donor / infant)44 Months (use only if less than 1 year old)

years

Sex (donor / infant)

male female

45

Bone marrow

yes no

46

PBSC

yes no

47

Single cord blood unit

yes no

48

Other product

yes no

49

Specify other product type:50

Specify number of products infused from this donor:51

Specify the number of these products intended to achieve hematopoietic engraftment:52

Did the recipient have more than one mobilization event to acquire cells for HCT?

yes no

53

Specify the total number of mobilization events performed for this HCT: (regardless of the number of collections or which collections were
used for this HCT)

54

G-CSF

yes no

55

GM-CSF

yes no

56

Pegylated G-CSF

yes no

57

Plerixafor (Mozobil)

yes no

58

Other CXCR4 inhibitor

yes no

59

Combined with chemotherapy

yes no

60

Was this donor used for any prior HCTs?

yes no

61

Donor CMV-antibodies (IgG or Total) (Allogeneic HCTs only)62

Reactive

Non-reactive

Not done

Not applicable (cord blood unit)

Was plerixafor (Mozobil) given at any time prior to the preparative regimen? (Related HCTs only)

yes no Unknown

63

Consent Questions: 64 - 71

Has the recipient signed an IRB-approved consent form for submitting research data to the NMDP / CIBMTR?64

Yes (patient consented)

No (patient declined)

Not approached

Date form was signed:65 __ __ __ __ - __ __- __ __

Did the recipient give permission to be directly contacted for future research?66

Yes (patient provided permission)

No (patient declined)

Not approached

Date form was signed:67 __ __ __ __ - __ __- __ __

Has the recipient signed an IRB-approved consent form to donate research blood samples to the NMDP / CIBMTR?68

Yes (patient consented)

No (patient declined)

Not approached

Not applicable (center not participating)

Date form was signed:69 __ __ __ __ - __ __- __ __

Has the donor signed an IRB-approved consent form to donate research blood samples to the NMDP / CIBMTR? (Allogeneic donors only)70

Yes (donor consented)

No (donor declined)

Not approached

Not applicable (center not participating)

Date form was signed:71 __ __ __ __ - __ __- __ __

Product Processing / Manipulation Questions: 72 - 90

Was the product manipulated prior to infusion?

yes no

72

Specify portion manipulated

entire product portion of product

73

Washed

yes no

74

Diluted

yes no

75

Buffy coat enriched (buffy coat preparation)

yes no

76

B-cell reduced

yes no

77

CD8 reduced

yes no

78

Plasma reduced (removal)

yes no

79

RBC reduced

yes no

80

Cultured (ex-vivo expansion)

yes no

81

Genetic manipulation (gene transfer / transduction)

yes no

82

PUVA treated

yes no

83

CD34 enriched (CD34+ selection)

yes no

84

CD133 enriched

yes no

85

Monocyte enriched

yes no

86

Mononuclear cells enriched

yes no

87

T-cell depletion

yes no

88

Other cell manipulation

yes no

89

Specify other cell manipulation:90

Clinical Status of Recipient Prior to the Preparative Regimen (Conditioning) Questions: 91 - 94

What scale was used to determine the recipient’s functional status?91

Karnofsky (recipient age ≥ 16 years)

Lansky (recipient age < 16 years) 

Karnofsky Scale (recipient age ≥ 16 years)92

Lansky Scale (recipient age < 16 years)93

Recipient CMV-antibodies (IgG or Total)

Reactive Non-reactive Not done

94

Comorbid Conditions Questions: 95 - 155

Is there a history of mechanical ventilation?

yes no

95

Is there a history of proven invasive fungal infection?

yes no

96

Were there clinically significant co-existing diseases or organ impairment at time of patient assessment prior to preparative regimen? Source: Blood, 2005 Oct 15;106(8):2912-2919

yes no

97

Arrhythmia - For example, any history of atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias requiring treatment

yes no Unknown

98

Cardiac - Any history of coronary artery disease (one or more vessel-coronary artery stenosis requiring medical treatment, stent, or bypass graft), congestive heart
failure, myocardial infarction, OR ejection fraction ≤ 50% on the most recent test

yes no Unknown

99

Cerebrovascular disease - Any history of transient ischemic attack, subarachnoid hemorrhage or cerebrovascular accident

yes no Unknown

100

Diabetes - Requiring treatment with insulin or oral hypoglycemics in the last 4 weeks but not diet alone

yes no Unknown

101

Heart valve disease - Except asymptomatic mitral valve prolapse

yes no Unknown

102

Hepatic, mild ­ Chronic hepatitis, bilirubin > upper limit of normal to 1.5 × upper limit of normal, or AST/ALT > upper limit of normal to 2.5 × upper limit of normal at the
time of transplant OR any history of hepatitis B or hepatitis C infection

yes no Unknown

103

Hepatic, moderate / severe ­ Liver cirrhosis, bilirubin > 1.5 × upper limit of normal, or AST/ALT > 2.5 × upper limit of normal

yes no Unknown

104

Infection - For example, documented infection, fever of unknown origin, or pulmonary nodules requiring continuation of antimicrobial treatment after day 0

yes no Unknown

105

Inflammatory bowel disease ­ Any history of Crohn’s disease or ulcerative colitis requiring treatment

yes no Unknown

106

Obesity - Patients with a body mass index > 35 kg/m2  prior to the start of conditioning

yes no Unknown

107

Peptic ulcer - Any history of peptic ulcer confirmed by endoscopy and requiring treatment

yes no Unknown

108

Psychiatric disturbance - For example, depression, anxiety, bipolar disorder or schizophrenia requiring psychiatric consult or treatment in the last 4 weeks

yes no Unknown

109

Pulmonary, moderate - Corrected diffusion capacity of carbon monoxide and/or FEV1 66-80% or dyspnea on slight activity at transplant

yes no Unknown

110

Pulmonary, severe - Corrected diffusion capacity of carbon monoxide and/or FEV1 ≤ 65% or dyspnea at rest or requiring oxygen at transplant

yes no Unknown

111

Renal, moderate / severe ­ Serum creatinine > 2 mg/dL or > 177 µmol/L or on dialysis at transplant, OR prior renal transplantation

yes no Unknown

112

Rheumatologic - For example, any history of systemic lupus erythmatosis, rheumatoid arthritis, polymyositis, mixed connective tissue disease, or polymyalgia
rheumatica requiring treatment (do NOT include degenerative joint disease, osteoarthritis)

yes no Unknown

113

Solid tumor, prior ­ Treated at any time point in the patient’s past history, excluding non­melanoma skin cancer, leukemia, lymphoma or multiple myeloma

yes no Unknown

114

Breast cancer

yes no

115

Year of diagnosis:116

Central nervous system (CNS) malignancy (glioblastoma, astrocytoma)

yes no

117

Year of diagnosis:118

Gastrointestinal malignancy (colon, rectum, stomach, pancreas, intestine)

yes no

119

Year of diagnosis:120

Genitourinary malignancy (kidney, bladder, ovary, testicle, genitalia, uterus, cervix)

yes no

121

Year of diagnosis:122

Lung cancer

yes no

123

Year of diagnosis:124

Melanoma

yes no

125

Year of diagnosis:126

Oropharyngeal cancer (tongue, buccal mucosa)

yes no

127

Year of diagnosis:128

Sarcoma

yes no

129

Year of diagnosis:130

Thyroid cancer

yes no

131

Year of diagnosis:132

Other co-morbid condition

yes no Unknown

133

Specify other co-morbid condition:134

Was there a history of malignancy (hematologic or non-melanoma skin cancer) other than the primary disease for which this HCT is being performed?

yes no

135

Acute myeloid leukemia (AML / ANLL)

yes no

136

Year of diagnosis:137

Other leukemia, including ALL

yes no

138

Year of diagnosis:139

Specify leukemia:140

Clonal cytogenetic abnormality without leukemia or MDS

yes no

141

Year of diagnosis:142

Hodgkin disease

yes no

143

Year of diagnosis:144

Lymphoma or lymphoproliferative disease

yes no

145

Year of diagnosis:146

Was the tumor EBV positive?

yes no

147

Other skin malignancy (basal cell, squamous)

yes no

148

Year of diagnosis:149

Specify other skin malignancy:150

Myelodysplasia (MDS) / myeloproliferative (MPN) disorder

yes no

151

Year of diagnosis:152

Other prior malignancy

yes no

153

Year of diagnosis:154

Specify other prior malignancy:155

Pre-HCT Preparative Regimen (Conditioning) Questions: 156 - 316

Height at initiation of pre-HCT preparative regimen:156 inches centimeters

Actual weight at initiation of pre-HCT preparative regimen:157 pounds kilograms

Was a pre-HCT preparative regimen prescribed?

yes no

158

Classify the recipient’s prescribed preparative regimen (Allogeneic HCTs only)159

Myeloablative

Non-myeloablative (NST)

Reduced intensity (RIC)

Date pre-HCT preparative regimen began: (irradiation or drugs)160 __ __ __ __ - __ __- __ __ (Use earliest date from question 164 radiation, or 169 - 316 chemotherapy)

Was irradiation planned as part of the pre-HCT preparative regimen?

yes no

161

What was the prescribed radiation field?162

Total body

Total body by intensity-modulated radiation therapy (IMRT)

Total lymphoid or nodal regions

Thoracoabdominal region

Total prescribed dose: (dose per fraction x total number of fractions) 163 Gy cGy

Date started:164 __ __ __ __ - __ __- __ __

Was the radiation fractionated?

yes no

165

Prescribed dose per fraction:166 Gy cGy

Number of days: (include "rest" days)167

Total number of fractions:168

ALG, ALS, ATG, ATS

yes no

169

Total prescribed dose:170 mg/kg

Date started:171 __ __ __ __ - __ __- __ __

Specify source172

ATGAM (horse)

ATG - Fresenius (rabbit)

Thymoglobulin (rabbit)

Other

Specify other source:173

Anthracycline

yes no

174

Daunorubicin

yes no

175

Total prescribed dose :176 mg/m2 mg/kg

Date started:177 __ __ __ __ - __ __- __ __

Doxorubicin (Adriamycin)

yes no

178

Total prescribed dose :179 mg/m2 mg/kg

Date started:180 __ __ __ __ - __ __- __ __

Idarubicin

yes no

181

Total prescribed dose :182 mg/m2 mg/kg

Date started:183 __ __ __ __ - __ __- __ __

Rubidazone

yes no

184

Total prescribed dose :185 mg/m2 mg/kg

Date started:186 __ __ __ __ - __ __- __ __

Other anthracycline

yes no

187

Total prescribed dose :188 mg/m2 mg/kg

Date started:189 __ __ __ __ - __ __- __ __

Specify other anthracycline:190

Bleomycin (BLM, Blenoxane)

yes no

191

Total prescribed dose :192 mg/m2 mg/kg

Date started:193 __ __ __ __ - __ __- __ __

Busulfan (Myleran)

yes no

194

Total prescribed dose :195 mg/m2

mg/kg

Target total AUC (µmol x min/L)

Date started:196 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

197

Carboplatin

yes no

198

Total prescribed dose :199 mg/m2 mg/kg

Date started:200 __ __ __ __ - __ __- __ __

Were pharmacokinetics performed to determine preparative regimen drug dosing?

yes no

201

Specify the target AUC:202 mg/mL/minute

Cisplatin (Platinol, CDDP)

yes no

203

Total prescribed dose :204 mg/m2 mg/kg

Date started:205 __ __ __ __ - __ __- __ __

Cladribine (2-CdA, Leustatin)

yes no

206

Total prescribed dose :207 mg/m2 mg/kg

Date started:208 __ __ __ __ - __ __- __ __

Corticosteroids (excluding anti-nausea medication)

yes no

209

Methylprednisolone (Solu-Medrol)

yes no

210

Total prescribed dose :211 mg/m2 mg/kg

Date started:212 __ __ __ __ - __ __- __ __

Prednisone

yes no

213

Total prescribed dose :214 mg/m2 mg/kg

Date started:215 __ __ __ __ - __ __- __ __

Dexamethasone

yes no

216

Total prescribed dose :217 mg/m2 mg/kg

Date started:218 __ __ __ __ - __ __- __ __

Other corticosteroid

yes no

219

Total prescribed dose :220 mg/m2 mg/kg

Date started:221 __ __ __ __ - __ __- __ __

Specify other corticosteroid:222

Cyclophosphamide (Cytoxan)

yes no

223

Total prescribed dose :224 mg/m2 mg/kg

Date started:225 __ __ __ __ - __ __- __ __

Cytarabine (Ara-C)

yes no

226

Total prescribed dose :227 mg/m2 mg/kg

Date started:228 __ __ __ __ - __ __- __ __

Etoposide (VP-16, VePesid)

yes no

229

Total prescribed dose :230 mg/m2 mg/kg

Date started:231 __ __ __ __ - __ __- __ __

Fludarabine

yes no

232

Total prescribed dose :233 mg/m2 mg/kg

Date started:234 __ __ __ __ - __ __- __ __

Ifosfamide

yes no

235

Total prescribed dose :236 mg/m2 mg/kg

Date started:237 __ __ __ __ - __ __- __ __

Intrathecal therapy (chemotherapy)

yes no

238

Intrathecal cytarabine (IT Ara-C)

yes no

239

Total prescribed dose :240 mg/m2 mg/kg

Date started:241 __ __ __ __ - __ __- __ __

Intrathecal methotrexate (IT MTX)

yes no

242

Total prescribed dose :243 mg/m2 mg/kg

Date started:244 __ __ __ __ - __ __- __ __

Intrathecal thiotepa

yes no

245

Total prescribed dose :246 mg/m2 mg/kg

Date started:247 __ __ __ __ - __ __- __ __

Other intrathecal drug

yes no

248

Total prescribed dose :249 mg/m2 mg/kg

Date started:250 __ __ __ __ - __ __- __ __

Specify other intrathecal drug:251

Melphalan (L-Pam)

yes no

252

Total prescribed dose :253 mg/m2 mg/kg

Date started:254 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

255

Mitoxantrone (Novantrone)

yes no

256

Total prescribed dose :257 mg/m2 mg/kg

Date started:258 __ __ __ __ - __ __- __ __

Monoclonal antibody

yes no

259

Radio labeled mAb

yes no

260

Total prescribed dose of radioactive component:261 mCi MBq

Date started:262 __ __ __ __ - __ __- __ __

Tositumomab (Bexxar)

yes no

263

Ibritumomab tiuxetan (Zevalin)

yes no

264

Other radio labeled mAb

yes no

265

Specify other radio labeled mAb:266

Alemtuzumab (Campath)

yes no

267

Total prescribed dose :268 mg/m2 mg/kg

Date started:269 __ __ __ __ - __ __- __ __

Rituximab (Rituxan, anti CD20)

yes no

270

Total prescribed dose :271 mg/m2 mg/kg

Date started:272 __ __ __ __ - __ __- __ __

Gemtuzumab (Mylotarg, anti CD33)

yes no

273

Total prescribed dose :274 mg/m2 mg/kg

Date started:275 __ __ __ __ - __ __- __ __

Other mAb

yes no

276

Total prescribed dose :277 mg/m2 mg/kg

Date started:278 __ __ __ __ - __ __- __ __

Specify other mAb:279

Nitrosourea

yes no

280

Carmustine (BCNU)

yes no

281

Total prescribed dose :282 mg/m2 mg/kg

Date started:283 __ __ __ __ - __ __- __ __

CCNU (Lomustine)

yes no

284

Total prescribed dose :285 mg/m2 mg/kg

Date started:286 __ __ __ __ - __ __- __ __

Other nitrosourea

yes no

287

Total prescribed dose :288 mg/m2 mg/kg

Date started:289 __ __ __ __ - __ __- __ __

Specify other nitrosourea:290

Paclitaxel (Taxol, Xyotax)

yes no

291

Total prescribed dose :292 mg/m2 mg/kg

Date started:293 __ __ __ __ - __ __- __ __

Teniposide (VM26)

yes no

294

Total prescribed dose :295 mg/m2 mg/kg

Date started:296 __ __ __ __ - __ __- __ __

Thiotepa

yes no

297

Total prescribed dose :298 mg/m2 mg/kg

Date started:299 __ __ __ __ - __ __- __ __

Treosulfan

yes no

300

Total prescribed dose :301 mg/m2 mg/kg

Date started:302 __ __ __ __ - __ __- __ __

Tyrosine kinase inhibitors

yes no

303

Dasatinib (Sprycel)

yes no

304

Total prescribed dose :305 mg/m2 mg/kg

Date started:306 __ __ __ __ - __ __- __ __

Imatinib mesylate (STI571, Gleevec)

yes no

307

Total prescribed dose :308 mg/m2 mg/kg

Date started:309 __ __ __ __ - __ __- __ __

Nilotinib

yes no

310

Total prescribed dose :311 mg/m2 mg/kg

Date started:312 __ __ __ __ - __ __- __ __

Other drug

yes no

313

Total prescribed dose :314 mg/m2 mg/kg

Date started:315 __ __ __ __ - __ __- __ __

Specify other drug:316

GVHD Prophylaxis Questions: 317 - 343

Was GVHD prophylaxis planned / given?

yes no

317

ALG, ALS, ATG, ATS

yes no

318

Total dose:319 mg/kg

Specify source320

ATGAM (horse)

ATG - Fresenius (rabbit)

Thymoglobulin (rabbit)

Other

Specify other source:321

Corticosteroids (systemic)

yes no

322

Cyclosporine (CSA, Neoral, Sandimmune)

yes no

323

Cyclophosphamide (Cytoxan)

yes no

324

Extra-corporeal photopheresis (ECP)

yes no

325

FK 506 (Tacrolimus, Prograf)

yes no

326

In vivo monoclonal antibody

yes no

327

Alemtuzumab (Campath)

yes no

328

Anti CD 25 (Zenapax, Daclizumab, AntiTAC)

yes no

329

Specify:330

Etanercept (Enbrel)

yes no

331

Infliximab (Remicade)

yes no

332

Other in vivo monoclonal antibody

yes no

333

Specify antibody:334

In vivo immunotoxin

yes no

335

Specify immunotoxin:336

Methotrexate (MTX) (Amethopterin)

yes no

337

Mycophenolate mofetil (MMF) (CellCept)

yes no

338

Sirolimus (Rapamycin, Rapamune)

yes no

339

Blinded randomized trial

yes no

340

Specify trial agent:341

Other agent

yes no

342

Specify other agent:343

Other Toxicity Modifying Regimen Questions: 344 - 344

Was KGF (palifermin, Kepivance) started or is there a plan to use it?

Yes No masked trial

344

Post-HCT Disease Therapy Planned as of Day 0 Questions: 345 - 357

Is this HCT part of a planned multiple (sequential) graft / HCT protocol?

yes no

345

Is additional post-HCT therapy planned?

yes no

346

Bortezomib (Velcade)

yes no

347

Cellular therapy (e.g. DCI, DLI)

yes no

348

Dexamethasone

yes no

349

Intrathecal therapy (chemotherapy)

yes no

350

Tyrosine kinase inhibitor (e.g. imatinib mesylate)

yes no

351

Lenalidomide (Revlimid)

yes no

352

Local radiotherapy

yes no

353

Rituximab (Rituxan, MabThera)

yes no

354

Thalidomide (Thalomid)

yes no

355

Other therapy

yes no

356

Specify other therapy:357

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

OMB No: 0915-0310

Expiration Date: 1/31/2020

Public Burden Statement:  An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control
number.  The OMB control number for this project is 0915-0310.  Public reporting burden for this collection of information is estimated to average 1.0 hours per response, including the
time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other
aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance Officer, 5600 Fishers Lane, Room 10-29, Rockville, Maryland, 20857.

Center Identification

Recipient Identification

Specify the HSC source(s) for all prior HCTs:

Specify the institution that performed the last HCT:

Specify product type: 

A series of collections should be considered a single product when they are all from the same donor and use the same collection method and technique (and mobilization, if
applicable), even if the collections are performed on different days.

Questions 53 – 60 are for autologous HCT recipients only.  If other than autologous skip to question 61

Specify all agents used in the mobilization events reported above:

Specify all methods used to manipulate the product:

Performance score prior to the preparative regimen:

Specify which malignancy(ies) occurred:

Indicate the total prescribed cumulative dose for the preparative regimen:

Specify radio labeled mAb:

This section is to be completed for allogeneic HCTs only; autologous HCTs continue with question 344.

Specify:

Specify in vivo monoclonal antibody:

Optional for non-U.S. Centers

Questions 347 – 357 are optional for non­U.S. centers

Center: CRID: 

Form 2400 R5.0: Pre-Transplant Essential Data

CIBMTR Form 2400 revision 5.0 last updated January 2017
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 4 / 12



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

EBMT Code (CIC):

Hospital:

Unit (check only one)

Adult Pediatric

CIBMTR Research ID:  (CRID)

Recipient Data Questions: 1 - 10

Date of birth:1 __ __ __ __ - __ __- __ __

Sex

male female

2

Ethnicity3

Hispanic or Latino

Not Hispanic or Latino

Not applicable (not a resident of the USA)

Unknown

Race (1) Questions: 4 - 4

Race4

Zip or postal code for place of recipient’s residence: (USA recipients only)5

Is the recipient participating in a clinical trial?

yes no

6

Clinical Trials (1) Questions: 7 - 10

Study Sponsor7

Specify other sponsor:8

Study ID Number9

Subject ID:10

Hematopoietic Cellular Transplant (HCT) Questions: 11 - 28

Date of this HCT:11 __ __ __ __ - __ __- __ __

Was this the first HCT for this recipient?

yes no

12

Is a subsequent HCT planned as part of the overall treatment protocol (not as a reaction to post-HCT disease assessment)? (For autologous HCTs only)

yes no

13

Specify subsequent HCT planned

Autologous Allogeneic

14

Specify the number of prior HCTs:15

Autologous

yes no

16

Allogeneic, unrelated

yes no

17

Allogeneic, related

yes no

18

Syngeneic

yes no

19

Date of the last HCT: (just before current HCT)20 __ __ __ __ - __ __- __ __

Was the last HCT performed at a different institution?

yes no

21

Name:22

City:

State:

Country:

What was the HSC source for the last HCT?23

Autologous

Allogeneic, unrelated donor

Allogeneic, related donor

Reason for current HCT24

Date of graft failure / rejection:25 __ __ __ __ - __ __- __ __

Date of relapse:26 __ __ __ __ - __ __- __ __

Date of secondary malignancy:27 __ __ __ __ - __ __- __ __

Specify other reason:28

Donor Information Questions: 29 - 63

Multiple donors?

yes no

29

Specify number of donors:30

Donor Information for this HCT (1) Questions: 31 - 63

Specify donor31

NMDP cord blood unit ID:32

NMDP donor ID:33

Non-NMDP unrelated donor ID: (not applicable for related donors)34

Non-NMDP cord blood unit ID: (include related and autologous CBUs)35

Is the CBU ID also the ISBT DIN number?

yes no

36

Specify the ISBT DIN number:37

Registry or UCB Bank ID38

Specify other Registry or UCB Bank:39

Specify the related donor type40

Syngeneic (monozygotic twin)

HLA-identical sibling (may include non-monozygotic twin)

HLA-matched other relative

HLA-mismatched relative

Date of birth (donor / infant)

Known Unknown

41

Date of birth: (donor / infant)42 __ __ __ __ - __ __- __ __

Age (donor / infant)

Known Unknown

43

Age: (donor / infant)44 Months (use only if less than 1 year old)

years

Sex (donor / infant)

male female

45

Bone marrow

yes no

46

PBSC

yes no

47

Single cord blood unit

yes no

48

Other product

yes no

49

Specify other product type:50

Specify number of products infused from this donor:51

Specify the number of these products intended to achieve hematopoietic engraftment:52

Did the recipient have more than one mobilization event to acquire cells for HCT?

yes no

53

Specify the total number of mobilization events performed for this HCT: (regardless of the number of collections or which collections were
used for this HCT)

54

G-CSF

yes no

55

GM-CSF

yes no

56

Pegylated G-CSF

yes no

57

Plerixafor (Mozobil)

yes no

58

Other CXCR4 inhibitor

yes no

59

Combined with chemotherapy

yes no

60

Was this donor used for any prior HCTs?

yes no

61

Donor CMV-antibodies (IgG or Total) (Allogeneic HCTs only)62

Reactive

Non-reactive

Not done

Not applicable (cord blood unit)

Was plerixafor (Mozobil) given at any time prior to the preparative regimen? (Related HCTs only)

yes no Unknown

63

Consent Questions: 64 - 71

Has the recipient signed an IRB-approved consent form for submitting research data to the NMDP / CIBMTR?64

Yes (patient consented)

No (patient declined)

Not approached

Date form was signed:65 __ __ __ __ - __ __- __ __

Did the recipient give permission to be directly contacted for future research?66

Yes (patient provided permission)

No (patient declined)

Not approached

Date form was signed:67 __ __ __ __ - __ __- __ __

Has the recipient signed an IRB-approved consent form to donate research blood samples to the NMDP / CIBMTR?68

Yes (patient consented)

No (patient declined)

Not approached

Not applicable (center not participating)

Date form was signed:69 __ __ __ __ - __ __- __ __

Has the donor signed an IRB-approved consent form to donate research blood samples to the NMDP / CIBMTR? (Allogeneic donors only)70

Yes (donor consented)

No (donor declined)

Not approached

Not applicable (center not participating)

Date form was signed:71 __ __ __ __ - __ __- __ __

Product Processing / Manipulation Questions: 72 - 90

Was the product manipulated prior to infusion?

yes no

72

Specify portion manipulated

entire product portion of product

73

Washed

yes no

74

Diluted

yes no

75

Buffy coat enriched (buffy coat preparation)

yes no

76

B-cell reduced

yes no

77

CD8 reduced

yes no

78

Plasma reduced (removal)

yes no

79

RBC reduced

yes no

80

Cultured (ex-vivo expansion)

yes no

81

Genetic manipulation (gene transfer / transduction)

yes no

82

PUVA treated

yes no

83

CD34 enriched (CD34+ selection)

yes no

84

CD133 enriched

yes no

85

Monocyte enriched

yes no

86

Mononuclear cells enriched

yes no

87

T-cell depletion

yes no

88

Other cell manipulation

yes no

89

Specify other cell manipulation:90

Clinical Status of Recipient Prior to the Preparative Regimen (Conditioning) Questions: 91 - 94

What scale was used to determine the recipient’s functional status?91

Karnofsky (recipient age ≥ 16 years)

Lansky (recipient age < 16 years) 

Karnofsky Scale (recipient age ≥ 16 years)92

Lansky Scale (recipient age < 16 years)93

Recipient CMV-antibodies (IgG or Total)

Reactive Non-reactive Not done

94

Comorbid Conditions Questions: 95 - 155

Is there a history of mechanical ventilation?

yes no

95

Is there a history of proven invasive fungal infection?

yes no

96

Were there clinically significant co-existing diseases or organ impairment at time of patient assessment prior to preparative regimen? Source: Blood, 2005 Oct 15;106(8):2912-2919

yes no

97

Arrhythmia - For example, any history of atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias requiring treatment

yes no Unknown

98

Cardiac - Any history of coronary artery disease (one or more vessel-coronary artery stenosis requiring medical treatment, stent, or bypass graft), congestive heart
failure, myocardial infarction, OR ejection fraction ≤ 50% on the most recent test

yes no Unknown

99

Cerebrovascular disease - Any history of transient ischemic attack, subarachnoid hemorrhage or cerebrovascular accident

yes no Unknown

100

Diabetes - Requiring treatment with insulin or oral hypoglycemics in the last 4 weeks but not diet alone

yes no Unknown

101

Heart valve disease - Except asymptomatic mitral valve prolapse

yes no Unknown

102

Hepatic, mild ­ Chronic hepatitis, bilirubin > upper limit of normal to 1.5 × upper limit of normal, or AST/ALT > upper limit of normal to 2.5 × upper limit of normal at the
time of transplant OR any history of hepatitis B or hepatitis C infection

yes no Unknown

103

Hepatic, moderate / severe ­ Liver cirrhosis, bilirubin > 1.5 × upper limit of normal, or AST/ALT > 2.5 × upper limit of normal

yes no Unknown

104

Infection - For example, documented infection, fever of unknown origin, or pulmonary nodules requiring continuation of antimicrobial treatment after day 0

yes no Unknown

105

Inflammatory bowel disease ­ Any history of Crohn’s disease or ulcerative colitis requiring treatment

yes no Unknown

106

Obesity - Patients with a body mass index > 35 kg/m2  prior to the start of conditioning

yes no Unknown

107

Peptic ulcer - Any history of peptic ulcer confirmed by endoscopy and requiring treatment

yes no Unknown

108

Psychiatric disturbance - For example, depression, anxiety, bipolar disorder or schizophrenia requiring psychiatric consult or treatment in the last 4 weeks

yes no Unknown

109

Pulmonary, moderate - Corrected diffusion capacity of carbon monoxide and/or FEV1 66-80% or dyspnea on slight activity at transplant

yes no Unknown

110

Pulmonary, severe - Corrected diffusion capacity of carbon monoxide and/or FEV1 ≤ 65% or dyspnea at rest or requiring oxygen at transplant

yes no Unknown

111

Renal, moderate / severe ­ Serum creatinine > 2 mg/dL or > 177 µmol/L or on dialysis at transplant, OR prior renal transplantation

yes no Unknown

112

Rheumatologic - For example, any history of systemic lupus erythmatosis, rheumatoid arthritis, polymyositis, mixed connective tissue disease, or polymyalgia
rheumatica requiring treatment (do NOT include degenerative joint disease, osteoarthritis)

yes no Unknown

113

Solid tumor, prior ­ Treated at any time point in the patient’s past history, excluding non­melanoma skin cancer, leukemia, lymphoma or multiple myeloma

yes no Unknown

114

Breast cancer

yes no

115

Year of diagnosis:116

Central nervous system (CNS) malignancy (glioblastoma, astrocytoma)

yes no

117

Year of diagnosis:118

Gastrointestinal malignancy (colon, rectum, stomach, pancreas, intestine)

yes no

119

Year of diagnosis:120

Genitourinary malignancy (kidney, bladder, ovary, testicle, genitalia, uterus, cervix)

yes no

121

Year of diagnosis:122

Lung cancer

yes no

123

Year of diagnosis:124

Melanoma

yes no

125

Year of diagnosis:126

Oropharyngeal cancer (tongue, buccal mucosa)

yes no

127

Year of diagnosis:128

Sarcoma

yes no

129

Year of diagnosis:130

Thyroid cancer

yes no

131

Year of diagnosis:132

Other co-morbid condition

yes no Unknown

133

Specify other co-morbid condition:134

Was there a history of malignancy (hematologic or non-melanoma skin cancer) other than the primary disease for which this HCT is being performed?

yes no

135

Acute myeloid leukemia (AML / ANLL)

yes no

136

Year of diagnosis:137

Other leukemia, including ALL

yes no

138

Year of diagnosis:139

Specify leukemia:140

Clonal cytogenetic abnormality without leukemia or MDS

yes no

141

Year of diagnosis:142

Hodgkin disease

yes no

143

Year of diagnosis:144

Lymphoma or lymphoproliferative disease

yes no

145

Year of diagnosis:146

Was the tumor EBV positive?

yes no

147

Other skin malignancy (basal cell, squamous)

yes no

148

Year of diagnosis:149

Specify other skin malignancy:150

Myelodysplasia (MDS) / myeloproliferative (MPN) disorder

yes no

151

Year of diagnosis:152

Other prior malignancy

yes no

153

Year of diagnosis:154

Specify other prior malignancy:155

Pre-HCT Preparative Regimen (Conditioning) Questions: 156 - 316

Height at initiation of pre-HCT preparative regimen:156 inches centimeters

Actual weight at initiation of pre-HCT preparative regimen:157 pounds kilograms

Was a pre-HCT preparative regimen prescribed?

yes no

158

Classify the recipient’s prescribed preparative regimen (Allogeneic HCTs only)159

Myeloablative

Non-myeloablative (NST)

Reduced intensity (RIC)

Date pre-HCT preparative regimen began: (irradiation or drugs)160 __ __ __ __ - __ __- __ __ (Use earliest date from question 164 radiation, or 169 - 316 chemotherapy)

Was irradiation planned as part of the pre-HCT preparative regimen?

yes no

161

What was the prescribed radiation field?162

Total body

Total body by intensity-modulated radiation therapy (IMRT)

Total lymphoid or nodal regions

Thoracoabdominal region

Total prescribed dose: (dose per fraction x total number of fractions) 163 Gy cGy

Date started:164 __ __ __ __ - __ __- __ __

Was the radiation fractionated?

yes no

165

Prescribed dose per fraction:166 Gy cGy

Number of days: (include "rest" days)167

Total number of fractions:168

ALG, ALS, ATG, ATS

yes no

169

Total prescribed dose:170 mg/kg

Date started:171 __ __ __ __ - __ __- __ __

Specify source172

ATGAM (horse)

ATG - Fresenius (rabbit)

Thymoglobulin (rabbit)

Other

Specify other source:173

Anthracycline

yes no

174

Daunorubicin

yes no

175

Total prescribed dose :176 mg/m2 mg/kg

Date started:177 __ __ __ __ - __ __- __ __

Doxorubicin (Adriamycin)

yes no

178

Total prescribed dose :179 mg/m2 mg/kg

Date started:180 __ __ __ __ - __ __- __ __

Idarubicin

yes no

181

Total prescribed dose :182 mg/m2 mg/kg

Date started:183 __ __ __ __ - __ __- __ __

Rubidazone

yes no

184

Total prescribed dose :185 mg/m2 mg/kg

Date started:186 __ __ __ __ - __ __- __ __

Other anthracycline

yes no

187

Total prescribed dose :188 mg/m2 mg/kg

Date started:189 __ __ __ __ - __ __- __ __

Specify other anthracycline:190

Bleomycin (BLM, Blenoxane)

yes no

191

Total prescribed dose :192 mg/m2 mg/kg

Date started:193 __ __ __ __ - __ __- __ __

Busulfan (Myleran)

yes no

194

Total prescribed dose :195 mg/m2

mg/kg

Target total AUC (µmol x min/L)

Date started:196 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

197

Carboplatin

yes no

198

Total prescribed dose :199 mg/m2 mg/kg

Date started:200 __ __ __ __ - __ __- __ __

Were pharmacokinetics performed to determine preparative regimen drug dosing?

yes no

201

Specify the target AUC:202 mg/mL/minute

Cisplatin (Platinol, CDDP)

yes no

203

Total prescribed dose :204 mg/m2 mg/kg

Date started:205 __ __ __ __ - __ __- __ __

Cladribine (2-CdA, Leustatin)

yes no

206

Total prescribed dose :207 mg/m2 mg/kg

Date started:208 __ __ __ __ - __ __- __ __

Corticosteroids (excluding anti-nausea medication)

yes no

209

Methylprednisolone (Solu-Medrol)

yes no

210

Total prescribed dose :211 mg/m2 mg/kg

Date started:212 __ __ __ __ - __ __- __ __

Prednisone

yes no

213

Total prescribed dose :214 mg/m2 mg/kg

Date started:215 __ __ __ __ - __ __- __ __

Dexamethasone

yes no

216

Total prescribed dose :217 mg/m2 mg/kg

Date started:218 __ __ __ __ - __ __- __ __

Other corticosteroid

yes no

219

Total prescribed dose :220 mg/m2 mg/kg

Date started:221 __ __ __ __ - __ __- __ __

Specify other corticosteroid:222

Cyclophosphamide (Cytoxan)

yes no

223

Total prescribed dose :224 mg/m2 mg/kg

Date started:225 __ __ __ __ - __ __- __ __

Cytarabine (Ara-C)

yes no

226

Total prescribed dose :227 mg/m2 mg/kg

Date started:228 __ __ __ __ - __ __- __ __

Etoposide (VP-16, VePesid)

yes no

229

Total prescribed dose :230 mg/m2 mg/kg

Date started:231 __ __ __ __ - __ __- __ __

Fludarabine

yes no

232

Total prescribed dose :233 mg/m2 mg/kg

Date started:234 __ __ __ __ - __ __- __ __

Ifosfamide

yes no

235

Total prescribed dose :236 mg/m2 mg/kg

Date started:237 __ __ __ __ - __ __- __ __

Intrathecal therapy (chemotherapy)

yes no

238

Intrathecal cytarabine (IT Ara-C)

yes no

239

Total prescribed dose :240 mg/m2 mg/kg

Date started:241 __ __ __ __ - __ __- __ __

Intrathecal methotrexate (IT MTX)

yes no

242

Total prescribed dose :243 mg/m2 mg/kg

Date started:244 __ __ __ __ - __ __- __ __

Intrathecal thiotepa

yes no

245

Total prescribed dose :246 mg/m2 mg/kg

Date started:247 __ __ __ __ - __ __- __ __

Other intrathecal drug

yes no

248

Total prescribed dose :249 mg/m2 mg/kg

Date started:250 __ __ __ __ - __ __- __ __

Specify other intrathecal drug:251

Melphalan (L-Pam)

yes no

252

Total prescribed dose :253 mg/m2 mg/kg

Date started:254 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

255

Mitoxantrone (Novantrone)

yes no

256

Total prescribed dose :257 mg/m2 mg/kg

Date started:258 __ __ __ __ - __ __- __ __

Monoclonal antibody

yes no

259

Radio labeled mAb

yes no

260

Total prescribed dose of radioactive component:261 mCi MBq

Date started:262 __ __ __ __ - __ __- __ __

Tositumomab (Bexxar)

yes no

263

Ibritumomab tiuxetan (Zevalin)

yes no

264

Other radio labeled mAb

yes no

265

Specify other radio labeled mAb:266

Alemtuzumab (Campath)

yes no

267

Total prescribed dose :268 mg/m2 mg/kg

Date started:269 __ __ __ __ - __ __- __ __

Rituximab (Rituxan, anti CD20)

yes no

270

Total prescribed dose :271 mg/m2 mg/kg

Date started:272 __ __ __ __ - __ __- __ __

Gemtuzumab (Mylotarg, anti CD33)

yes no

273

Total prescribed dose :274 mg/m2 mg/kg

Date started:275 __ __ __ __ - __ __- __ __

Other mAb

yes no

276

Total prescribed dose :277 mg/m2 mg/kg

Date started:278 __ __ __ __ - __ __- __ __

Specify other mAb:279

Nitrosourea

yes no

280

Carmustine (BCNU)

yes no

281

Total prescribed dose :282 mg/m2 mg/kg

Date started:283 __ __ __ __ - __ __- __ __

CCNU (Lomustine)

yes no

284

Total prescribed dose :285 mg/m2 mg/kg

Date started:286 __ __ __ __ - __ __- __ __

Other nitrosourea

yes no

287

Total prescribed dose :288 mg/m2 mg/kg

Date started:289 __ __ __ __ - __ __- __ __

Specify other nitrosourea:290

Paclitaxel (Taxol, Xyotax)

yes no

291

Total prescribed dose :292 mg/m2 mg/kg

Date started:293 __ __ __ __ - __ __- __ __

Teniposide (VM26)

yes no

294

Total prescribed dose :295 mg/m2 mg/kg

Date started:296 __ __ __ __ - __ __- __ __

Thiotepa

yes no

297

Total prescribed dose :298 mg/m2 mg/kg

Date started:299 __ __ __ __ - __ __- __ __

Treosulfan

yes no

300

Total prescribed dose :301 mg/m2 mg/kg

Date started:302 __ __ __ __ - __ __- __ __

Tyrosine kinase inhibitors

yes no

303

Dasatinib (Sprycel)

yes no

304

Total prescribed dose :305 mg/m2 mg/kg

Date started:306 __ __ __ __ - __ __- __ __

Imatinib mesylate (STI571, Gleevec)

yes no

307

Total prescribed dose :308 mg/m2 mg/kg

Date started:309 __ __ __ __ - __ __- __ __

Nilotinib

yes no

310

Total prescribed dose :311 mg/m2 mg/kg

Date started:312 __ __ __ __ - __ __- __ __

Other drug

yes no

313

Total prescribed dose :314 mg/m2 mg/kg

Date started:315 __ __ __ __ - __ __- __ __

Specify other drug:316

GVHD Prophylaxis Questions: 317 - 343

Was GVHD prophylaxis planned / given?

yes no

317

ALG, ALS, ATG, ATS

yes no

318

Total dose:319 mg/kg

Specify source320

ATGAM (horse)

ATG - Fresenius (rabbit)

Thymoglobulin (rabbit)

Other

Specify other source:321

Corticosteroids (systemic)

yes no

322

Cyclosporine (CSA, Neoral, Sandimmune)

yes no

323

Cyclophosphamide (Cytoxan)

yes no

324

Extra-corporeal photopheresis (ECP)

yes no

325

FK 506 (Tacrolimus, Prograf)

yes no

326

In vivo monoclonal antibody

yes no

327

Alemtuzumab (Campath)

yes no

328

Anti CD 25 (Zenapax, Daclizumab, AntiTAC)

yes no

329

Specify:330

Etanercept (Enbrel)

yes no

331

Infliximab (Remicade)

yes no

332

Other in vivo monoclonal antibody

yes no

333

Specify antibody:334

In vivo immunotoxin

yes no

335

Specify immunotoxin:336

Methotrexate (MTX) (Amethopterin)

yes no

337

Mycophenolate mofetil (MMF) (CellCept)

yes no

338

Sirolimus (Rapamycin, Rapamune)

yes no

339

Blinded randomized trial

yes no

340

Specify trial agent:341

Other agent

yes no

342

Specify other agent:343

Other Toxicity Modifying Regimen Questions: 344 - 344

Was KGF (palifermin, Kepivance) started or is there a plan to use it?

Yes No masked trial

344

Post-HCT Disease Therapy Planned as of Day 0 Questions: 345 - 357

Is this HCT part of a planned multiple (sequential) graft / HCT protocol?

yes no

345

Is additional post-HCT therapy planned?

yes no

346

Bortezomib (Velcade)

yes no

347

Cellular therapy (e.g. DCI, DLI)

yes no

348

Dexamethasone

yes no

349

Intrathecal therapy (chemotherapy)

yes no

350

Tyrosine kinase inhibitor (e.g. imatinib mesylate)

yes no

351

Lenalidomide (Revlimid)

yes no

352

Local radiotherapy

yes no

353

Rituximab (Rituxan, MabThera)

yes no

354

Thalidomide (Thalomid)

yes no

355

Other therapy

yes no

356

Specify other therapy:357

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

OMB No: 0915-0310

Expiration Date: 1/31/2020

Public Burden Statement:  An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control
number.  The OMB control number for this project is 0915-0310.  Public reporting burden for this collection of information is estimated to average 1.0 hours per response, including the
time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other
aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance Officer, 5600 Fishers Lane, Room 10-29, Rockville, Maryland, 20857.

Center Identification

Recipient Identification

Specify the HSC source(s) for all prior HCTs:

Specify the institution that performed the last HCT:

Specify product type: 

A series of collections should be considered a single product when they are all from the same donor and use the same collection method and technique (and mobilization, if
applicable), even if the collections are performed on different days.

Questions 53 – 60 are for autologous HCT recipients only.  If other than autologous skip to question 61

Specify all agents used in the mobilization events reported above:

Specify all methods used to manipulate the product:

Performance score prior to the preparative regimen:

Specify which malignancy(ies) occurred:

Indicate the total prescribed cumulative dose for the preparative regimen:

Specify radio labeled mAb:

This section is to be completed for allogeneic HCTs only; autologous HCTs continue with question 344.

Specify:

Specify in vivo monoclonal antibody:

Optional for non-U.S. Centers

Questions 347 – 357 are optional for non­U.S. centers

Center: CRID: 

Form 2400 R5.0: Pre-Transplant Essential Data

CIBMTR Form 2400 revision 5.0 last updated January 2017
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 5 / 12



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

EBMT Code (CIC):

Hospital:

Unit (check only one)

Adult Pediatric

CIBMTR Research ID:  (CRID)

Recipient Data Questions: 1 - 10

Date of birth:1 __ __ __ __ - __ __- __ __

Sex

male female

2

Ethnicity3

Hispanic or Latino

Not Hispanic or Latino

Not applicable (not a resident of the USA)

Unknown

Race (1) Questions: 4 - 4

Race4

Zip or postal code for place of recipient’s residence: (USA recipients only)5

Is the recipient participating in a clinical trial?

yes no

6

Clinical Trials (1) Questions: 7 - 10

Study Sponsor7

Specify other sponsor:8

Study ID Number9

Subject ID:10

Hematopoietic Cellular Transplant (HCT) Questions: 11 - 28

Date of this HCT:11 __ __ __ __ - __ __- __ __

Was this the first HCT for this recipient?

yes no

12

Is a subsequent HCT planned as part of the overall treatment protocol (not as a reaction to post-HCT disease assessment)? (For autologous HCTs only)

yes no

13

Specify subsequent HCT planned

Autologous Allogeneic

14

Specify the number of prior HCTs:15

Autologous

yes no

16

Allogeneic, unrelated

yes no

17

Allogeneic, related

yes no

18

Syngeneic

yes no

19

Date of the last HCT: (just before current HCT)20 __ __ __ __ - __ __- __ __

Was the last HCT performed at a different institution?

yes no

21

Name:22

City:

State:

Country:

What was the HSC source for the last HCT?23

Autologous

Allogeneic, unrelated donor

Allogeneic, related donor

Reason for current HCT24

Date of graft failure / rejection:25 __ __ __ __ - __ __- __ __

Date of relapse:26 __ __ __ __ - __ __- __ __

Date of secondary malignancy:27 __ __ __ __ - __ __- __ __

Specify other reason:28

Donor Information Questions: 29 - 63

Multiple donors?

yes no

29

Specify number of donors:30

Donor Information for this HCT (1) Questions: 31 - 63

Specify donor31

NMDP cord blood unit ID:32

NMDP donor ID:33

Non-NMDP unrelated donor ID: (not applicable for related donors)34

Non-NMDP cord blood unit ID: (include related and autologous CBUs)35

Is the CBU ID also the ISBT DIN number?

yes no

36

Specify the ISBT DIN number:37

Registry or UCB Bank ID38

Specify other Registry or UCB Bank:39

Specify the related donor type40

Syngeneic (monozygotic twin)

HLA-identical sibling (may include non-monozygotic twin)

HLA-matched other relative

HLA-mismatched relative

Date of birth (donor / infant)

Known Unknown

41

Date of birth: (donor / infant)42 __ __ __ __ - __ __- __ __

Age (donor / infant)

Known Unknown

43

Age: (donor / infant)44 Months (use only if less than 1 year old)

years

Sex (donor / infant)

male female

45

Bone marrow

yes no

46

PBSC

yes no

47

Single cord blood unit

yes no

48

Other product

yes no

49

Specify other product type:50

Specify number of products infused from this donor:51

Specify the number of these products intended to achieve hematopoietic engraftment:52

Did the recipient have more than one mobilization event to acquire cells for HCT?

yes no

53

Specify the total number of mobilization events performed for this HCT: (regardless of the number of collections or which collections were
used for this HCT)

54

G-CSF

yes no

55

GM-CSF

yes no

56

Pegylated G-CSF

yes no

57

Plerixafor (Mozobil)

yes no

58

Other CXCR4 inhibitor

yes no

59

Combined with chemotherapy

yes no

60

Was this donor used for any prior HCTs?

yes no

61

Donor CMV-antibodies (IgG or Total) (Allogeneic HCTs only)62

Reactive

Non-reactive

Not done

Not applicable (cord blood unit)

Was plerixafor (Mozobil) given at any time prior to the preparative regimen? (Related HCTs only)

yes no Unknown

63

Consent Questions: 64 - 71

Has the recipient signed an IRB-approved consent form for submitting research data to the NMDP / CIBMTR?64

Yes (patient consented)

No (patient declined)

Not approached

Date form was signed:65 __ __ __ __ - __ __- __ __

Did the recipient give permission to be directly contacted for future research?66

Yes (patient provided permission)

No (patient declined)

Not approached

Date form was signed:67 __ __ __ __ - __ __- __ __

Has the recipient signed an IRB-approved consent form to donate research blood samples to the NMDP / CIBMTR?68

Yes (patient consented)

No (patient declined)

Not approached

Not applicable (center not participating)

Date form was signed:69 __ __ __ __ - __ __- __ __

Has the donor signed an IRB-approved consent form to donate research blood samples to the NMDP / CIBMTR? (Allogeneic donors only)70

Yes (donor consented)

No (donor declined)

Not approached

Not applicable (center not participating)

Date form was signed:71 __ __ __ __ - __ __- __ __

Product Processing / Manipulation Questions: 72 - 90

Was the product manipulated prior to infusion?

yes no

72

Specify portion manipulated

entire product portion of product

73

Washed

yes no

74

Diluted

yes no

75

Buffy coat enriched (buffy coat preparation)

yes no

76

B-cell reduced

yes no

77

CD8 reduced

yes no

78

Plasma reduced (removal)

yes no

79

RBC reduced

yes no

80

Cultured (ex-vivo expansion)

yes no

81

Genetic manipulation (gene transfer / transduction)

yes no

82

PUVA treated

yes no

83

CD34 enriched (CD34+ selection)

yes no

84

CD133 enriched

yes no

85

Monocyte enriched

yes no

86

Mononuclear cells enriched

yes no

87

T-cell depletion

yes no

88

Other cell manipulation

yes no

89

Specify other cell manipulation:90

Clinical Status of Recipient Prior to the Preparative Regimen (Conditioning) Questions: 91 - 94

What scale was used to determine the recipient’s functional status?91

Karnofsky (recipient age ≥ 16 years)

Lansky (recipient age < 16 years) 

Karnofsky Scale (recipient age ≥ 16 years)92

Lansky Scale (recipient age < 16 years)93

Recipient CMV-antibodies (IgG or Total)

Reactive Non-reactive Not done

94

Comorbid Conditions Questions: 95 - 155

Is there a history of mechanical ventilation?

yes no

95

Is there a history of proven invasive fungal infection?

yes no

96

Were there clinically significant co-existing diseases or organ impairment at time of patient assessment prior to preparative regimen? Source: Blood, 2005 Oct 15;106(8):2912-2919

yes no

97

Arrhythmia - For example, any history of atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias requiring treatment

yes no Unknown

98

Cardiac - Any history of coronary artery disease (one or more vessel-coronary artery stenosis requiring medical treatment, stent, or bypass graft), congestive heart
failure, myocardial infarction, OR ejection fraction ≤ 50% on the most recent test

yes no Unknown

99

Cerebrovascular disease - Any history of transient ischemic attack, subarachnoid hemorrhage or cerebrovascular accident

yes no Unknown

100

Diabetes - Requiring treatment with insulin or oral hypoglycemics in the last 4 weeks but not diet alone

yes no Unknown

101

Heart valve disease - Except asymptomatic mitral valve prolapse

yes no Unknown

102

Hepatic, mild ­ Chronic hepatitis, bilirubin > upper limit of normal to 1.5 × upper limit of normal, or AST/ALT > upper limit of normal to 2.5 × upper limit of normal at the
time of transplant OR any history of hepatitis B or hepatitis C infection

yes no Unknown

103

Hepatic, moderate / severe ­ Liver cirrhosis, bilirubin > 1.5 × upper limit of normal, or AST/ALT > 2.5 × upper limit of normal

yes no Unknown

104

Infection - For example, documented infection, fever of unknown origin, or pulmonary nodules requiring continuation of antimicrobial treatment after day 0

yes no Unknown

105

Inflammatory bowel disease ­ Any history of Crohn’s disease or ulcerative colitis requiring treatment

yes no Unknown

106

Obesity - Patients with a body mass index > 35 kg/m2  prior to the start of conditioning

yes no Unknown

107

Peptic ulcer - Any history of peptic ulcer confirmed by endoscopy and requiring treatment

yes no Unknown

108

Psychiatric disturbance - For example, depression, anxiety, bipolar disorder or schizophrenia requiring psychiatric consult or treatment in the last 4 weeks

yes no Unknown

109

Pulmonary, moderate - Corrected diffusion capacity of carbon monoxide and/or FEV1 66-80% or dyspnea on slight activity at transplant

yes no Unknown

110

Pulmonary, severe - Corrected diffusion capacity of carbon monoxide and/or FEV1 ≤ 65% or dyspnea at rest or requiring oxygen at transplant

yes no Unknown

111

Renal, moderate / severe ­ Serum creatinine > 2 mg/dL or > 177 µmol/L or on dialysis at transplant, OR prior renal transplantation

yes no Unknown

112

Rheumatologic - For example, any history of systemic lupus erythmatosis, rheumatoid arthritis, polymyositis, mixed connective tissue disease, or polymyalgia
rheumatica requiring treatment (do NOT include degenerative joint disease, osteoarthritis)

yes no Unknown

113

Solid tumor, prior ­ Treated at any time point in the patient’s past history, excluding non­melanoma skin cancer, leukemia, lymphoma or multiple myeloma

yes no Unknown

114

Breast cancer

yes no

115

Year of diagnosis:116

Central nervous system (CNS) malignancy (glioblastoma, astrocytoma)

yes no

117

Year of diagnosis:118

Gastrointestinal malignancy (colon, rectum, stomach, pancreas, intestine)

yes no

119

Year of diagnosis:120

Genitourinary malignancy (kidney, bladder, ovary, testicle, genitalia, uterus, cervix)

yes no

121

Year of diagnosis:122

Lung cancer

yes no

123

Year of diagnosis:124

Melanoma

yes no

125

Year of diagnosis:126

Oropharyngeal cancer (tongue, buccal mucosa)

yes no

127

Year of diagnosis:128

Sarcoma

yes no

129

Year of diagnosis:130

Thyroid cancer

yes no

131

Year of diagnosis:132

Other co-morbid condition

yes no Unknown

133

Specify other co-morbid condition:134

Was there a history of malignancy (hematologic or non-melanoma skin cancer) other than the primary disease for which this HCT is being performed?

yes no

135

Acute myeloid leukemia (AML / ANLL)

yes no

136

Year of diagnosis:137

Other leukemia, including ALL

yes no

138

Year of diagnosis:139

Specify leukemia:140

Clonal cytogenetic abnormality without leukemia or MDS

yes no

141

Year of diagnosis:142

Hodgkin disease

yes no

143

Year of diagnosis:144

Lymphoma or lymphoproliferative disease

yes no

145

Year of diagnosis:146

Was the tumor EBV positive?

yes no

147

Other skin malignancy (basal cell, squamous)

yes no

148

Year of diagnosis:149

Specify other skin malignancy:150

Myelodysplasia (MDS) / myeloproliferative (MPN) disorder

yes no

151

Year of diagnosis:152

Other prior malignancy

yes no

153

Year of diagnosis:154

Specify other prior malignancy:155

Pre-HCT Preparative Regimen (Conditioning) Questions: 156 - 316

Height at initiation of pre-HCT preparative regimen:156 inches centimeters

Actual weight at initiation of pre-HCT preparative regimen:157 pounds kilograms

Was a pre-HCT preparative regimen prescribed?

yes no

158

Classify the recipient’s prescribed preparative regimen (Allogeneic HCTs only)159

Myeloablative

Non-myeloablative (NST)

Reduced intensity (RIC)

Date pre-HCT preparative regimen began: (irradiation or drugs)160 __ __ __ __ - __ __- __ __ (Use earliest date from question 164 radiation, or 169 - 316 chemotherapy)

Was irradiation planned as part of the pre-HCT preparative regimen?

yes no

161

What was the prescribed radiation field?162

Total body

Total body by intensity-modulated radiation therapy (IMRT)

Total lymphoid or nodal regions

Thoracoabdominal region

Total prescribed dose: (dose per fraction x total number of fractions) 163 Gy cGy

Date started:164 __ __ __ __ - __ __- __ __

Was the radiation fractionated?

yes no

165

Prescribed dose per fraction:166 Gy cGy

Number of days: (include "rest" days)167

Total number of fractions:168

ALG, ALS, ATG, ATS

yes no

169

Total prescribed dose:170 mg/kg

Date started:171 __ __ __ __ - __ __- __ __

Specify source172

ATGAM (horse)

ATG - Fresenius (rabbit)

Thymoglobulin (rabbit)

Other

Specify other source:173

Anthracycline

yes no

174

Daunorubicin

yes no

175

Total prescribed dose :176 mg/m2 mg/kg

Date started:177 __ __ __ __ - __ __- __ __

Doxorubicin (Adriamycin)

yes no

178

Total prescribed dose :179 mg/m2 mg/kg

Date started:180 __ __ __ __ - __ __- __ __

Idarubicin

yes no

181

Total prescribed dose :182 mg/m2 mg/kg

Date started:183 __ __ __ __ - __ __- __ __

Rubidazone

yes no

184

Total prescribed dose :185 mg/m2 mg/kg

Date started:186 __ __ __ __ - __ __- __ __

Other anthracycline

yes no

187

Total prescribed dose :188 mg/m2 mg/kg

Date started:189 __ __ __ __ - __ __- __ __

Specify other anthracycline:190

Bleomycin (BLM, Blenoxane)

yes no

191

Total prescribed dose :192 mg/m2 mg/kg

Date started:193 __ __ __ __ - __ __- __ __

Busulfan (Myleran)

yes no

194

Total prescribed dose :195 mg/m2

mg/kg

Target total AUC (µmol x min/L)

Date started:196 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

197

Carboplatin

yes no

198

Total prescribed dose :199 mg/m2 mg/kg

Date started:200 __ __ __ __ - __ __- __ __

Were pharmacokinetics performed to determine preparative regimen drug dosing?

yes no

201

Specify the target AUC:202 mg/mL/minute

Cisplatin (Platinol, CDDP)

yes no

203

Total prescribed dose :204 mg/m2 mg/kg

Date started:205 __ __ __ __ - __ __- __ __

Cladribine (2-CdA, Leustatin)

yes no

206

Total prescribed dose :207 mg/m2 mg/kg

Date started:208 __ __ __ __ - __ __- __ __

Corticosteroids (excluding anti-nausea medication)

yes no

209

Methylprednisolone (Solu-Medrol)

yes no

210

Total prescribed dose :211 mg/m2 mg/kg

Date started:212 __ __ __ __ - __ __- __ __

Prednisone

yes no

213

Total prescribed dose :214 mg/m2 mg/kg

Date started:215 __ __ __ __ - __ __- __ __

Dexamethasone

yes no

216

Total prescribed dose :217 mg/m2 mg/kg

Date started:218 __ __ __ __ - __ __- __ __

Other corticosteroid

yes no

219

Total prescribed dose :220 mg/m2 mg/kg

Date started:221 __ __ __ __ - __ __- __ __

Specify other corticosteroid:222

Cyclophosphamide (Cytoxan)

yes no

223

Total prescribed dose :224 mg/m2 mg/kg

Date started:225 __ __ __ __ - __ __- __ __

Cytarabine (Ara-C)

yes no

226

Total prescribed dose :227 mg/m2 mg/kg

Date started:228 __ __ __ __ - __ __- __ __

Etoposide (VP-16, VePesid)

yes no

229

Total prescribed dose :230 mg/m2 mg/kg

Date started:231 __ __ __ __ - __ __- __ __

Fludarabine

yes no

232

Total prescribed dose :233 mg/m2 mg/kg

Date started:234 __ __ __ __ - __ __- __ __

Ifosfamide

yes no

235

Total prescribed dose :236 mg/m2 mg/kg

Date started:237 __ __ __ __ - __ __- __ __

Intrathecal therapy (chemotherapy)

yes no

238

Intrathecal cytarabine (IT Ara-C)

yes no

239

Total prescribed dose :240 mg/m2 mg/kg

Date started:241 __ __ __ __ - __ __- __ __

Intrathecal methotrexate (IT MTX)

yes no

242

Total prescribed dose :243 mg/m2 mg/kg

Date started:244 __ __ __ __ - __ __- __ __

Intrathecal thiotepa

yes no

245

Total prescribed dose :246 mg/m2 mg/kg

Date started:247 __ __ __ __ - __ __- __ __

Other intrathecal drug

yes no

248

Total prescribed dose :249 mg/m2 mg/kg

Date started:250 __ __ __ __ - __ __- __ __

Specify other intrathecal drug:251

Melphalan (L-Pam)

yes no

252

Total prescribed dose :253 mg/m2 mg/kg

Date started:254 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

255

Mitoxantrone (Novantrone)

yes no

256

Total prescribed dose :257 mg/m2 mg/kg

Date started:258 __ __ __ __ - __ __- __ __

Monoclonal antibody

yes no

259

Radio labeled mAb

yes no

260

Total prescribed dose of radioactive component:261 mCi MBq

Date started:262 __ __ __ __ - __ __- __ __

Tositumomab (Bexxar)

yes no

263

Ibritumomab tiuxetan (Zevalin)

yes no

264

Other radio labeled mAb

yes no

265

Specify other radio labeled mAb:266

Alemtuzumab (Campath)

yes no

267

Total prescribed dose :268 mg/m2 mg/kg

Date started:269 __ __ __ __ - __ __- __ __

Rituximab (Rituxan, anti CD20)

yes no

270

Total prescribed dose :271 mg/m2 mg/kg

Date started:272 __ __ __ __ - __ __- __ __

Gemtuzumab (Mylotarg, anti CD33)

yes no

273

Total prescribed dose :274 mg/m2 mg/kg

Date started:275 __ __ __ __ - __ __- __ __

Other mAb

yes no

276

Total prescribed dose :277 mg/m2 mg/kg

Date started:278 __ __ __ __ - __ __- __ __

Specify other mAb:279

Nitrosourea

yes no

280

Carmustine (BCNU)

yes no

281

Total prescribed dose :282 mg/m2 mg/kg

Date started:283 __ __ __ __ - __ __- __ __

CCNU (Lomustine)

yes no

284

Total prescribed dose :285 mg/m2 mg/kg

Date started:286 __ __ __ __ - __ __- __ __

Other nitrosourea

yes no

287

Total prescribed dose :288 mg/m2 mg/kg

Date started:289 __ __ __ __ - __ __- __ __

Specify other nitrosourea:290

Paclitaxel (Taxol, Xyotax)

yes no

291

Total prescribed dose :292 mg/m2 mg/kg

Date started:293 __ __ __ __ - __ __- __ __

Teniposide (VM26)

yes no

294

Total prescribed dose :295 mg/m2 mg/kg

Date started:296 __ __ __ __ - __ __- __ __

Thiotepa

yes no

297

Total prescribed dose :298 mg/m2 mg/kg

Date started:299 __ __ __ __ - __ __- __ __

Treosulfan

yes no

300

Total prescribed dose :301 mg/m2 mg/kg

Date started:302 __ __ __ __ - __ __- __ __

Tyrosine kinase inhibitors

yes no

303

Dasatinib (Sprycel)

yes no

304

Total prescribed dose :305 mg/m2 mg/kg

Date started:306 __ __ __ __ - __ __- __ __

Imatinib mesylate (STI571, Gleevec)

yes no

307

Total prescribed dose :308 mg/m2 mg/kg

Date started:309 __ __ __ __ - __ __- __ __

Nilotinib

yes no

310

Total prescribed dose :311 mg/m2 mg/kg

Date started:312 __ __ __ __ - __ __- __ __

Other drug

yes no

313

Total prescribed dose :314 mg/m2 mg/kg

Date started:315 __ __ __ __ - __ __- __ __

Specify other drug:316

GVHD Prophylaxis Questions: 317 - 343

Was GVHD prophylaxis planned / given?

yes no

317

ALG, ALS, ATG, ATS

yes no

318

Total dose:319 mg/kg

Specify source320

ATGAM (horse)

ATG - Fresenius (rabbit)

Thymoglobulin (rabbit)

Other

Specify other source:321

Corticosteroids (systemic)

yes no

322

Cyclosporine (CSA, Neoral, Sandimmune)

yes no

323

Cyclophosphamide (Cytoxan)

yes no

324

Extra-corporeal photopheresis (ECP)

yes no

325

FK 506 (Tacrolimus, Prograf)

yes no

326

In vivo monoclonal antibody

yes no

327

Alemtuzumab (Campath)

yes no

328

Anti CD 25 (Zenapax, Daclizumab, AntiTAC)

yes no

329

Specify:330

Etanercept (Enbrel)

yes no

331

Infliximab (Remicade)

yes no

332

Other in vivo monoclonal antibody

yes no

333

Specify antibody:334

In vivo immunotoxin

yes no

335

Specify immunotoxin:336

Methotrexate (MTX) (Amethopterin)

yes no

337

Mycophenolate mofetil (MMF) (CellCept)

yes no

338

Sirolimus (Rapamycin, Rapamune)

yes no

339

Blinded randomized trial

yes no

340

Specify trial agent:341

Other agent

yes no

342

Specify other agent:343

Other Toxicity Modifying Regimen Questions: 344 - 344

Was KGF (palifermin, Kepivance) started or is there a plan to use it?

Yes No masked trial

344

Post-HCT Disease Therapy Planned as of Day 0 Questions: 345 - 357

Is this HCT part of a planned multiple (sequential) graft / HCT protocol?

yes no

345

Is additional post-HCT therapy planned?

yes no

346

Bortezomib (Velcade)

yes no

347

Cellular therapy (e.g. DCI, DLI)

yes no

348

Dexamethasone

yes no

349

Intrathecal therapy (chemotherapy)

yes no

350

Tyrosine kinase inhibitor (e.g. imatinib mesylate)

yes no

351

Lenalidomide (Revlimid)

yes no

352

Local radiotherapy

yes no

353

Rituximab (Rituxan, MabThera)

yes no

354

Thalidomide (Thalomid)

yes no

355

Other therapy

yes no

356

Specify other therapy:357

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

OMB No: 0915-0310

Expiration Date: 1/31/2020

Public Burden Statement:  An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control
number.  The OMB control number for this project is 0915-0310.  Public reporting burden for this collection of information is estimated to average 1.0 hours per response, including the
time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other
aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance Officer, 5600 Fishers Lane, Room 10-29, Rockville, Maryland, 20857.

Center Identification

Recipient Identification

Specify the HSC source(s) for all prior HCTs:

Specify the institution that performed the last HCT:

Specify product type: 

A series of collections should be considered a single product when they are all from the same donor and use the same collection method and technique (and mobilization, if
applicable), even if the collections are performed on different days.

Questions 53 – 60 are for autologous HCT recipients only.  If other than autologous skip to question 61

Specify all agents used in the mobilization events reported above:

Specify all methods used to manipulate the product:

Performance score prior to the preparative regimen:

Specify which malignancy(ies) occurred:

Indicate the total prescribed cumulative dose for the preparative regimen:

Specify radio labeled mAb:

This section is to be completed for allogeneic HCTs only; autologous HCTs continue with question 344.

Specify:

Specify in vivo monoclonal antibody:

Optional for non-U.S. Centers

Questions 347 – 357 are optional for non­U.S. centers

Center: CRID: 

Form 2400 R5.0: Pre-Transplant Essential Data

CIBMTR Form 2400 revision 5.0 last updated January 2017
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 6 / 12



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

EBMT Code (CIC):

Hospital:

Unit (check only one)

Adult Pediatric

CIBMTR Research ID:  (CRID)

Recipient Data Questions: 1 - 10

Date of birth:1 __ __ __ __ - __ __- __ __

Sex

male female

2

Ethnicity3

Hispanic or Latino

Not Hispanic or Latino

Not applicable (not a resident of the USA)

Unknown

Race (1) Questions: 4 - 4

Race4

Zip or postal code for place of recipient’s residence: (USA recipients only)5

Is the recipient participating in a clinical trial?

yes no

6

Clinical Trials (1) Questions: 7 - 10

Study Sponsor7

Specify other sponsor:8

Study ID Number9

Subject ID:10

Hematopoietic Cellular Transplant (HCT) Questions: 11 - 28

Date of this HCT:11 __ __ __ __ - __ __- __ __

Was this the first HCT for this recipient?

yes no

12

Is a subsequent HCT planned as part of the overall treatment protocol (not as a reaction to post-HCT disease assessment)? (For autologous HCTs only)

yes no

13

Specify subsequent HCT planned

Autologous Allogeneic

14

Specify the number of prior HCTs:15

Autologous

yes no

16

Allogeneic, unrelated

yes no

17

Allogeneic, related

yes no

18

Syngeneic

yes no

19

Date of the last HCT: (just before current HCT)20 __ __ __ __ - __ __- __ __

Was the last HCT performed at a different institution?

yes no

21

Name:22

City:

State:

Country:

What was the HSC source for the last HCT?23

Autologous

Allogeneic, unrelated donor

Allogeneic, related donor

Reason for current HCT24

Date of graft failure / rejection:25 __ __ __ __ - __ __- __ __

Date of relapse:26 __ __ __ __ - __ __- __ __

Date of secondary malignancy:27 __ __ __ __ - __ __- __ __

Specify other reason:28

Donor Information Questions: 29 - 63

Multiple donors?

yes no

29

Specify number of donors:30

Donor Information for this HCT (1) Questions: 31 - 63

Specify donor31

NMDP cord blood unit ID:32

NMDP donor ID:33

Non-NMDP unrelated donor ID: (not applicable for related donors)34

Non-NMDP cord blood unit ID: (include related and autologous CBUs)35

Is the CBU ID also the ISBT DIN number?

yes no

36

Specify the ISBT DIN number:37

Registry or UCB Bank ID38

Specify other Registry or UCB Bank:39

Specify the related donor type40

Syngeneic (monozygotic twin)

HLA-identical sibling (may include non-monozygotic twin)

HLA-matched other relative

HLA-mismatched relative

Date of birth (donor / infant)

Known Unknown

41

Date of birth: (donor / infant)42 __ __ __ __ - __ __- __ __

Age (donor / infant)

Known Unknown

43

Age: (donor / infant)44 Months (use only if less than 1 year old)

years

Sex (donor / infant)

male female

45

Bone marrow

yes no

46

PBSC

yes no

47

Single cord blood unit

yes no

48

Other product

yes no

49

Specify other product type:50

Specify number of products infused from this donor:51

Specify the number of these products intended to achieve hematopoietic engraftment:52

Did the recipient have more than one mobilization event to acquire cells for HCT?

yes no

53

Specify the total number of mobilization events performed for this HCT: (regardless of the number of collections or which collections were
used for this HCT)

54

G-CSF

yes no

55

GM-CSF

yes no

56

Pegylated G-CSF

yes no

57

Plerixafor (Mozobil)

yes no

58

Other CXCR4 inhibitor

yes no

59

Combined with chemotherapy

yes no

60

Was this donor used for any prior HCTs?

yes no

61

Donor CMV-antibodies (IgG or Total) (Allogeneic HCTs only)62

Reactive

Non-reactive

Not done

Not applicable (cord blood unit)

Was plerixafor (Mozobil) given at any time prior to the preparative regimen? (Related HCTs only)

yes no Unknown

63

Consent Questions: 64 - 71

Has the recipient signed an IRB-approved consent form for submitting research data to the NMDP / CIBMTR?64

Yes (patient consented)

No (patient declined)

Not approached

Date form was signed:65 __ __ __ __ - __ __- __ __

Did the recipient give permission to be directly contacted for future research?66

Yes (patient provided permission)

No (patient declined)

Not approached

Date form was signed:67 __ __ __ __ - __ __- __ __

Has the recipient signed an IRB-approved consent form to donate research blood samples to the NMDP / CIBMTR?68

Yes (patient consented)

No (patient declined)

Not approached

Not applicable (center not participating)

Date form was signed:69 __ __ __ __ - __ __- __ __

Has the donor signed an IRB-approved consent form to donate research blood samples to the NMDP / CIBMTR? (Allogeneic donors only)70

Yes (donor consented)

No (donor declined)

Not approached

Not applicable (center not participating)

Date form was signed:71 __ __ __ __ - __ __- __ __

Product Processing / Manipulation Questions: 72 - 90

Was the product manipulated prior to infusion?

yes no

72

Specify portion manipulated

entire product portion of product

73

Washed

yes no

74

Diluted

yes no

75

Buffy coat enriched (buffy coat preparation)

yes no

76

B-cell reduced

yes no

77

CD8 reduced

yes no

78

Plasma reduced (removal)

yes no

79

RBC reduced

yes no

80

Cultured (ex-vivo expansion)

yes no

81

Genetic manipulation (gene transfer / transduction)

yes no

82

PUVA treated

yes no

83

CD34 enriched (CD34+ selection)

yes no

84

CD133 enriched

yes no

85

Monocyte enriched

yes no

86

Mononuclear cells enriched

yes no

87

T-cell depletion

yes no

88

Other cell manipulation

yes no

89

Specify other cell manipulation:90

Clinical Status of Recipient Prior to the Preparative Regimen (Conditioning) Questions: 91 - 94

What scale was used to determine the recipient’s functional status?91

Karnofsky (recipient age ≥ 16 years)

Lansky (recipient age < 16 years) 

Karnofsky Scale (recipient age ≥ 16 years)92

Lansky Scale (recipient age < 16 years)93

Recipient CMV-antibodies (IgG or Total)

Reactive Non-reactive Not done

94

Comorbid Conditions Questions: 95 - 155

Is there a history of mechanical ventilation?

yes no

95

Is there a history of proven invasive fungal infection?

yes no

96

Were there clinically significant co-existing diseases or organ impairment at time of patient assessment prior to preparative regimen? Source: Blood, 2005 Oct 15;106(8):2912-2919

yes no

97

Arrhythmia - For example, any history of atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias requiring treatment

yes no Unknown

98

Cardiac - Any history of coronary artery disease (one or more vessel-coronary artery stenosis requiring medical treatment, stent, or bypass graft), congestive heart
failure, myocardial infarction, OR ejection fraction ≤ 50% on the most recent test

yes no Unknown

99

Cerebrovascular disease - Any history of transient ischemic attack, subarachnoid hemorrhage or cerebrovascular accident

yes no Unknown

100

Diabetes - Requiring treatment with insulin or oral hypoglycemics in the last 4 weeks but not diet alone

yes no Unknown

101

Heart valve disease - Except asymptomatic mitral valve prolapse

yes no Unknown

102

Hepatic, mild ­ Chronic hepatitis, bilirubin > upper limit of normal to 1.5 × upper limit of normal, or AST/ALT > upper limit of normal to 2.5 × upper limit of normal at the
time of transplant OR any history of hepatitis B or hepatitis C infection

yes no Unknown

103

Hepatic, moderate / severe ­ Liver cirrhosis, bilirubin > 1.5 × upper limit of normal, or AST/ALT > 2.5 × upper limit of normal

yes no Unknown

104

Infection - For example, documented infection, fever of unknown origin, or pulmonary nodules requiring continuation of antimicrobial treatment after day 0

yes no Unknown

105

Inflammatory bowel disease ­ Any history of Crohn’s disease or ulcerative colitis requiring treatment

yes no Unknown

106

Obesity - Patients with a body mass index > 35 kg/m2  prior to the start of conditioning

yes no Unknown

107

Peptic ulcer - Any history of peptic ulcer confirmed by endoscopy and requiring treatment

yes no Unknown

108

Psychiatric disturbance - For example, depression, anxiety, bipolar disorder or schizophrenia requiring psychiatric consult or treatment in the last 4 weeks

yes no Unknown

109

Pulmonary, moderate - Corrected diffusion capacity of carbon monoxide and/or FEV1 66-80% or dyspnea on slight activity at transplant

yes no Unknown

110

Pulmonary, severe - Corrected diffusion capacity of carbon monoxide and/or FEV1 ≤ 65% or dyspnea at rest or requiring oxygen at transplant

yes no Unknown

111

Renal, moderate / severe ­ Serum creatinine > 2 mg/dL or > 177 µmol/L or on dialysis at transplant, OR prior renal transplantation

yes no Unknown

112

Rheumatologic - For example, any history of systemic lupus erythmatosis, rheumatoid arthritis, polymyositis, mixed connective tissue disease, or polymyalgia
rheumatica requiring treatment (do NOT include degenerative joint disease, osteoarthritis)

yes no Unknown

113

Solid tumor, prior ­ Treated at any time point in the patient’s past history, excluding non­melanoma skin cancer, leukemia, lymphoma or multiple myeloma

yes no Unknown

114

Breast cancer

yes no

115

Year of diagnosis:116

Central nervous system (CNS) malignancy (glioblastoma, astrocytoma)

yes no

117

Year of diagnosis:118

Gastrointestinal malignancy (colon, rectum, stomach, pancreas, intestine)

yes no

119

Year of diagnosis:120

Genitourinary malignancy (kidney, bladder, ovary, testicle, genitalia, uterus, cervix)

yes no

121

Year of diagnosis:122

Lung cancer

yes no

123

Year of diagnosis:124

Melanoma

yes no

125

Year of diagnosis:126

Oropharyngeal cancer (tongue, buccal mucosa)

yes no

127

Year of diagnosis:128

Sarcoma

yes no

129

Year of diagnosis:130

Thyroid cancer

yes no

131

Year of diagnosis:132

Other co-morbid condition

yes no Unknown

133

Specify other co-morbid condition:134

Was there a history of malignancy (hematologic or non-melanoma skin cancer) other than the primary disease for which this HCT is being performed?

yes no

135

Acute myeloid leukemia (AML / ANLL)

yes no

136

Year of diagnosis:137

Other leukemia, including ALL

yes no

138

Year of diagnosis:139

Specify leukemia:140

Clonal cytogenetic abnormality without leukemia or MDS

yes no

141

Year of diagnosis:142

Hodgkin disease

yes no

143

Year of diagnosis:144

Lymphoma or lymphoproliferative disease

yes no

145

Year of diagnosis:146

Was the tumor EBV positive?

yes no

147

Other skin malignancy (basal cell, squamous)

yes no

148

Year of diagnosis:149

Specify other skin malignancy:150

Myelodysplasia (MDS) / myeloproliferative (MPN) disorder

yes no

151

Year of diagnosis:152

Other prior malignancy

yes no

153

Year of diagnosis:154

Specify other prior malignancy:155

Pre-HCT Preparative Regimen (Conditioning) Questions: 156 - 316

Height at initiation of pre-HCT preparative regimen:156 inches centimeters

Actual weight at initiation of pre-HCT preparative regimen:157 pounds kilograms

Was a pre-HCT preparative regimen prescribed?

yes no

158

Classify the recipient’s prescribed preparative regimen (Allogeneic HCTs only)159

Myeloablative

Non-myeloablative (NST)

Reduced intensity (RIC)

Date pre-HCT preparative regimen began: (irradiation or drugs)160 __ __ __ __ - __ __- __ __ (Use earliest date from question 164 radiation, or 169 - 316 chemotherapy)

Was irradiation planned as part of the pre-HCT preparative regimen?

yes no

161

What was the prescribed radiation field?162

Total body

Total body by intensity-modulated radiation therapy (IMRT)

Total lymphoid or nodal regions

Thoracoabdominal region

Total prescribed dose: (dose per fraction x total number of fractions) 163 Gy cGy

Date started:164 __ __ __ __ - __ __- __ __

Was the radiation fractionated?

yes no

165

Prescribed dose per fraction:166 Gy cGy

Number of days: (include "rest" days)167

Total number of fractions:168

ALG, ALS, ATG, ATS

yes no

169

Total prescribed dose:170 mg/kg

Date started:171 __ __ __ __ - __ __- __ __

Specify source172

ATGAM (horse)

ATG - Fresenius (rabbit)

Thymoglobulin (rabbit)

Other

Specify other source:173

Anthracycline

yes no

174

Daunorubicin

yes no

175

Total prescribed dose :176 mg/m2 mg/kg

Date started:177 __ __ __ __ - __ __- __ __

Doxorubicin (Adriamycin)

yes no

178

Total prescribed dose :179 mg/m2 mg/kg

Date started:180 __ __ __ __ - __ __- __ __

Idarubicin

yes no

181

Total prescribed dose :182 mg/m2 mg/kg

Date started:183 __ __ __ __ - __ __- __ __

Rubidazone

yes no

184

Total prescribed dose :185 mg/m2 mg/kg

Date started:186 __ __ __ __ - __ __- __ __

Other anthracycline

yes no

187

Total prescribed dose :188 mg/m2 mg/kg

Date started:189 __ __ __ __ - __ __- __ __

Specify other anthracycline:190

Bleomycin (BLM, Blenoxane)

yes no

191

Total prescribed dose :192 mg/m2 mg/kg

Date started:193 __ __ __ __ - __ __- __ __

Busulfan (Myleran)

yes no

194

Total prescribed dose :195 mg/m2

mg/kg

Target total AUC (µmol x min/L)

Date started:196 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

197

Carboplatin

yes no

198

Total prescribed dose :199 mg/m2 mg/kg

Date started:200 __ __ __ __ - __ __- __ __

Were pharmacokinetics performed to determine preparative regimen drug dosing?

yes no

201

Specify the target AUC:202 mg/mL/minute

Cisplatin (Platinol, CDDP)

yes no

203

Total prescribed dose :204 mg/m2 mg/kg

Date started:205 __ __ __ __ - __ __- __ __

Cladribine (2-CdA, Leustatin)

yes no

206

Total prescribed dose :207 mg/m2 mg/kg

Date started:208 __ __ __ __ - __ __- __ __

Corticosteroids (excluding anti-nausea medication)

yes no

209

Methylprednisolone (Solu-Medrol)

yes no

210

Total prescribed dose :211 mg/m2 mg/kg

Date started:212 __ __ __ __ - __ __- __ __

Prednisone

yes no

213

Total prescribed dose :214 mg/m2 mg/kg

Date started:215 __ __ __ __ - __ __- __ __

Dexamethasone

yes no

216

Total prescribed dose :217 mg/m2 mg/kg

Date started:218 __ __ __ __ - __ __- __ __

Other corticosteroid

yes no

219

Total prescribed dose :220 mg/m2 mg/kg

Date started:221 __ __ __ __ - __ __- __ __

Specify other corticosteroid:222

Cyclophosphamide (Cytoxan)

yes no

223

Total prescribed dose :224 mg/m2 mg/kg

Date started:225 __ __ __ __ - __ __- __ __

Cytarabine (Ara-C)

yes no

226

Total prescribed dose :227 mg/m2 mg/kg

Date started:228 __ __ __ __ - __ __- __ __

Etoposide (VP-16, VePesid)

yes no

229

Total prescribed dose :230 mg/m2 mg/kg

Date started:231 __ __ __ __ - __ __- __ __

Fludarabine

yes no

232

Total prescribed dose :233 mg/m2 mg/kg

Date started:234 __ __ __ __ - __ __- __ __

Ifosfamide

yes no

235

Total prescribed dose :236 mg/m2 mg/kg

Date started:237 __ __ __ __ - __ __- __ __

Intrathecal therapy (chemotherapy)

yes no

238

Intrathecal cytarabine (IT Ara-C)

yes no

239

Total prescribed dose :240 mg/m2 mg/kg

Date started:241 __ __ __ __ - __ __- __ __

Intrathecal methotrexate (IT MTX)

yes no

242

Total prescribed dose :243 mg/m2 mg/kg

Date started:244 __ __ __ __ - __ __- __ __

Intrathecal thiotepa

yes no

245

Total prescribed dose :246 mg/m2 mg/kg

Date started:247 __ __ __ __ - __ __- __ __

Other intrathecal drug

yes no

248

Total prescribed dose :249 mg/m2 mg/kg

Date started:250 __ __ __ __ - __ __- __ __

Specify other intrathecal drug:251

Melphalan (L-Pam)

yes no

252

Total prescribed dose :253 mg/m2 mg/kg

Date started:254 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

255

Mitoxantrone (Novantrone)

yes no

256

Total prescribed dose :257 mg/m2 mg/kg

Date started:258 __ __ __ __ - __ __- __ __

Monoclonal antibody

yes no

259

Radio labeled mAb

yes no

260

Total prescribed dose of radioactive component:261 mCi MBq

Date started:262 __ __ __ __ - __ __- __ __

Tositumomab (Bexxar)

yes no

263

Ibritumomab tiuxetan (Zevalin)

yes no

264

Other radio labeled mAb

yes no

265

Specify other radio labeled mAb:266

Alemtuzumab (Campath)

yes no

267

Total prescribed dose :268 mg/m2 mg/kg

Date started:269 __ __ __ __ - __ __- __ __

Rituximab (Rituxan, anti CD20)

yes no

270

Total prescribed dose :271 mg/m2 mg/kg

Date started:272 __ __ __ __ - __ __- __ __

Gemtuzumab (Mylotarg, anti CD33)

yes no

273

Total prescribed dose :274 mg/m2 mg/kg

Date started:275 __ __ __ __ - __ __- __ __

Other mAb

yes no

276

Total prescribed dose :277 mg/m2 mg/kg

Date started:278 __ __ __ __ - __ __- __ __

Specify other mAb:279

Nitrosourea

yes no

280

Carmustine (BCNU)

yes no

281

Total prescribed dose :282 mg/m2 mg/kg

Date started:283 __ __ __ __ - __ __- __ __

CCNU (Lomustine)

yes no

284

Total prescribed dose :285 mg/m2 mg/kg

Date started:286 __ __ __ __ - __ __- __ __

Other nitrosourea

yes no

287

Total prescribed dose :288 mg/m2 mg/kg

Date started:289 __ __ __ __ - __ __- __ __

Specify other nitrosourea:290

Paclitaxel (Taxol, Xyotax)

yes no

291

Total prescribed dose :292 mg/m2 mg/kg

Date started:293 __ __ __ __ - __ __- __ __

Teniposide (VM26)

yes no

294

Total prescribed dose :295 mg/m2 mg/kg

Date started:296 __ __ __ __ - __ __- __ __

Thiotepa

yes no

297

Total prescribed dose :298 mg/m2 mg/kg

Date started:299 __ __ __ __ - __ __- __ __

Treosulfan

yes no

300

Total prescribed dose :301 mg/m2 mg/kg

Date started:302 __ __ __ __ - __ __- __ __

Tyrosine kinase inhibitors

yes no

303

Dasatinib (Sprycel)

yes no

304

Total prescribed dose :305 mg/m2 mg/kg

Date started:306 __ __ __ __ - __ __- __ __

Imatinib mesylate (STI571, Gleevec)

yes no

307

Total prescribed dose :308 mg/m2 mg/kg

Date started:309 __ __ __ __ - __ __- __ __

Nilotinib

yes no

310

Total prescribed dose :311 mg/m2 mg/kg

Date started:312 __ __ __ __ - __ __- __ __

Other drug

yes no

313

Total prescribed dose :314 mg/m2 mg/kg

Date started:315 __ __ __ __ - __ __- __ __

Specify other drug:316

GVHD Prophylaxis Questions: 317 - 343

Was GVHD prophylaxis planned / given?

yes no

317

ALG, ALS, ATG, ATS

yes no

318

Total dose:319 mg/kg

Specify source320

ATGAM (horse)

ATG - Fresenius (rabbit)

Thymoglobulin (rabbit)

Other

Specify other source:321

Corticosteroids (systemic)

yes no

322

Cyclosporine (CSA, Neoral, Sandimmune)

yes no

323

Cyclophosphamide (Cytoxan)

yes no

324

Extra-corporeal photopheresis (ECP)

yes no

325

FK 506 (Tacrolimus, Prograf)

yes no

326

In vivo monoclonal antibody

yes no

327

Alemtuzumab (Campath)

yes no

328

Anti CD 25 (Zenapax, Daclizumab, AntiTAC)

yes no

329

Specify:330

Etanercept (Enbrel)

yes no

331

Infliximab (Remicade)

yes no

332

Other in vivo monoclonal antibody

yes no

333

Specify antibody:334

In vivo immunotoxin

yes no

335

Specify immunotoxin:336

Methotrexate (MTX) (Amethopterin)

yes no

337

Mycophenolate mofetil (MMF) (CellCept)

yes no

338

Sirolimus (Rapamycin, Rapamune)

yes no

339

Blinded randomized trial

yes no

340

Specify trial agent:341

Other agent

yes no

342

Specify other agent:343

Other Toxicity Modifying Regimen Questions: 344 - 344

Was KGF (palifermin, Kepivance) started or is there a plan to use it?

Yes No masked trial

344

Post-HCT Disease Therapy Planned as of Day 0 Questions: 345 - 357

Is this HCT part of a planned multiple (sequential) graft / HCT protocol?

yes no

345

Is additional post-HCT therapy planned?

yes no

346

Bortezomib (Velcade)

yes no

347

Cellular therapy (e.g. DCI, DLI)

yes no

348

Dexamethasone

yes no

349

Intrathecal therapy (chemotherapy)

yes no

350

Tyrosine kinase inhibitor (e.g. imatinib mesylate)

yes no

351

Lenalidomide (Revlimid)

yes no

352

Local radiotherapy

yes no

353

Rituximab (Rituxan, MabThera)

yes no

354

Thalidomide (Thalomid)

yes no

355

Other therapy

yes no

356

Specify other therapy:357

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

OMB No: 0915-0310

Expiration Date: 1/31/2020

Public Burden Statement:  An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control
number.  The OMB control number for this project is 0915-0310.  Public reporting burden for this collection of information is estimated to average 1.0 hours per response, including the
time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other
aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance Officer, 5600 Fishers Lane, Room 10-29, Rockville, Maryland, 20857.

Center Identification

Recipient Identification

Specify the HSC source(s) for all prior HCTs:

Specify the institution that performed the last HCT:

Specify product type: 

A series of collections should be considered a single product when they are all from the same donor and use the same collection method and technique (and mobilization, if
applicable), even if the collections are performed on different days.

Questions 53 – 60 are for autologous HCT recipients only.  If other than autologous skip to question 61

Specify all agents used in the mobilization events reported above:

Specify all methods used to manipulate the product:

Performance score prior to the preparative regimen:

Specify which malignancy(ies) occurred:

Indicate the total prescribed cumulative dose for the preparative regimen:

Specify radio labeled mAb:

This section is to be completed for allogeneic HCTs only; autologous HCTs continue with question 344.

Specify:

Specify in vivo monoclonal antibody:

Optional for non-U.S. Centers

Questions 347 – 357 are optional for non­U.S. centers

Center: CRID: 

Form 2400 R5.0: Pre-Transplant Essential Data

CIBMTR Form 2400 revision 5.0 last updated January 2017
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 7 / 12



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

EBMT Code (CIC):

Hospital:

Unit (check only one)

Adult Pediatric

CIBMTR Research ID:  (CRID)

Recipient Data Questions: 1 - 10

Date of birth:1 __ __ __ __ - __ __- __ __

Sex

male female

2

Ethnicity3

Hispanic or Latino

Not Hispanic or Latino

Not applicable (not a resident of the USA)

Unknown

Race (1) Questions: 4 - 4

Race4

Zip or postal code for place of recipient’s residence: (USA recipients only)5

Is the recipient participating in a clinical trial?

yes no

6

Clinical Trials (1) Questions: 7 - 10

Study Sponsor7

Specify other sponsor:8

Study ID Number9

Subject ID:10

Hematopoietic Cellular Transplant (HCT) Questions: 11 - 28

Date of this HCT:11 __ __ __ __ - __ __- __ __

Was this the first HCT for this recipient?

yes no

12

Is a subsequent HCT planned as part of the overall treatment protocol (not as a reaction to post-HCT disease assessment)? (For autologous HCTs only)

yes no

13

Specify subsequent HCT planned

Autologous Allogeneic

14

Specify the number of prior HCTs:15

Autologous

yes no

16

Allogeneic, unrelated

yes no

17

Allogeneic, related

yes no

18

Syngeneic

yes no

19

Date of the last HCT: (just before current HCT)20 __ __ __ __ - __ __- __ __

Was the last HCT performed at a different institution?

yes no

21

Name:22

City:

State:

Country:

What was the HSC source for the last HCT?23

Autologous

Allogeneic, unrelated donor

Allogeneic, related donor

Reason for current HCT24

Date of graft failure / rejection:25 __ __ __ __ - __ __- __ __

Date of relapse:26 __ __ __ __ - __ __- __ __

Date of secondary malignancy:27 __ __ __ __ - __ __- __ __

Specify other reason:28

Donor Information Questions: 29 - 63

Multiple donors?

yes no

29

Specify number of donors:30

Donor Information for this HCT (1) Questions: 31 - 63

Specify donor31

NMDP cord blood unit ID:32

NMDP donor ID:33

Non-NMDP unrelated donor ID: (not applicable for related donors)34

Non-NMDP cord blood unit ID: (include related and autologous CBUs)35

Is the CBU ID also the ISBT DIN number?

yes no

36

Specify the ISBT DIN number:37

Registry or UCB Bank ID38

Specify other Registry or UCB Bank:39

Specify the related donor type40

Syngeneic (monozygotic twin)

HLA-identical sibling (may include non-monozygotic twin)

HLA-matched other relative

HLA-mismatched relative

Date of birth (donor / infant)

Known Unknown

41

Date of birth: (donor / infant)42 __ __ __ __ - __ __- __ __

Age (donor / infant)

Known Unknown

43

Age: (donor / infant)44 Months (use only if less than 1 year old)

years

Sex (donor / infant)

male female

45

Bone marrow

yes no

46

PBSC

yes no

47

Single cord blood unit

yes no

48

Other product

yes no

49

Specify other product type:50

Specify number of products infused from this donor:51

Specify the number of these products intended to achieve hematopoietic engraftment:52

Did the recipient have more than one mobilization event to acquire cells for HCT?

yes no

53

Specify the total number of mobilization events performed for this HCT: (regardless of the number of collections or which collections were
used for this HCT)

54

G-CSF

yes no

55

GM-CSF

yes no

56

Pegylated G-CSF

yes no

57

Plerixafor (Mozobil)

yes no

58

Other CXCR4 inhibitor

yes no

59

Combined with chemotherapy

yes no

60

Was this donor used for any prior HCTs?

yes no

61

Donor CMV-antibodies (IgG or Total) (Allogeneic HCTs only)62

Reactive

Non-reactive

Not done

Not applicable (cord blood unit)

Was plerixafor (Mozobil) given at any time prior to the preparative regimen? (Related HCTs only)

yes no Unknown

63

Consent Questions: 64 - 71

Has the recipient signed an IRB-approved consent form for submitting research data to the NMDP / CIBMTR?64

Yes (patient consented)

No (patient declined)

Not approached

Date form was signed:65 __ __ __ __ - __ __- __ __

Did the recipient give permission to be directly contacted for future research?66

Yes (patient provided permission)

No (patient declined)

Not approached

Date form was signed:67 __ __ __ __ - __ __- __ __

Has the recipient signed an IRB-approved consent form to donate research blood samples to the NMDP / CIBMTR?68

Yes (patient consented)

No (patient declined)

Not approached

Not applicable (center not participating)

Date form was signed:69 __ __ __ __ - __ __- __ __

Has the donor signed an IRB-approved consent form to donate research blood samples to the NMDP / CIBMTR? (Allogeneic donors only)70

Yes (donor consented)

No (donor declined)

Not approached

Not applicable (center not participating)

Date form was signed:71 __ __ __ __ - __ __- __ __

Product Processing / Manipulation Questions: 72 - 90

Was the product manipulated prior to infusion?

yes no

72

Specify portion manipulated

entire product portion of product

73

Washed

yes no

74

Diluted

yes no

75

Buffy coat enriched (buffy coat preparation)

yes no

76

B-cell reduced

yes no

77

CD8 reduced

yes no

78

Plasma reduced (removal)

yes no

79

RBC reduced

yes no

80

Cultured (ex-vivo expansion)

yes no

81

Genetic manipulation (gene transfer / transduction)

yes no

82

PUVA treated

yes no

83

CD34 enriched (CD34+ selection)

yes no

84

CD133 enriched

yes no

85

Monocyte enriched

yes no

86

Mononuclear cells enriched

yes no

87

T-cell depletion

yes no

88

Other cell manipulation

yes no

89

Specify other cell manipulation:90

Clinical Status of Recipient Prior to the Preparative Regimen (Conditioning) Questions: 91 - 94

What scale was used to determine the recipient’s functional status?91

Karnofsky (recipient age ≥ 16 years)

Lansky (recipient age < 16 years) 

Karnofsky Scale (recipient age ≥ 16 years)92

Lansky Scale (recipient age < 16 years)93

Recipient CMV-antibodies (IgG or Total)

Reactive Non-reactive Not done

94

Comorbid Conditions Questions: 95 - 155

Is there a history of mechanical ventilation?

yes no

95

Is there a history of proven invasive fungal infection?

yes no

96

Were there clinically significant co-existing diseases or organ impairment at time of patient assessment prior to preparative regimen? Source: Blood, 2005 Oct 15;106(8):2912-2919

yes no

97

Arrhythmia - For example, any history of atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias requiring treatment

yes no Unknown

98

Cardiac - Any history of coronary artery disease (one or more vessel-coronary artery stenosis requiring medical treatment, stent, or bypass graft), congestive heart
failure, myocardial infarction, OR ejection fraction ≤ 50% on the most recent test

yes no Unknown

99

Cerebrovascular disease - Any history of transient ischemic attack, subarachnoid hemorrhage or cerebrovascular accident

yes no Unknown

100

Diabetes - Requiring treatment with insulin or oral hypoglycemics in the last 4 weeks but not diet alone

yes no Unknown

101

Heart valve disease - Except asymptomatic mitral valve prolapse

yes no Unknown

102

Hepatic, mild ­ Chronic hepatitis, bilirubin > upper limit of normal to 1.5 × upper limit of normal, or AST/ALT > upper limit of normal to 2.5 × upper limit of normal at the
time of transplant OR any history of hepatitis B or hepatitis C infection

yes no Unknown

103

Hepatic, moderate / severe ­ Liver cirrhosis, bilirubin > 1.5 × upper limit of normal, or AST/ALT > 2.5 × upper limit of normal

yes no Unknown

104

Infection - For example, documented infection, fever of unknown origin, or pulmonary nodules requiring continuation of antimicrobial treatment after day 0

yes no Unknown

105

Inflammatory bowel disease ­ Any history of Crohn’s disease or ulcerative colitis requiring treatment

yes no Unknown

106

Obesity - Patients with a body mass index > 35 kg/m2  prior to the start of conditioning

yes no Unknown

107

Peptic ulcer - Any history of peptic ulcer confirmed by endoscopy and requiring treatment

yes no Unknown

108

Psychiatric disturbance - For example, depression, anxiety, bipolar disorder or schizophrenia requiring psychiatric consult or treatment in the last 4 weeks

yes no Unknown

109

Pulmonary, moderate - Corrected diffusion capacity of carbon monoxide and/or FEV1 66-80% or dyspnea on slight activity at transplant

yes no Unknown

110

Pulmonary, severe - Corrected diffusion capacity of carbon monoxide and/or FEV1 ≤ 65% or dyspnea at rest or requiring oxygen at transplant

yes no Unknown

111

Renal, moderate / severe ­ Serum creatinine > 2 mg/dL or > 177 µmol/L or on dialysis at transplant, OR prior renal transplantation

yes no Unknown

112

Rheumatologic - For example, any history of systemic lupus erythmatosis, rheumatoid arthritis, polymyositis, mixed connective tissue disease, or polymyalgia
rheumatica requiring treatment (do NOT include degenerative joint disease, osteoarthritis)

yes no Unknown

113

Solid tumor, prior ­ Treated at any time point in the patient’s past history, excluding non­melanoma skin cancer, leukemia, lymphoma or multiple myeloma

yes no Unknown

114

Breast cancer

yes no

115

Year of diagnosis:116

Central nervous system (CNS) malignancy (glioblastoma, astrocytoma)

yes no

117

Year of diagnosis:118

Gastrointestinal malignancy (colon, rectum, stomach, pancreas, intestine)

yes no

119

Year of diagnosis:120

Genitourinary malignancy (kidney, bladder, ovary, testicle, genitalia, uterus, cervix)

yes no

121

Year of diagnosis:122

Lung cancer

yes no

123

Year of diagnosis:124

Melanoma

yes no

125

Year of diagnosis:126

Oropharyngeal cancer (tongue, buccal mucosa)

yes no

127

Year of diagnosis:128

Sarcoma

yes no

129

Year of diagnosis:130

Thyroid cancer

yes no

131

Year of diagnosis:132

Other co-morbid condition

yes no Unknown

133

Specify other co-morbid condition:134

Was there a history of malignancy (hematologic or non-melanoma skin cancer) other than the primary disease for which this HCT is being performed?

yes no

135

Acute myeloid leukemia (AML / ANLL)

yes no

136

Year of diagnosis:137

Other leukemia, including ALL

yes no

138

Year of diagnosis:139

Specify leukemia:140

Clonal cytogenetic abnormality without leukemia or MDS

yes no

141

Year of diagnosis:142

Hodgkin disease

yes no

143

Year of diagnosis:144

Lymphoma or lymphoproliferative disease

yes no

145

Year of diagnosis:146

Was the tumor EBV positive?

yes no

147

Other skin malignancy (basal cell, squamous)

yes no

148

Year of diagnosis:149

Specify other skin malignancy:150

Myelodysplasia (MDS) / myeloproliferative (MPN) disorder

yes no

151

Year of diagnosis:152

Other prior malignancy

yes no

153

Year of diagnosis:154

Specify other prior malignancy:155

Pre-HCT Preparative Regimen (Conditioning) Questions: 156 - 316

Height at initiation of pre-HCT preparative regimen:156 inches centimeters

Actual weight at initiation of pre-HCT preparative regimen:157 pounds kilograms

Was a pre-HCT preparative regimen prescribed?

yes no

158

Classify the recipient’s prescribed preparative regimen (Allogeneic HCTs only)159

Myeloablative

Non-myeloablative (NST)

Reduced intensity (RIC)

Date pre-HCT preparative regimen began: (irradiation or drugs)160 __ __ __ __ - __ __- __ __ (Use earliest date from question 164 radiation, or 169 - 316 chemotherapy)

Was irradiation planned as part of the pre-HCT preparative regimen?

yes no

161

What was the prescribed radiation field?162

Total body

Total body by intensity-modulated radiation therapy (IMRT)

Total lymphoid or nodal regions

Thoracoabdominal region

Total prescribed dose: (dose per fraction x total number of fractions) 163 Gy cGy

Date started:164 __ __ __ __ - __ __- __ __

Was the radiation fractionated?

yes no

165

Prescribed dose per fraction:166 Gy cGy

Number of days: (include "rest" days)167

Total number of fractions:168

ALG, ALS, ATG, ATS

yes no

169

Total prescribed dose:170 mg/kg

Date started:171 __ __ __ __ - __ __- __ __

Specify source172

ATGAM (horse)

ATG - Fresenius (rabbit)

Thymoglobulin (rabbit)

Other

Specify other source:173

Anthracycline

yes no

174

Daunorubicin

yes no

175

Total prescribed dose :176 mg/m2 mg/kg

Date started:177 __ __ __ __ - __ __- __ __

Doxorubicin (Adriamycin)

yes no

178

Total prescribed dose :179 mg/m2 mg/kg

Date started:180 __ __ __ __ - __ __- __ __

Idarubicin

yes no

181

Total prescribed dose :182 mg/m2 mg/kg

Date started:183 __ __ __ __ - __ __- __ __

Rubidazone

yes no

184

Total prescribed dose :185 mg/m2 mg/kg

Date started:186 __ __ __ __ - __ __- __ __

Other anthracycline

yes no

187

Total prescribed dose :188 mg/m2 mg/kg

Date started:189 __ __ __ __ - __ __- __ __

Specify other anthracycline:190

Bleomycin (BLM, Blenoxane)

yes no

191

Total prescribed dose :192 mg/m2 mg/kg

Date started:193 __ __ __ __ - __ __- __ __

Busulfan (Myleran)

yes no

194

Total prescribed dose :195 mg/m2

mg/kg

Target total AUC (µmol x min/L)

Date started:196 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

197

Carboplatin

yes no

198

Total prescribed dose :199 mg/m2 mg/kg

Date started:200 __ __ __ __ - __ __- __ __

Were pharmacokinetics performed to determine preparative regimen drug dosing?

yes no

201

Specify the target AUC:202 mg/mL/minute

Cisplatin (Platinol, CDDP)

yes no

203

Total prescribed dose :204 mg/m2 mg/kg

Date started:205 __ __ __ __ - __ __- __ __

Cladribine (2-CdA, Leustatin)

yes no

206

Total prescribed dose :207 mg/m2 mg/kg

Date started:208 __ __ __ __ - __ __- __ __

Corticosteroids (excluding anti-nausea medication)

yes no

209

Methylprednisolone (Solu-Medrol)

yes no

210

Total prescribed dose :211 mg/m2 mg/kg

Date started:212 __ __ __ __ - __ __- __ __

Prednisone

yes no

213

Total prescribed dose :214 mg/m2 mg/kg

Date started:215 __ __ __ __ - __ __- __ __

Dexamethasone

yes no

216

Total prescribed dose :217 mg/m2 mg/kg

Date started:218 __ __ __ __ - __ __- __ __

Other corticosteroid

yes no

219

Total prescribed dose :220 mg/m2 mg/kg

Date started:221 __ __ __ __ - __ __- __ __

Specify other corticosteroid:222

Cyclophosphamide (Cytoxan)

yes no

223

Total prescribed dose :224 mg/m2 mg/kg

Date started:225 __ __ __ __ - __ __- __ __

Cytarabine (Ara-C)

yes no

226

Total prescribed dose :227 mg/m2 mg/kg

Date started:228 __ __ __ __ - __ __- __ __

Etoposide (VP-16, VePesid)

yes no

229

Total prescribed dose :230 mg/m2 mg/kg

Date started:231 __ __ __ __ - __ __- __ __

Fludarabine

yes no

232

Total prescribed dose :233 mg/m2 mg/kg

Date started:234 __ __ __ __ - __ __- __ __

Ifosfamide

yes no

235

Total prescribed dose :236 mg/m2 mg/kg

Date started:237 __ __ __ __ - __ __- __ __

Intrathecal therapy (chemotherapy)

yes no

238

Intrathecal cytarabine (IT Ara-C)

yes no

239

Total prescribed dose :240 mg/m2 mg/kg

Date started:241 __ __ __ __ - __ __- __ __

Intrathecal methotrexate (IT MTX)

yes no

242

Total prescribed dose :243 mg/m2 mg/kg

Date started:244 __ __ __ __ - __ __- __ __

Intrathecal thiotepa

yes no

245

Total prescribed dose :246 mg/m2 mg/kg

Date started:247 __ __ __ __ - __ __- __ __

Other intrathecal drug

yes no

248

Total prescribed dose :249 mg/m2 mg/kg

Date started:250 __ __ __ __ - __ __- __ __

Specify other intrathecal drug:251

Melphalan (L-Pam)

yes no

252

Total prescribed dose :253 mg/m2 mg/kg

Date started:254 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

255

Mitoxantrone (Novantrone)

yes no

256

Total prescribed dose :257 mg/m2 mg/kg

Date started:258 __ __ __ __ - __ __- __ __

Monoclonal antibody

yes no

259

Radio labeled mAb

yes no

260

Total prescribed dose of radioactive component:261 mCi MBq

Date started:262 __ __ __ __ - __ __- __ __

Tositumomab (Bexxar)

yes no

263

Ibritumomab tiuxetan (Zevalin)

yes no

264

Other radio labeled mAb

yes no

265

Specify other radio labeled mAb:266

Alemtuzumab (Campath)

yes no

267

Total prescribed dose :268 mg/m2 mg/kg

Date started:269 __ __ __ __ - __ __- __ __

Rituximab (Rituxan, anti CD20)

yes no

270

Total prescribed dose :271 mg/m2 mg/kg

Date started:272 __ __ __ __ - __ __- __ __

Gemtuzumab (Mylotarg, anti CD33)

yes no

273

Total prescribed dose :274 mg/m2 mg/kg

Date started:275 __ __ __ __ - __ __- __ __

Other mAb

yes no

276

Total prescribed dose :277 mg/m2 mg/kg

Date started:278 __ __ __ __ - __ __- __ __

Specify other mAb:279

Nitrosourea

yes no

280

Carmustine (BCNU)

yes no

281

Total prescribed dose :282 mg/m2 mg/kg

Date started:283 __ __ __ __ - __ __- __ __

CCNU (Lomustine)

yes no

284

Total prescribed dose :285 mg/m2 mg/kg

Date started:286 __ __ __ __ - __ __- __ __

Other nitrosourea

yes no

287

Total prescribed dose :288 mg/m2 mg/kg

Date started:289 __ __ __ __ - __ __- __ __

Specify other nitrosourea:290

Paclitaxel (Taxol, Xyotax)

yes no

291

Total prescribed dose :292 mg/m2 mg/kg

Date started:293 __ __ __ __ - __ __- __ __

Teniposide (VM26)

yes no

294

Total prescribed dose :295 mg/m2 mg/kg

Date started:296 __ __ __ __ - __ __- __ __

Thiotepa

yes no

297

Total prescribed dose :298 mg/m2 mg/kg

Date started:299 __ __ __ __ - __ __- __ __

Treosulfan

yes no

300

Total prescribed dose :301 mg/m2 mg/kg

Date started:302 __ __ __ __ - __ __- __ __

Tyrosine kinase inhibitors

yes no

303

Dasatinib (Sprycel)

yes no

304

Total prescribed dose :305 mg/m2 mg/kg

Date started:306 __ __ __ __ - __ __- __ __

Imatinib mesylate (STI571, Gleevec)

yes no

307

Total prescribed dose :308 mg/m2 mg/kg

Date started:309 __ __ __ __ - __ __- __ __

Nilotinib

yes no

310

Total prescribed dose :311 mg/m2 mg/kg

Date started:312 __ __ __ __ - __ __- __ __

Other drug

yes no

313

Total prescribed dose :314 mg/m2 mg/kg

Date started:315 __ __ __ __ - __ __- __ __

Specify other drug:316

GVHD Prophylaxis Questions: 317 - 343

Was GVHD prophylaxis planned / given?

yes no

317

ALG, ALS, ATG, ATS

yes no

318

Total dose:319 mg/kg

Specify source320

ATGAM (horse)

ATG - Fresenius (rabbit)

Thymoglobulin (rabbit)

Other

Specify other source:321

Corticosteroids (systemic)

yes no

322

Cyclosporine (CSA, Neoral, Sandimmune)

yes no

323

Cyclophosphamide (Cytoxan)

yes no

324

Extra-corporeal photopheresis (ECP)

yes no

325

FK 506 (Tacrolimus, Prograf)

yes no

326

In vivo monoclonal antibody

yes no

327

Alemtuzumab (Campath)

yes no

328

Anti CD 25 (Zenapax, Daclizumab, AntiTAC)

yes no

329

Specify:330

Etanercept (Enbrel)

yes no

331

Infliximab (Remicade)

yes no

332

Other in vivo monoclonal antibody

yes no

333

Specify antibody:334

In vivo immunotoxin

yes no

335

Specify immunotoxin:336

Methotrexate (MTX) (Amethopterin)

yes no

337

Mycophenolate mofetil (MMF) (CellCept)

yes no

338

Sirolimus (Rapamycin, Rapamune)

yes no

339

Blinded randomized trial

yes no

340

Specify trial agent:341

Other agent

yes no

342

Specify other agent:343

Other Toxicity Modifying Regimen Questions: 344 - 344

Was KGF (palifermin, Kepivance) started or is there a plan to use it?

Yes No masked trial

344

Post-HCT Disease Therapy Planned as of Day 0 Questions: 345 - 357

Is this HCT part of a planned multiple (sequential) graft / HCT protocol?

yes no

345

Is additional post-HCT therapy planned?

yes no

346

Bortezomib (Velcade)

yes no

347

Cellular therapy (e.g. DCI, DLI)

yes no

348

Dexamethasone

yes no

349

Intrathecal therapy (chemotherapy)

yes no

350

Tyrosine kinase inhibitor (e.g. imatinib mesylate)

yes no

351

Lenalidomide (Revlimid)

yes no

352

Local radiotherapy

yes no

353

Rituximab (Rituxan, MabThera)

yes no

354

Thalidomide (Thalomid)

yes no

355

Other therapy

yes no

356

Specify other therapy:357

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

OMB No: 0915-0310

Expiration Date: 1/31/2020

Public Burden Statement:  An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control
number.  The OMB control number for this project is 0915-0310.  Public reporting burden for this collection of information is estimated to average 1.0 hours per response, including the
time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other
aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance Officer, 5600 Fishers Lane, Room 10-29, Rockville, Maryland, 20857.

Center Identification

Recipient Identification

Specify the HSC source(s) for all prior HCTs:

Specify the institution that performed the last HCT:

Specify product type: 

A series of collections should be considered a single product when they are all from the same donor and use the same collection method and technique (and mobilization, if
applicable), even if the collections are performed on different days.

Questions 53 – 60 are for autologous HCT recipients only.  If other than autologous skip to question 61

Specify all agents used in the mobilization events reported above:

Specify all methods used to manipulate the product:

Performance score prior to the preparative regimen:

Specify which malignancy(ies) occurred:

Indicate the total prescribed cumulative dose for the preparative regimen:

Specify radio labeled mAb:

This section is to be completed for allogeneic HCTs only; autologous HCTs continue with question 344.

Specify:

Specify in vivo monoclonal antibody:

Optional for non-U.S. Centers

Questions 347 – 357 are optional for non­U.S. centers

Center: CRID: 

Form 2400 R5.0: Pre-Transplant Essential Data

CIBMTR Form 2400 revision 5.0 last updated January 2017
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 8 / 12



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

EBMT Code (CIC):

Hospital:

Unit (check only one)

Adult Pediatric

CIBMTR Research ID:  (CRID)

Recipient Data Questions: 1 - 10

Date of birth:1 __ __ __ __ - __ __- __ __

Sex

male female

2

Ethnicity3

Hispanic or Latino

Not Hispanic or Latino

Not applicable (not a resident of the USA)

Unknown

Race (1) Questions: 4 - 4

Race4

Zip or postal code for place of recipient’s residence: (USA recipients only)5

Is the recipient participating in a clinical trial?

yes no

6

Clinical Trials (1) Questions: 7 - 10

Study Sponsor7

Specify other sponsor:8

Study ID Number9

Subject ID:10

Hematopoietic Cellular Transplant (HCT) Questions: 11 - 28

Date of this HCT:11 __ __ __ __ - __ __- __ __

Was this the first HCT for this recipient?

yes no

12

Is a subsequent HCT planned as part of the overall treatment protocol (not as a reaction to post-HCT disease assessment)? (For autologous HCTs only)

yes no

13

Specify subsequent HCT planned

Autologous Allogeneic

14

Specify the number of prior HCTs:15

Autologous

yes no

16

Allogeneic, unrelated

yes no

17

Allogeneic, related

yes no

18

Syngeneic

yes no

19

Date of the last HCT: (just before current HCT)20 __ __ __ __ - __ __- __ __

Was the last HCT performed at a different institution?

yes no

21

Name:22

City:

State:

Country:

What was the HSC source for the last HCT?23

Autologous

Allogeneic, unrelated donor

Allogeneic, related donor

Reason for current HCT24

Date of graft failure / rejection:25 __ __ __ __ - __ __- __ __

Date of relapse:26 __ __ __ __ - __ __- __ __

Date of secondary malignancy:27 __ __ __ __ - __ __- __ __

Specify other reason:28

Donor Information Questions: 29 - 63

Multiple donors?

yes no

29

Specify number of donors:30

Donor Information for this HCT (1) Questions: 31 - 63

Specify donor31

NMDP cord blood unit ID:32

NMDP donor ID:33

Non-NMDP unrelated donor ID: (not applicable for related donors)34

Non-NMDP cord blood unit ID: (include related and autologous CBUs)35

Is the CBU ID also the ISBT DIN number?

yes no

36

Specify the ISBT DIN number:37

Registry or UCB Bank ID38

Specify other Registry or UCB Bank:39

Specify the related donor type40

Syngeneic (monozygotic twin)

HLA-identical sibling (may include non-monozygotic twin)

HLA-matched other relative

HLA-mismatched relative

Date of birth (donor / infant)

Known Unknown

41

Date of birth: (donor / infant)42 __ __ __ __ - __ __- __ __

Age (donor / infant)

Known Unknown

43

Age: (donor / infant)44 Months (use only if less than 1 year old)

years

Sex (donor / infant)

male female

45

Bone marrow

yes no

46

PBSC

yes no

47

Single cord blood unit

yes no

48

Other product

yes no

49

Specify other product type:50

Specify number of products infused from this donor:51

Specify the number of these products intended to achieve hematopoietic engraftment:52

Did the recipient have more than one mobilization event to acquire cells for HCT?

yes no

53

Specify the total number of mobilization events performed for this HCT: (regardless of the number of collections or which collections were
used for this HCT)

54

G-CSF

yes no

55

GM-CSF

yes no

56

Pegylated G-CSF

yes no

57

Plerixafor (Mozobil)

yes no

58

Other CXCR4 inhibitor

yes no

59

Combined with chemotherapy

yes no

60

Was this donor used for any prior HCTs?

yes no

61

Donor CMV-antibodies (IgG or Total) (Allogeneic HCTs only)62

Reactive

Non-reactive

Not done

Not applicable (cord blood unit)

Was plerixafor (Mozobil) given at any time prior to the preparative regimen? (Related HCTs only)

yes no Unknown

63

Consent Questions: 64 - 71

Has the recipient signed an IRB-approved consent form for submitting research data to the NMDP / CIBMTR?64

Yes (patient consented)

No (patient declined)

Not approached

Date form was signed:65 __ __ __ __ - __ __- __ __

Did the recipient give permission to be directly contacted for future research?66

Yes (patient provided permission)

No (patient declined)

Not approached

Date form was signed:67 __ __ __ __ - __ __- __ __

Has the recipient signed an IRB-approved consent form to donate research blood samples to the NMDP / CIBMTR?68

Yes (patient consented)

No (patient declined)

Not approached

Not applicable (center not participating)

Date form was signed:69 __ __ __ __ - __ __- __ __

Has the donor signed an IRB-approved consent form to donate research blood samples to the NMDP / CIBMTR? (Allogeneic donors only)70

Yes (donor consented)

No (donor declined)

Not approached

Not applicable (center not participating)

Date form was signed:71 __ __ __ __ - __ __- __ __

Product Processing / Manipulation Questions: 72 - 90

Was the product manipulated prior to infusion?

yes no

72

Specify portion manipulated

entire product portion of product

73

Washed

yes no

74

Diluted

yes no

75

Buffy coat enriched (buffy coat preparation)

yes no

76

B-cell reduced

yes no

77

CD8 reduced

yes no

78

Plasma reduced (removal)

yes no

79

RBC reduced

yes no

80

Cultured (ex-vivo expansion)

yes no

81

Genetic manipulation (gene transfer / transduction)

yes no

82

PUVA treated

yes no

83

CD34 enriched (CD34+ selection)

yes no

84

CD133 enriched

yes no

85

Monocyte enriched

yes no

86

Mononuclear cells enriched

yes no

87

T-cell depletion

yes no

88

Other cell manipulation

yes no

89

Specify other cell manipulation:90

Clinical Status of Recipient Prior to the Preparative Regimen (Conditioning) Questions: 91 - 94

What scale was used to determine the recipient’s functional status?91

Karnofsky (recipient age ≥ 16 years)

Lansky (recipient age < 16 years) 

Karnofsky Scale (recipient age ≥ 16 years)92

Lansky Scale (recipient age < 16 years)93

Recipient CMV-antibodies (IgG or Total)

Reactive Non-reactive Not done

94

Comorbid Conditions Questions: 95 - 155

Is there a history of mechanical ventilation?

yes no

95

Is there a history of proven invasive fungal infection?

yes no

96

Were there clinically significant co-existing diseases or organ impairment at time of patient assessment prior to preparative regimen? Source: Blood, 2005 Oct 15;106(8):2912-2919

yes no

97

Arrhythmia - For example, any history of atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias requiring treatment

yes no Unknown

98

Cardiac - Any history of coronary artery disease (one or more vessel-coronary artery stenosis requiring medical treatment, stent, or bypass graft), congestive heart
failure, myocardial infarction, OR ejection fraction ≤ 50% on the most recent test

yes no Unknown

99

Cerebrovascular disease - Any history of transient ischemic attack, subarachnoid hemorrhage or cerebrovascular accident

yes no Unknown

100

Diabetes - Requiring treatment with insulin or oral hypoglycemics in the last 4 weeks but not diet alone

yes no Unknown

101

Heart valve disease - Except asymptomatic mitral valve prolapse

yes no Unknown

102

Hepatic, mild ­ Chronic hepatitis, bilirubin > upper limit of normal to 1.5 × upper limit of normal, or AST/ALT > upper limit of normal to 2.5 × upper limit of normal at the
time of transplant OR any history of hepatitis B or hepatitis C infection

yes no Unknown

103

Hepatic, moderate / severe ­ Liver cirrhosis, bilirubin > 1.5 × upper limit of normal, or AST/ALT > 2.5 × upper limit of normal

yes no Unknown

104

Infection - For example, documented infection, fever of unknown origin, or pulmonary nodules requiring continuation of antimicrobial treatment after day 0

yes no Unknown

105

Inflammatory bowel disease ­ Any history of Crohn’s disease or ulcerative colitis requiring treatment

yes no Unknown

106

Obesity - Patients with a body mass index > 35 kg/m2  prior to the start of conditioning

yes no Unknown

107

Peptic ulcer - Any history of peptic ulcer confirmed by endoscopy and requiring treatment

yes no Unknown

108

Psychiatric disturbance - For example, depression, anxiety, bipolar disorder or schizophrenia requiring psychiatric consult or treatment in the last 4 weeks

yes no Unknown

109

Pulmonary, moderate - Corrected diffusion capacity of carbon monoxide and/or FEV1 66-80% or dyspnea on slight activity at transplant

yes no Unknown

110

Pulmonary, severe - Corrected diffusion capacity of carbon monoxide and/or FEV1 ≤ 65% or dyspnea at rest or requiring oxygen at transplant

yes no Unknown

111

Renal, moderate / severe ­ Serum creatinine > 2 mg/dL or > 177 µmol/L or on dialysis at transplant, OR prior renal transplantation

yes no Unknown

112

Rheumatologic - For example, any history of systemic lupus erythmatosis, rheumatoid arthritis, polymyositis, mixed connective tissue disease, or polymyalgia
rheumatica requiring treatment (do NOT include degenerative joint disease, osteoarthritis)

yes no Unknown

113

Solid tumor, prior ­ Treated at any time point in the patient’s past history, excluding non­melanoma skin cancer, leukemia, lymphoma or multiple myeloma

yes no Unknown

114

Breast cancer

yes no

115

Year of diagnosis:116

Central nervous system (CNS) malignancy (glioblastoma, astrocytoma)

yes no

117

Year of diagnosis:118

Gastrointestinal malignancy (colon, rectum, stomach, pancreas, intestine)

yes no

119

Year of diagnosis:120

Genitourinary malignancy (kidney, bladder, ovary, testicle, genitalia, uterus, cervix)

yes no

121

Year of diagnosis:122

Lung cancer

yes no

123

Year of diagnosis:124

Melanoma

yes no

125

Year of diagnosis:126

Oropharyngeal cancer (tongue, buccal mucosa)

yes no

127

Year of diagnosis:128

Sarcoma

yes no

129

Year of diagnosis:130

Thyroid cancer

yes no

131

Year of diagnosis:132

Other co-morbid condition

yes no Unknown

133

Specify other co-morbid condition:134

Was there a history of malignancy (hematologic or non-melanoma skin cancer) other than the primary disease for which this HCT is being performed?

yes no

135

Acute myeloid leukemia (AML / ANLL)

yes no

136

Year of diagnosis:137

Other leukemia, including ALL

yes no

138

Year of diagnosis:139

Specify leukemia:140

Clonal cytogenetic abnormality without leukemia or MDS

yes no

141

Year of diagnosis:142

Hodgkin disease

yes no

143

Year of diagnosis:144

Lymphoma or lymphoproliferative disease

yes no

145

Year of diagnosis:146

Was the tumor EBV positive?

yes no

147

Other skin malignancy (basal cell, squamous)

yes no

148

Year of diagnosis:149

Specify other skin malignancy:150

Myelodysplasia (MDS) / myeloproliferative (MPN) disorder

yes no

151

Year of diagnosis:152

Other prior malignancy

yes no

153

Year of diagnosis:154

Specify other prior malignancy:155

Pre-HCT Preparative Regimen (Conditioning) Questions: 156 - 316

Height at initiation of pre-HCT preparative regimen:156 inches centimeters

Actual weight at initiation of pre-HCT preparative regimen:157 pounds kilograms

Was a pre-HCT preparative regimen prescribed?

yes no

158

Classify the recipient’s prescribed preparative regimen (Allogeneic HCTs only)159

Myeloablative

Non-myeloablative (NST)

Reduced intensity (RIC)

Date pre-HCT preparative regimen began: (irradiation or drugs)160 __ __ __ __ - __ __- __ __ (Use earliest date from question 164 radiation, or 169 - 316 chemotherapy)

Was irradiation planned as part of the pre-HCT preparative regimen?

yes no

161

What was the prescribed radiation field?162

Total body

Total body by intensity-modulated radiation therapy (IMRT)

Total lymphoid or nodal regions

Thoracoabdominal region

Total prescribed dose: (dose per fraction x total number of fractions) 163 Gy cGy

Date started:164 __ __ __ __ - __ __- __ __

Was the radiation fractionated?

yes no

165

Prescribed dose per fraction:166 Gy cGy

Number of days: (include "rest" days)167

Total number of fractions:168

ALG, ALS, ATG, ATS

yes no

169

Total prescribed dose:170 mg/kg

Date started:171 __ __ __ __ - __ __- __ __

Specify source172

ATGAM (horse)

ATG - Fresenius (rabbit)

Thymoglobulin (rabbit)

Other

Specify other source:173

Anthracycline

yes no

174

Daunorubicin

yes no

175

Total prescribed dose :176 mg/m2 mg/kg

Date started:177 __ __ __ __ - __ __- __ __

Doxorubicin (Adriamycin)

yes no

178

Total prescribed dose :179 mg/m2 mg/kg

Date started:180 __ __ __ __ - __ __- __ __

Idarubicin

yes no

181

Total prescribed dose :182 mg/m2 mg/kg

Date started:183 __ __ __ __ - __ __- __ __

Rubidazone

yes no

184

Total prescribed dose :185 mg/m2 mg/kg

Date started:186 __ __ __ __ - __ __- __ __

Other anthracycline

yes no

187

Total prescribed dose :188 mg/m2 mg/kg

Date started:189 __ __ __ __ - __ __- __ __

Specify other anthracycline:190

Bleomycin (BLM, Blenoxane)

yes no

191

Total prescribed dose :192 mg/m2 mg/kg

Date started:193 __ __ __ __ - __ __- __ __

Busulfan (Myleran)

yes no

194

Total prescribed dose :195 mg/m2

mg/kg

Target total AUC (µmol x min/L)

Date started:196 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

197

Carboplatin

yes no

198

Total prescribed dose :199 mg/m2 mg/kg

Date started:200 __ __ __ __ - __ __- __ __

Were pharmacokinetics performed to determine preparative regimen drug dosing?

yes no

201

Specify the target AUC:202 mg/mL/minute

Cisplatin (Platinol, CDDP)

yes no

203

Total prescribed dose :204 mg/m2 mg/kg

Date started:205 __ __ __ __ - __ __- __ __

Cladribine (2-CdA, Leustatin)

yes no

206

Total prescribed dose :207 mg/m2 mg/kg

Date started:208 __ __ __ __ - __ __- __ __

Corticosteroids (excluding anti-nausea medication)

yes no

209

Methylprednisolone (Solu-Medrol)

yes no

210

Total prescribed dose :211 mg/m2 mg/kg

Date started:212 __ __ __ __ - __ __- __ __

Prednisone

yes no

213

Total prescribed dose :214 mg/m2 mg/kg

Date started:215 __ __ __ __ - __ __- __ __

Dexamethasone

yes no

216

Total prescribed dose :217 mg/m2 mg/kg

Date started:218 __ __ __ __ - __ __- __ __

Other corticosteroid

yes no

219

Total prescribed dose :220 mg/m2 mg/kg

Date started:221 __ __ __ __ - __ __- __ __

Specify other corticosteroid:222

Cyclophosphamide (Cytoxan)

yes no

223

Total prescribed dose :224 mg/m2 mg/kg

Date started:225 __ __ __ __ - __ __- __ __

Cytarabine (Ara-C)

yes no

226

Total prescribed dose :227 mg/m2 mg/kg

Date started:228 __ __ __ __ - __ __- __ __

Etoposide (VP-16, VePesid)

yes no

229

Total prescribed dose :230 mg/m2 mg/kg

Date started:231 __ __ __ __ - __ __- __ __

Fludarabine

yes no

232

Total prescribed dose :233 mg/m2 mg/kg

Date started:234 __ __ __ __ - __ __- __ __

Ifosfamide

yes no

235

Total prescribed dose :236 mg/m2 mg/kg

Date started:237 __ __ __ __ - __ __- __ __

Intrathecal therapy (chemotherapy)

yes no

238

Intrathecal cytarabine (IT Ara-C)

yes no

239

Total prescribed dose :240 mg/m2 mg/kg

Date started:241 __ __ __ __ - __ __- __ __

Intrathecal methotrexate (IT MTX)

yes no

242

Total prescribed dose :243 mg/m2 mg/kg

Date started:244 __ __ __ __ - __ __- __ __

Intrathecal thiotepa

yes no

245

Total prescribed dose :246 mg/m2 mg/kg

Date started:247 __ __ __ __ - __ __- __ __

Other intrathecal drug

yes no

248

Total prescribed dose :249 mg/m2 mg/kg

Date started:250 __ __ __ __ - __ __- __ __

Specify other intrathecal drug:251

Melphalan (L-Pam)

yes no

252

Total prescribed dose :253 mg/m2 mg/kg

Date started:254 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

255

Mitoxantrone (Novantrone)

yes no

256

Total prescribed dose :257 mg/m2 mg/kg

Date started:258 __ __ __ __ - __ __- __ __

Monoclonal antibody

yes no

259

Radio labeled mAb

yes no

260

Total prescribed dose of radioactive component:261 mCi MBq

Date started:262 __ __ __ __ - __ __- __ __

Tositumomab (Bexxar)

yes no

263

Ibritumomab tiuxetan (Zevalin)

yes no

264

Other radio labeled mAb

yes no

265

Specify other radio labeled mAb:266

Alemtuzumab (Campath)

yes no

267

Total prescribed dose :268 mg/m2 mg/kg

Date started:269 __ __ __ __ - __ __- __ __

Rituximab (Rituxan, anti CD20)

yes no

270

Total prescribed dose :271 mg/m2 mg/kg

Date started:272 __ __ __ __ - __ __- __ __

Gemtuzumab (Mylotarg, anti CD33)

yes no

273

Total prescribed dose :274 mg/m2 mg/kg

Date started:275 __ __ __ __ - __ __- __ __

Other mAb

yes no

276

Total prescribed dose :277 mg/m2 mg/kg

Date started:278 __ __ __ __ - __ __- __ __

Specify other mAb:279

Nitrosourea

yes no

280

Carmustine (BCNU)

yes no

281

Total prescribed dose :282 mg/m2 mg/kg

Date started:283 __ __ __ __ - __ __- __ __

CCNU (Lomustine)

yes no

284

Total prescribed dose :285 mg/m2 mg/kg

Date started:286 __ __ __ __ - __ __- __ __

Other nitrosourea

yes no

287

Total prescribed dose :288 mg/m2 mg/kg

Date started:289 __ __ __ __ - __ __- __ __

Specify other nitrosourea:290

Paclitaxel (Taxol, Xyotax)

yes no

291

Total prescribed dose :292 mg/m2 mg/kg

Date started:293 __ __ __ __ - __ __- __ __

Teniposide (VM26)

yes no

294

Total prescribed dose :295 mg/m2 mg/kg

Date started:296 __ __ __ __ - __ __- __ __

Thiotepa

yes no

297

Total prescribed dose :298 mg/m2 mg/kg

Date started:299 __ __ __ __ - __ __- __ __

Treosulfan

yes no

300

Total prescribed dose :301 mg/m2 mg/kg

Date started:302 __ __ __ __ - __ __- __ __

Tyrosine kinase inhibitors

yes no

303

Dasatinib (Sprycel)

yes no

304

Total prescribed dose :305 mg/m2 mg/kg

Date started:306 __ __ __ __ - __ __- __ __

Imatinib mesylate (STI571, Gleevec)

yes no

307

Total prescribed dose :308 mg/m2 mg/kg

Date started:309 __ __ __ __ - __ __- __ __

Nilotinib

yes no

310

Total prescribed dose :311 mg/m2 mg/kg

Date started:312 __ __ __ __ - __ __- __ __

Other drug

yes no

313

Total prescribed dose :314 mg/m2 mg/kg

Date started:315 __ __ __ __ - __ __- __ __

Specify other drug:316

GVHD Prophylaxis Questions: 317 - 343

Was GVHD prophylaxis planned / given?

yes no

317

ALG, ALS, ATG, ATS

yes no

318

Total dose:319 mg/kg

Specify source320

ATGAM (horse)

ATG - Fresenius (rabbit)

Thymoglobulin (rabbit)

Other

Specify other source:321

Corticosteroids (systemic)

yes no

322

Cyclosporine (CSA, Neoral, Sandimmune)

yes no

323

Cyclophosphamide (Cytoxan)

yes no

324

Extra-corporeal photopheresis (ECP)

yes no

325

FK 506 (Tacrolimus, Prograf)

yes no

326

In vivo monoclonal antibody

yes no

327

Alemtuzumab (Campath)

yes no

328

Anti CD 25 (Zenapax, Daclizumab, AntiTAC)

yes no

329

Specify:330

Etanercept (Enbrel)

yes no

331

Infliximab (Remicade)

yes no

332

Other in vivo monoclonal antibody

yes no

333

Specify antibody:334

In vivo immunotoxin

yes no

335

Specify immunotoxin:336

Methotrexate (MTX) (Amethopterin)

yes no

337

Mycophenolate mofetil (MMF) (CellCept)

yes no

338

Sirolimus (Rapamycin, Rapamune)

yes no

339

Blinded randomized trial

yes no

340

Specify trial agent:341

Other agent

yes no

342

Specify other agent:343

Other Toxicity Modifying Regimen Questions: 344 - 344

Was KGF (palifermin, Kepivance) started or is there a plan to use it?

Yes No masked trial

344

Post-HCT Disease Therapy Planned as of Day 0 Questions: 345 - 357

Is this HCT part of a planned multiple (sequential) graft / HCT protocol?

yes no

345

Is additional post-HCT therapy planned?

yes no

346

Bortezomib (Velcade)

yes no

347

Cellular therapy (e.g. DCI, DLI)

yes no

348

Dexamethasone

yes no

349

Intrathecal therapy (chemotherapy)

yes no

350

Tyrosine kinase inhibitor (e.g. imatinib mesylate)

yes no

351

Lenalidomide (Revlimid)

yes no

352

Local radiotherapy

yes no

353

Rituximab (Rituxan, MabThera)

yes no

354

Thalidomide (Thalomid)

yes no

355

Other therapy

yes no

356

Specify other therapy:357

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

OMB No: 0915-0310

Expiration Date: 1/31/2020

Public Burden Statement:  An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control
number.  The OMB control number for this project is 0915-0310.  Public reporting burden for this collection of information is estimated to average 1.0 hours per response, including the
time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other
aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance Officer, 5600 Fishers Lane, Room 10-29, Rockville, Maryland, 20857.

Center Identification

Recipient Identification

Specify the HSC source(s) for all prior HCTs:

Specify the institution that performed the last HCT:

Specify product type: 

A series of collections should be considered a single product when they are all from the same donor and use the same collection method and technique (and mobilization, if
applicable), even if the collections are performed on different days.

Questions 53 – 60 are for autologous HCT recipients only.  If other than autologous skip to question 61

Specify all agents used in the mobilization events reported above:

Specify all methods used to manipulate the product:

Performance score prior to the preparative regimen:

Specify which malignancy(ies) occurred:

Indicate the total prescribed cumulative dose for the preparative regimen:

Specify radio labeled mAb:

This section is to be completed for allogeneic HCTs only; autologous HCTs continue with question 344.

Specify:

Specify in vivo monoclonal antibody:

Optional for non-U.S. Centers

Questions 347 – 357 are optional for non­U.S. centers

Center: CRID: 

Form 2400 R5.0: Pre-Transplant Essential Data

CIBMTR Form 2400 revision 5.0 last updated January 2017
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 9 / 12



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

EBMT Code (CIC):

Hospital:

Unit (check only one)

Adult Pediatric

CIBMTR Research ID:  (CRID)

Recipient Data Questions: 1 - 10

Date of birth:1 __ __ __ __ - __ __- __ __

Sex

male female

2

Ethnicity3

Hispanic or Latino

Not Hispanic or Latino

Not applicable (not a resident of the USA)

Unknown

Race (1) Questions: 4 - 4

Race4

Zip or postal code for place of recipient’s residence: (USA recipients only)5

Is the recipient participating in a clinical trial?

yes no

6

Clinical Trials (1) Questions: 7 - 10

Study Sponsor7

Specify other sponsor:8

Study ID Number9

Subject ID:10

Hematopoietic Cellular Transplant (HCT) Questions: 11 - 28

Date of this HCT:11 __ __ __ __ - __ __- __ __

Was this the first HCT for this recipient?

yes no

12

Is a subsequent HCT planned as part of the overall treatment protocol (not as a reaction to post-HCT disease assessment)? (For autologous HCTs only)

yes no

13

Specify subsequent HCT planned

Autologous Allogeneic

14

Specify the number of prior HCTs:15

Autologous

yes no

16

Allogeneic, unrelated

yes no

17

Allogeneic, related

yes no

18

Syngeneic

yes no

19

Date of the last HCT: (just before current HCT)20 __ __ __ __ - __ __- __ __

Was the last HCT performed at a different institution?

yes no

21

Name:22

City:

State:

Country:

What was the HSC source for the last HCT?23

Autologous

Allogeneic, unrelated donor

Allogeneic, related donor

Reason for current HCT24

Date of graft failure / rejection:25 __ __ __ __ - __ __- __ __

Date of relapse:26 __ __ __ __ - __ __- __ __

Date of secondary malignancy:27 __ __ __ __ - __ __- __ __

Specify other reason:28

Donor Information Questions: 29 - 63

Multiple donors?

yes no

29

Specify number of donors:30

Donor Information for this HCT (1) Questions: 31 - 63

Specify donor31

NMDP cord blood unit ID:32

NMDP donor ID:33

Non-NMDP unrelated donor ID: (not applicable for related donors)34

Non-NMDP cord blood unit ID: (include related and autologous CBUs)35

Is the CBU ID also the ISBT DIN number?

yes no

36

Specify the ISBT DIN number:37

Registry or UCB Bank ID38

Specify other Registry or UCB Bank:39

Specify the related donor type40

Syngeneic (monozygotic twin)

HLA-identical sibling (may include non-monozygotic twin)

HLA-matched other relative

HLA-mismatched relative

Date of birth (donor / infant)

Known Unknown

41

Date of birth: (donor / infant)42 __ __ __ __ - __ __- __ __

Age (donor / infant)

Known Unknown

43

Age: (donor / infant)44 Months (use only if less than 1 year old)

years

Sex (donor / infant)

male female

45

Bone marrow

yes no

46

PBSC

yes no

47

Single cord blood unit

yes no

48

Other product

yes no

49

Specify other product type:50

Specify number of products infused from this donor:51

Specify the number of these products intended to achieve hematopoietic engraftment:52

Did the recipient have more than one mobilization event to acquire cells for HCT?

yes no

53

Specify the total number of mobilization events performed for this HCT: (regardless of the number of collections or which collections were
used for this HCT)

54

G-CSF

yes no

55

GM-CSF

yes no

56

Pegylated G-CSF

yes no

57

Plerixafor (Mozobil)

yes no

58

Other CXCR4 inhibitor

yes no

59

Combined with chemotherapy

yes no

60

Was this donor used for any prior HCTs?

yes no

61

Donor CMV-antibodies (IgG or Total) (Allogeneic HCTs only)62

Reactive

Non-reactive

Not done

Not applicable (cord blood unit)

Was plerixafor (Mozobil) given at any time prior to the preparative regimen? (Related HCTs only)

yes no Unknown

63

Consent Questions: 64 - 71

Has the recipient signed an IRB-approved consent form for submitting research data to the NMDP / CIBMTR?64

Yes (patient consented)

No (patient declined)

Not approached

Date form was signed:65 __ __ __ __ - __ __- __ __

Did the recipient give permission to be directly contacted for future research?66

Yes (patient provided permission)

No (patient declined)

Not approached

Date form was signed:67 __ __ __ __ - __ __- __ __

Has the recipient signed an IRB-approved consent form to donate research blood samples to the NMDP / CIBMTR?68

Yes (patient consented)

No (patient declined)

Not approached

Not applicable (center not participating)

Date form was signed:69 __ __ __ __ - __ __- __ __

Has the donor signed an IRB-approved consent form to donate research blood samples to the NMDP / CIBMTR? (Allogeneic donors only)70

Yes (donor consented)

No (donor declined)

Not approached

Not applicable (center not participating)

Date form was signed:71 __ __ __ __ - __ __- __ __

Product Processing / Manipulation Questions: 72 - 90

Was the product manipulated prior to infusion?

yes no

72

Specify portion manipulated

entire product portion of product

73

Washed

yes no

74

Diluted

yes no

75

Buffy coat enriched (buffy coat preparation)

yes no

76

B-cell reduced

yes no

77

CD8 reduced

yes no

78

Plasma reduced (removal)

yes no

79

RBC reduced

yes no

80

Cultured (ex-vivo expansion)

yes no

81

Genetic manipulation (gene transfer / transduction)

yes no

82

PUVA treated

yes no

83

CD34 enriched (CD34+ selection)

yes no

84

CD133 enriched

yes no

85

Monocyte enriched

yes no

86

Mononuclear cells enriched

yes no

87

T-cell depletion

yes no

88

Other cell manipulation

yes no

89

Specify other cell manipulation:90

Clinical Status of Recipient Prior to the Preparative Regimen (Conditioning) Questions: 91 - 94

What scale was used to determine the recipient’s functional status?91

Karnofsky (recipient age ≥ 16 years)

Lansky (recipient age < 16 years) 

Karnofsky Scale (recipient age ≥ 16 years)92

Lansky Scale (recipient age < 16 years)93

Recipient CMV-antibodies (IgG or Total)

Reactive Non-reactive Not done

94

Comorbid Conditions Questions: 95 - 155

Is there a history of mechanical ventilation?

yes no

95

Is there a history of proven invasive fungal infection?

yes no

96

Were there clinically significant co-existing diseases or organ impairment at time of patient assessment prior to preparative regimen? Source: Blood, 2005 Oct 15;106(8):2912-2919

yes no

97

Arrhythmia - For example, any history of atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias requiring treatment

yes no Unknown

98

Cardiac - Any history of coronary artery disease (one or more vessel-coronary artery stenosis requiring medical treatment, stent, or bypass graft), congestive heart
failure, myocardial infarction, OR ejection fraction ≤ 50% on the most recent test

yes no Unknown

99

Cerebrovascular disease - Any history of transient ischemic attack, subarachnoid hemorrhage or cerebrovascular accident

yes no Unknown

100

Diabetes - Requiring treatment with insulin or oral hypoglycemics in the last 4 weeks but not diet alone

yes no Unknown

101

Heart valve disease - Except asymptomatic mitral valve prolapse

yes no Unknown

102

Hepatic, mild ­ Chronic hepatitis, bilirubin > upper limit of normal to 1.5 × upper limit of normal, or AST/ALT > upper limit of normal to 2.5 × upper limit of normal at the
time of transplant OR any history of hepatitis B or hepatitis C infection

yes no Unknown

103

Hepatic, moderate / severe ­ Liver cirrhosis, bilirubin > 1.5 × upper limit of normal, or AST/ALT > 2.5 × upper limit of normal

yes no Unknown

104

Infection - For example, documented infection, fever of unknown origin, or pulmonary nodules requiring continuation of antimicrobial treatment after day 0

yes no Unknown

105

Inflammatory bowel disease ­ Any history of Crohn’s disease or ulcerative colitis requiring treatment

yes no Unknown

106

Obesity - Patients with a body mass index > 35 kg/m2  prior to the start of conditioning

yes no Unknown

107

Peptic ulcer - Any history of peptic ulcer confirmed by endoscopy and requiring treatment

yes no Unknown

108

Psychiatric disturbance - For example, depression, anxiety, bipolar disorder or schizophrenia requiring psychiatric consult or treatment in the last 4 weeks

yes no Unknown

109

Pulmonary, moderate - Corrected diffusion capacity of carbon monoxide and/or FEV1 66-80% or dyspnea on slight activity at transplant

yes no Unknown

110

Pulmonary, severe - Corrected diffusion capacity of carbon monoxide and/or FEV1 ≤ 65% or dyspnea at rest or requiring oxygen at transplant

yes no Unknown

111

Renal, moderate / severe ­ Serum creatinine > 2 mg/dL or > 177 µmol/L or on dialysis at transplant, OR prior renal transplantation

yes no Unknown

112

Rheumatologic - For example, any history of systemic lupus erythmatosis, rheumatoid arthritis, polymyositis, mixed connective tissue disease, or polymyalgia
rheumatica requiring treatment (do NOT include degenerative joint disease, osteoarthritis)

yes no Unknown

113

Solid tumor, prior ­ Treated at any time point in the patient’s past history, excluding non­melanoma skin cancer, leukemia, lymphoma or multiple myeloma

yes no Unknown

114

Breast cancer

yes no

115

Year of diagnosis:116

Central nervous system (CNS) malignancy (glioblastoma, astrocytoma)

yes no

117

Year of diagnosis:118

Gastrointestinal malignancy (colon, rectum, stomach, pancreas, intestine)

yes no

119

Year of diagnosis:120

Genitourinary malignancy (kidney, bladder, ovary, testicle, genitalia, uterus, cervix)

yes no

121

Year of diagnosis:122

Lung cancer

yes no

123

Year of diagnosis:124

Melanoma

yes no

125

Year of diagnosis:126

Oropharyngeal cancer (tongue, buccal mucosa)

yes no

127

Year of diagnosis:128

Sarcoma

yes no

129

Year of diagnosis:130

Thyroid cancer

yes no

131

Year of diagnosis:132

Other co-morbid condition

yes no Unknown

133

Specify other co-morbid condition:134

Was there a history of malignancy (hematologic or non-melanoma skin cancer) other than the primary disease for which this HCT is being performed?

yes no

135

Acute myeloid leukemia (AML / ANLL)

yes no

136

Year of diagnosis:137

Other leukemia, including ALL

yes no

138

Year of diagnosis:139

Specify leukemia:140

Clonal cytogenetic abnormality without leukemia or MDS

yes no

141

Year of diagnosis:142

Hodgkin disease

yes no

143

Year of diagnosis:144

Lymphoma or lymphoproliferative disease

yes no

145

Year of diagnosis:146

Was the tumor EBV positive?

yes no

147

Other skin malignancy (basal cell, squamous)

yes no

148

Year of diagnosis:149

Specify other skin malignancy:150

Myelodysplasia (MDS) / myeloproliferative (MPN) disorder

yes no

151

Year of diagnosis:152

Other prior malignancy

yes no

153

Year of diagnosis:154

Specify other prior malignancy:155

Pre-HCT Preparative Regimen (Conditioning) Questions: 156 - 316

Height at initiation of pre-HCT preparative regimen:156 inches centimeters

Actual weight at initiation of pre-HCT preparative regimen:157 pounds kilograms

Was a pre-HCT preparative regimen prescribed?

yes no

158

Classify the recipient’s prescribed preparative regimen (Allogeneic HCTs only)159

Myeloablative

Non-myeloablative (NST)

Reduced intensity (RIC)

Date pre-HCT preparative regimen began: (irradiation or drugs)160 __ __ __ __ - __ __- __ __ (Use earliest date from question 164 radiation, or 169 - 316 chemotherapy)

Was irradiation planned as part of the pre-HCT preparative regimen?

yes no

161

What was the prescribed radiation field?162

Total body

Total body by intensity-modulated radiation therapy (IMRT)

Total lymphoid or nodal regions

Thoracoabdominal region

Total prescribed dose: (dose per fraction x total number of fractions) 163 Gy cGy

Date started:164 __ __ __ __ - __ __- __ __

Was the radiation fractionated?

yes no

165

Prescribed dose per fraction:166 Gy cGy

Number of days: (include "rest" days)167

Total number of fractions:168

ALG, ALS, ATG, ATS

yes no

169

Total prescribed dose:170 mg/kg

Date started:171 __ __ __ __ - __ __- __ __

Specify source172

ATGAM (horse)

ATG - Fresenius (rabbit)

Thymoglobulin (rabbit)

Other

Specify other source:173

Anthracycline

yes no

174

Daunorubicin

yes no

175

Total prescribed dose :176 mg/m2 mg/kg

Date started:177 __ __ __ __ - __ __- __ __

Doxorubicin (Adriamycin)

yes no

178

Total prescribed dose :179 mg/m2 mg/kg

Date started:180 __ __ __ __ - __ __- __ __

Idarubicin

yes no

181

Total prescribed dose :182 mg/m2 mg/kg

Date started:183 __ __ __ __ - __ __- __ __

Rubidazone

yes no

184

Total prescribed dose :185 mg/m2 mg/kg

Date started:186 __ __ __ __ - __ __- __ __

Other anthracycline

yes no

187

Total prescribed dose :188 mg/m2 mg/kg

Date started:189 __ __ __ __ - __ __- __ __

Specify other anthracycline:190

Bleomycin (BLM, Blenoxane)

yes no

191

Total prescribed dose :192 mg/m2 mg/kg

Date started:193 __ __ __ __ - __ __- __ __

Busulfan (Myleran)

yes no

194

Total prescribed dose :195 mg/m2

mg/kg

Target total AUC (µmol x min/L)

Date started:196 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

197

Carboplatin

yes no

198

Total prescribed dose :199 mg/m2 mg/kg

Date started:200 __ __ __ __ - __ __- __ __

Were pharmacokinetics performed to determine preparative regimen drug dosing?

yes no

201

Specify the target AUC:202 mg/mL/minute

Cisplatin (Platinol, CDDP)

yes no

203

Total prescribed dose :204 mg/m2 mg/kg

Date started:205 __ __ __ __ - __ __- __ __

Cladribine (2-CdA, Leustatin)

yes no

206

Total prescribed dose :207 mg/m2 mg/kg

Date started:208 __ __ __ __ - __ __- __ __

Corticosteroids (excluding anti-nausea medication)

yes no

209

Methylprednisolone (Solu-Medrol)

yes no

210

Total prescribed dose :211 mg/m2 mg/kg

Date started:212 __ __ __ __ - __ __- __ __

Prednisone

yes no

213

Total prescribed dose :214 mg/m2 mg/kg

Date started:215 __ __ __ __ - __ __- __ __

Dexamethasone

yes no

216

Total prescribed dose :217 mg/m2 mg/kg

Date started:218 __ __ __ __ - __ __- __ __

Other corticosteroid

yes no

219

Total prescribed dose :220 mg/m2 mg/kg

Date started:221 __ __ __ __ - __ __- __ __

Specify other corticosteroid:222

Cyclophosphamide (Cytoxan)

yes no

223

Total prescribed dose :224 mg/m2 mg/kg

Date started:225 __ __ __ __ - __ __- __ __

Cytarabine (Ara-C)

yes no

226

Total prescribed dose :227 mg/m2 mg/kg

Date started:228 __ __ __ __ - __ __- __ __

Etoposide (VP-16, VePesid)

yes no

229

Total prescribed dose :230 mg/m2 mg/kg

Date started:231 __ __ __ __ - __ __- __ __

Fludarabine

yes no

232

Total prescribed dose :233 mg/m2 mg/kg

Date started:234 __ __ __ __ - __ __- __ __

Ifosfamide

yes no

235

Total prescribed dose :236 mg/m2 mg/kg

Date started:237 __ __ __ __ - __ __- __ __

Intrathecal therapy (chemotherapy)

yes no

238

Intrathecal cytarabine (IT Ara-C)

yes no

239

Total prescribed dose :240 mg/m2 mg/kg

Date started:241 __ __ __ __ - __ __- __ __

Intrathecal methotrexate (IT MTX)

yes no

242

Total prescribed dose :243 mg/m2 mg/kg

Date started:244 __ __ __ __ - __ __- __ __

Intrathecal thiotepa

yes no

245

Total prescribed dose :246 mg/m2 mg/kg

Date started:247 __ __ __ __ - __ __- __ __

Other intrathecal drug

yes no

248

Total prescribed dose :249 mg/m2 mg/kg

Date started:250 __ __ __ __ - __ __- __ __

Specify other intrathecal drug:251

Melphalan (L-Pam)

yes no

252

Total prescribed dose :253 mg/m2 mg/kg

Date started:254 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

255

Mitoxantrone (Novantrone)

yes no

256

Total prescribed dose :257 mg/m2 mg/kg

Date started:258 __ __ __ __ - __ __- __ __

Monoclonal antibody

yes no

259

Radio labeled mAb

yes no

260

Total prescribed dose of radioactive component:261 mCi MBq

Date started:262 __ __ __ __ - __ __- __ __

Tositumomab (Bexxar)

yes no

263

Ibritumomab tiuxetan (Zevalin)

yes no

264

Other radio labeled mAb

yes no

265

Specify other radio labeled mAb:266

Alemtuzumab (Campath)

yes no

267

Total prescribed dose :268 mg/m2 mg/kg

Date started:269 __ __ __ __ - __ __- __ __

Rituximab (Rituxan, anti CD20)

yes no

270

Total prescribed dose :271 mg/m2 mg/kg

Date started:272 __ __ __ __ - __ __- __ __

Gemtuzumab (Mylotarg, anti CD33)

yes no

273

Total prescribed dose :274 mg/m2 mg/kg

Date started:275 __ __ __ __ - __ __- __ __

Other mAb

yes no

276

Total prescribed dose :277 mg/m2 mg/kg

Date started:278 __ __ __ __ - __ __- __ __

Specify other mAb:279

Nitrosourea

yes no

280

Carmustine (BCNU)

yes no

281

Total prescribed dose :282 mg/m2 mg/kg

Date started:283 __ __ __ __ - __ __- __ __

CCNU (Lomustine)

yes no

284

Total prescribed dose :285 mg/m2 mg/kg

Date started:286 __ __ __ __ - __ __- __ __

Other nitrosourea

yes no

287

Total prescribed dose :288 mg/m2 mg/kg

Date started:289 __ __ __ __ - __ __- __ __

Specify other nitrosourea:290

Paclitaxel (Taxol, Xyotax)

yes no

291

Total prescribed dose :292 mg/m2 mg/kg

Date started:293 __ __ __ __ - __ __- __ __

Teniposide (VM26)

yes no

294

Total prescribed dose :295 mg/m2 mg/kg

Date started:296 __ __ __ __ - __ __- __ __

Thiotepa

yes no

297

Total prescribed dose :298 mg/m2 mg/kg

Date started:299 __ __ __ __ - __ __- __ __

Treosulfan

yes no

300

Total prescribed dose :301 mg/m2 mg/kg

Date started:302 __ __ __ __ - __ __- __ __

Tyrosine kinase inhibitors

yes no

303

Dasatinib (Sprycel)

yes no

304

Total prescribed dose :305 mg/m2 mg/kg

Date started:306 __ __ __ __ - __ __- __ __

Imatinib mesylate (STI571, Gleevec)

yes no

307

Total prescribed dose :308 mg/m2 mg/kg

Date started:309 __ __ __ __ - __ __- __ __

Nilotinib

yes no

310

Total prescribed dose :311 mg/m2 mg/kg

Date started:312 __ __ __ __ - __ __- __ __

Other drug

yes no

313

Total prescribed dose :314 mg/m2 mg/kg

Date started:315 __ __ __ __ - __ __- __ __

Specify other drug:316

GVHD Prophylaxis Questions: 317 - 343

Was GVHD prophylaxis planned / given?

yes no

317

ALG, ALS, ATG, ATS

yes no

318

Total dose:319 mg/kg

Specify source320

ATGAM (horse)

ATG - Fresenius (rabbit)

Thymoglobulin (rabbit)

Other

Specify other source:321

Corticosteroids (systemic)

yes no

322

Cyclosporine (CSA, Neoral, Sandimmune)

yes no

323

Cyclophosphamide (Cytoxan)

yes no

324

Extra-corporeal photopheresis (ECP)

yes no

325

FK 506 (Tacrolimus, Prograf)

yes no

326

In vivo monoclonal antibody

yes no

327

Alemtuzumab (Campath)

yes no

328

Anti CD 25 (Zenapax, Daclizumab, AntiTAC)

yes no

329

Specify:330

Etanercept (Enbrel)

yes no

331

Infliximab (Remicade)

yes no

332

Other in vivo monoclonal antibody

yes no

333

Specify antibody:334

In vivo immunotoxin

yes no

335

Specify immunotoxin:336

Methotrexate (MTX) (Amethopterin)

yes no

337

Mycophenolate mofetil (MMF) (CellCept)

yes no

338

Sirolimus (Rapamycin, Rapamune)

yes no

339

Blinded randomized trial

yes no

340

Specify trial agent:341

Other agent

yes no

342

Specify other agent:343

Other Toxicity Modifying Regimen Questions: 344 - 344

Was KGF (palifermin, Kepivance) started or is there a plan to use it?

Yes No masked trial

344

Post-HCT Disease Therapy Planned as of Day 0 Questions: 345 - 357

Is this HCT part of a planned multiple (sequential) graft / HCT protocol?

yes no

345

Is additional post-HCT therapy planned?

yes no

346

Bortezomib (Velcade)

yes no

347

Cellular therapy (e.g. DCI, DLI)

yes no

348

Dexamethasone

yes no

349

Intrathecal therapy (chemotherapy)

yes no

350

Tyrosine kinase inhibitor (e.g. imatinib mesylate)

yes no

351

Lenalidomide (Revlimid)

yes no

352

Local radiotherapy

yes no

353

Rituximab (Rituxan, MabThera)

yes no

354

Thalidomide (Thalomid)

yes no

355

Other therapy

yes no

356

Specify other therapy:357

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

OMB No: 0915-0310

Expiration Date: 1/31/2020

Public Burden Statement:  An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control
number.  The OMB control number for this project is 0915-0310.  Public reporting burden for this collection of information is estimated to average 1.0 hours per response, including the
time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other
aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance Officer, 5600 Fishers Lane, Room 10-29, Rockville, Maryland, 20857.

Center Identification

Recipient Identification

Specify the HSC source(s) for all prior HCTs:

Specify the institution that performed the last HCT:

Specify product type: 

A series of collections should be considered a single product when they are all from the same donor and use the same collection method and technique (and mobilization, if
applicable), even if the collections are performed on different days.

Questions 53 – 60 are for autologous HCT recipients only.  If other than autologous skip to question 61

Specify all agents used in the mobilization events reported above:

Specify all methods used to manipulate the product:

Performance score prior to the preparative regimen:

Specify which malignancy(ies) occurred:

Indicate the total prescribed cumulative dose for the preparative regimen:

Specify radio labeled mAb:

This section is to be completed for allogeneic HCTs only; autologous HCTs continue with question 344.

Specify:

Specify in vivo monoclonal antibody:

Optional for non-U.S. Centers

Questions 347 – 357 are optional for non­U.S. centers

Center: CRID: 

Form 2400 R5.0: Pre-Transplant Essential Data

CIBMTR Form 2400 revision 5.0 last updated January 2017
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 10 / 12



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

EBMT Code (CIC):

Hospital:

Unit (check only one)

Adult Pediatric

CIBMTR Research ID:  (CRID)

Recipient Data Questions: 1 - 10

Date of birth:1 __ __ __ __ - __ __- __ __

Sex

male female

2

Ethnicity3

Hispanic or Latino

Not Hispanic or Latino

Not applicable (not a resident of the USA)

Unknown

Race (1) Questions: 4 - 4

Race4

Zip or postal code for place of recipient’s residence: (USA recipients only)5

Is the recipient participating in a clinical trial?

yes no

6

Clinical Trials (1) Questions: 7 - 10

Study Sponsor7

Specify other sponsor:8

Study ID Number9

Subject ID:10

Hematopoietic Cellular Transplant (HCT) Questions: 11 - 28

Date of this HCT:11 __ __ __ __ - __ __- __ __

Was this the first HCT for this recipient?

yes no

12

Is a subsequent HCT planned as part of the overall treatment protocol (not as a reaction to post-HCT disease assessment)? (For autologous HCTs only)

yes no

13

Specify subsequent HCT planned

Autologous Allogeneic

14

Specify the number of prior HCTs:15

Autologous

yes no

16

Allogeneic, unrelated

yes no

17

Allogeneic, related

yes no

18

Syngeneic

yes no

19

Date of the last HCT: (just before current HCT)20 __ __ __ __ - __ __- __ __

Was the last HCT performed at a different institution?

yes no

21

Name:22

City:

State:

Country:

What was the HSC source for the last HCT?23

Autologous

Allogeneic, unrelated donor

Allogeneic, related donor

Reason for current HCT24

Date of graft failure / rejection:25 __ __ __ __ - __ __- __ __

Date of relapse:26 __ __ __ __ - __ __- __ __

Date of secondary malignancy:27 __ __ __ __ - __ __- __ __

Specify other reason:28

Donor Information Questions: 29 - 63

Multiple donors?

yes no

29

Specify number of donors:30

Donor Information for this HCT (1) Questions: 31 - 63

Specify donor31

NMDP cord blood unit ID:32

NMDP donor ID:33

Non-NMDP unrelated donor ID: (not applicable for related donors)34

Non-NMDP cord blood unit ID: (include related and autologous CBUs)35

Is the CBU ID also the ISBT DIN number?

yes no

36

Specify the ISBT DIN number:37

Registry or UCB Bank ID38

Specify other Registry or UCB Bank:39

Specify the related donor type40

Syngeneic (monozygotic twin)

HLA-identical sibling (may include non-monozygotic twin)

HLA-matched other relative

HLA-mismatched relative

Date of birth (donor / infant)

Known Unknown

41

Date of birth: (donor / infant)42 __ __ __ __ - __ __- __ __

Age (donor / infant)

Known Unknown

43

Age: (donor / infant)44 Months (use only if less than 1 year old)

years

Sex (donor / infant)

male female

45

Bone marrow

yes no

46

PBSC

yes no

47

Single cord blood unit

yes no

48

Other product

yes no

49

Specify other product type:50

Specify number of products infused from this donor:51

Specify the number of these products intended to achieve hematopoietic engraftment:52

Did the recipient have more than one mobilization event to acquire cells for HCT?

yes no

53

Specify the total number of mobilization events performed for this HCT: (regardless of the number of collections or which collections were
used for this HCT)

54

G-CSF

yes no

55

GM-CSF

yes no

56

Pegylated G-CSF

yes no

57

Plerixafor (Mozobil)

yes no

58

Other CXCR4 inhibitor

yes no

59

Combined with chemotherapy

yes no

60

Was this donor used for any prior HCTs?

yes no

61

Donor CMV-antibodies (IgG or Total) (Allogeneic HCTs only)62

Reactive

Non-reactive

Not done

Not applicable (cord blood unit)

Was plerixafor (Mozobil) given at any time prior to the preparative regimen? (Related HCTs only)

yes no Unknown

63

Consent Questions: 64 - 71

Has the recipient signed an IRB-approved consent form for submitting research data to the NMDP / CIBMTR?64

Yes (patient consented)

No (patient declined)

Not approached

Date form was signed:65 __ __ __ __ - __ __- __ __

Did the recipient give permission to be directly contacted for future research?66

Yes (patient provided permission)

No (patient declined)

Not approached

Date form was signed:67 __ __ __ __ - __ __- __ __

Has the recipient signed an IRB-approved consent form to donate research blood samples to the NMDP / CIBMTR?68

Yes (patient consented)

No (patient declined)

Not approached

Not applicable (center not participating)

Date form was signed:69 __ __ __ __ - __ __- __ __

Has the donor signed an IRB-approved consent form to donate research blood samples to the NMDP / CIBMTR? (Allogeneic donors only)70

Yes (donor consented)

No (donor declined)

Not approached

Not applicable (center not participating)

Date form was signed:71 __ __ __ __ - __ __- __ __

Product Processing / Manipulation Questions: 72 - 90

Was the product manipulated prior to infusion?

yes no

72

Specify portion manipulated

entire product portion of product

73

Washed

yes no

74

Diluted

yes no

75

Buffy coat enriched (buffy coat preparation)

yes no

76

B-cell reduced

yes no

77

CD8 reduced

yes no

78

Plasma reduced (removal)

yes no

79

RBC reduced

yes no

80

Cultured (ex-vivo expansion)

yes no

81

Genetic manipulation (gene transfer / transduction)

yes no

82

PUVA treated

yes no

83

CD34 enriched (CD34+ selection)

yes no

84

CD133 enriched

yes no

85

Monocyte enriched

yes no

86

Mononuclear cells enriched

yes no

87

T-cell depletion

yes no

88

Other cell manipulation

yes no

89

Specify other cell manipulation:90

Clinical Status of Recipient Prior to the Preparative Regimen (Conditioning) Questions: 91 - 94

What scale was used to determine the recipient’s functional status?91

Karnofsky (recipient age ≥ 16 years)

Lansky (recipient age < 16 years) 

Karnofsky Scale (recipient age ≥ 16 years)92

Lansky Scale (recipient age < 16 years)93

Recipient CMV-antibodies (IgG or Total)

Reactive Non-reactive Not done

94

Comorbid Conditions Questions: 95 - 155

Is there a history of mechanical ventilation?

yes no

95

Is there a history of proven invasive fungal infection?

yes no

96

Were there clinically significant co-existing diseases or organ impairment at time of patient assessment prior to preparative regimen? Source: Blood, 2005 Oct 15;106(8):2912-2919

yes no

97

Arrhythmia - For example, any history of atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias requiring treatment

yes no Unknown

98

Cardiac - Any history of coronary artery disease (one or more vessel-coronary artery stenosis requiring medical treatment, stent, or bypass graft), congestive heart
failure, myocardial infarction, OR ejection fraction ≤ 50% on the most recent test

yes no Unknown

99

Cerebrovascular disease - Any history of transient ischemic attack, subarachnoid hemorrhage or cerebrovascular accident

yes no Unknown

100

Diabetes - Requiring treatment with insulin or oral hypoglycemics in the last 4 weeks but not diet alone

yes no Unknown

101

Heart valve disease - Except asymptomatic mitral valve prolapse

yes no Unknown

102

Hepatic, mild ­ Chronic hepatitis, bilirubin > upper limit of normal to 1.5 × upper limit of normal, or AST/ALT > upper limit of normal to 2.5 × upper limit of normal at the
time of transplant OR any history of hepatitis B or hepatitis C infection

yes no Unknown

103

Hepatic, moderate / severe ­ Liver cirrhosis, bilirubin > 1.5 × upper limit of normal, or AST/ALT > 2.5 × upper limit of normal

yes no Unknown

104

Infection - For example, documented infection, fever of unknown origin, or pulmonary nodules requiring continuation of antimicrobial treatment after day 0

yes no Unknown

105

Inflammatory bowel disease ­ Any history of Crohn’s disease or ulcerative colitis requiring treatment

yes no Unknown

106

Obesity - Patients with a body mass index > 35 kg/m2  prior to the start of conditioning

yes no Unknown

107

Peptic ulcer - Any history of peptic ulcer confirmed by endoscopy and requiring treatment

yes no Unknown

108

Psychiatric disturbance - For example, depression, anxiety, bipolar disorder or schizophrenia requiring psychiatric consult or treatment in the last 4 weeks

yes no Unknown

109

Pulmonary, moderate - Corrected diffusion capacity of carbon monoxide and/or FEV1 66-80% or dyspnea on slight activity at transplant

yes no Unknown

110

Pulmonary, severe - Corrected diffusion capacity of carbon monoxide and/or FEV1 ≤ 65% or dyspnea at rest or requiring oxygen at transplant

yes no Unknown

111

Renal, moderate / severe ­ Serum creatinine > 2 mg/dL or > 177 µmol/L or on dialysis at transplant, OR prior renal transplantation

yes no Unknown

112

Rheumatologic - For example, any history of systemic lupus erythmatosis, rheumatoid arthritis, polymyositis, mixed connective tissue disease, or polymyalgia
rheumatica requiring treatment (do NOT include degenerative joint disease, osteoarthritis)

yes no Unknown

113

Solid tumor, prior ­ Treated at any time point in the patient’s past history, excluding non­melanoma skin cancer, leukemia, lymphoma or multiple myeloma

yes no Unknown

114

Breast cancer

yes no

115

Year of diagnosis:116

Central nervous system (CNS) malignancy (glioblastoma, astrocytoma)

yes no

117

Year of diagnosis:118

Gastrointestinal malignancy (colon, rectum, stomach, pancreas, intestine)

yes no

119

Year of diagnosis:120

Genitourinary malignancy (kidney, bladder, ovary, testicle, genitalia, uterus, cervix)

yes no

121

Year of diagnosis:122

Lung cancer

yes no

123

Year of diagnosis:124

Melanoma

yes no

125

Year of diagnosis:126

Oropharyngeal cancer (tongue, buccal mucosa)

yes no

127

Year of diagnosis:128

Sarcoma

yes no

129

Year of diagnosis:130

Thyroid cancer

yes no

131

Year of diagnosis:132

Other co-morbid condition

yes no Unknown

133

Specify other co-morbid condition:134

Was there a history of malignancy (hematologic or non-melanoma skin cancer) other than the primary disease for which this HCT is being performed?

yes no

135

Acute myeloid leukemia (AML / ANLL)

yes no

136

Year of diagnosis:137

Other leukemia, including ALL

yes no

138

Year of diagnosis:139

Specify leukemia:140

Clonal cytogenetic abnormality without leukemia or MDS

yes no

141

Year of diagnosis:142

Hodgkin disease

yes no

143

Year of diagnosis:144

Lymphoma or lymphoproliferative disease

yes no

145

Year of diagnosis:146

Was the tumor EBV positive?

yes no

147

Other skin malignancy (basal cell, squamous)

yes no

148

Year of diagnosis:149

Specify other skin malignancy:150

Myelodysplasia (MDS) / myeloproliferative (MPN) disorder

yes no

151

Year of diagnosis:152

Other prior malignancy

yes no

153

Year of diagnosis:154

Specify other prior malignancy:155

Pre-HCT Preparative Regimen (Conditioning) Questions: 156 - 316

Height at initiation of pre-HCT preparative regimen:156 inches centimeters

Actual weight at initiation of pre-HCT preparative regimen:157 pounds kilograms

Was a pre-HCT preparative regimen prescribed?

yes no

158

Classify the recipient’s prescribed preparative regimen (Allogeneic HCTs only)159

Myeloablative

Non-myeloablative (NST)

Reduced intensity (RIC)

Date pre-HCT preparative regimen began: (irradiation or drugs)160 __ __ __ __ - __ __- __ __ (Use earliest date from question 164 radiation, or 169 - 316 chemotherapy)

Was irradiation planned as part of the pre-HCT preparative regimen?

yes no

161

What was the prescribed radiation field?162

Total body

Total body by intensity-modulated radiation therapy (IMRT)

Total lymphoid or nodal regions

Thoracoabdominal region

Total prescribed dose: (dose per fraction x total number of fractions) 163 Gy cGy

Date started:164 __ __ __ __ - __ __- __ __

Was the radiation fractionated?

yes no

165

Prescribed dose per fraction:166 Gy cGy

Number of days: (include "rest" days)167

Total number of fractions:168

ALG, ALS, ATG, ATS

yes no

169

Total prescribed dose:170 mg/kg

Date started:171 __ __ __ __ - __ __- __ __

Specify source172

ATGAM (horse)

ATG - Fresenius (rabbit)

Thymoglobulin (rabbit)

Other

Specify other source:173

Anthracycline

yes no

174

Daunorubicin

yes no

175

Total prescribed dose :176 mg/m2 mg/kg

Date started:177 __ __ __ __ - __ __- __ __

Doxorubicin (Adriamycin)

yes no

178

Total prescribed dose :179 mg/m2 mg/kg

Date started:180 __ __ __ __ - __ __- __ __

Idarubicin

yes no

181

Total prescribed dose :182 mg/m2 mg/kg

Date started:183 __ __ __ __ - __ __- __ __

Rubidazone

yes no

184

Total prescribed dose :185 mg/m2 mg/kg

Date started:186 __ __ __ __ - __ __- __ __

Other anthracycline

yes no

187

Total prescribed dose :188 mg/m2 mg/kg

Date started:189 __ __ __ __ - __ __- __ __

Specify other anthracycline:190

Bleomycin (BLM, Blenoxane)

yes no

191

Total prescribed dose :192 mg/m2 mg/kg

Date started:193 __ __ __ __ - __ __- __ __

Busulfan (Myleran)

yes no

194

Total prescribed dose :195 mg/m2

mg/kg

Target total AUC (µmol x min/L)

Date started:196 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

197

Carboplatin

yes no

198

Total prescribed dose :199 mg/m2 mg/kg

Date started:200 __ __ __ __ - __ __- __ __

Were pharmacokinetics performed to determine preparative regimen drug dosing?

yes no

201

Specify the target AUC:202 mg/mL/minute

Cisplatin (Platinol, CDDP)

yes no

203

Total prescribed dose :204 mg/m2 mg/kg

Date started:205 __ __ __ __ - __ __- __ __

Cladribine (2-CdA, Leustatin)

yes no

206

Total prescribed dose :207 mg/m2 mg/kg

Date started:208 __ __ __ __ - __ __- __ __

Corticosteroids (excluding anti-nausea medication)

yes no

209

Methylprednisolone (Solu-Medrol)

yes no

210

Total prescribed dose :211 mg/m2 mg/kg

Date started:212 __ __ __ __ - __ __- __ __

Prednisone

yes no

213

Total prescribed dose :214 mg/m2 mg/kg

Date started:215 __ __ __ __ - __ __- __ __

Dexamethasone

yes no

216

Total prescribed dose :217 mg/m2 mg/kg

Date started:218 __ __ __ __ - __ __- __ __

Other corticosteroid

yes no

219

Total prescribed dose :220 mg/m2 mg/kg

Date started:221 __ __ __ __ - __ __- __ __

Specify other corticosteroid:222

Cyclophosphamide (Cytoxan)

yes no

223

Total prescribed dose :224 mg/m2 mg/kg

Date started:225 __ __ __ __ - __ __- __ __

Cytarabine (Ara-C)

yes no

226

Total prescribed dose :227 mg/m2 mg/kg

Date started:228 __ __ __ __ - __ __- __ __

Etoposide (VP-16, VePesid)

yes no

229

Total prescribed dose :230 mg/m2 mg/kg

Date started:231 __ __ __ __ - __ __- __ __

Fludarabine

yes no

232

Total prescribed dose :233 mg/m2 mg/kg

Date started:234 __ __ __ __ - __ __- __ __

Ifosfamide

yes no

235

Total prescribed dose :236 mg/m2 mg/kg

Date started:237 __ __ __ __ - __ __- __ __

Intrathecal therapy (chemotherapy)

yes no

238

Intrathecal cytarabine (IT Ara-C)

yes no

239

Total prescribed dose :240 mg/m2 mg/kg

Date started:241 __ __ __ __ - __ __- __ __

Intrathecal methotrexate (IT MTX)

yes no

242

Total prescribed dose :243 mg/m2 mg/kg

Date started:244 __ __ __ __ - __ __- __ __

Intrathecal thiotepa

yes no

245

Total prescribed dose :246 mg/m2 mg/kg

Date started:247 __ __ __ __ - __ __- __ __

Other intrathecal drug

yes no

248

Total prescribed dose :249 mg/m2 mg/kg

Date started:250 __ __ __ __ - __ __- __ __

Specify other intrathecal drug:251

Melphalan (L-Pam)

yes no

252

Total prescribed dose :253 mg/m2 mg/kg

Date started:254 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

255

Mitoxantrone (Novantrone)

yes no

256

Total prescribed dose :257 mg/m2 mg/kg

Date started:258 __ __ __ __ - __ __- __ __

Monoclonal antibody

yes no

259

Radio labeled mAb

yes no

260

Total prescribed dose of radioactive component:261 mCi MBq

Date started:262 __ __ __ __ - __ __- __ __

Tositumomab (Bexxar)

yes no

263

Ibritumomab tiuxetan (Zevalin)

yes no

264

Other radio labeled mAb

yes no

265

Specify other radio labeled mAb:266

Alemtuzumab (Campath)

yes no

267

Total prescribed dose :268 mg/m2 mg/kg

Date started:269 __ __ __ __ - __ __- __ __

Rituximab (Rituxan, anti CD20)

yes no

270

Total prescribed dose :271 mg/m2 mg/kg

Date started:272 __ __ __ __ - __ __- __ __

Gemtuzumab (Mylotarg, anti CD33)

yes no

273

Total prescribed dose :274 mg/m2 mg/kg

Date started:275 __ __ __ __ - __ __- __ __

Other mAb

yes no

276

Total prescribed dose :277 mg/m2 mg/kg

Date started:278 __ __ __ __ - __ __- __ __

Specify other mAb:279

Nitrosourea

yes no

280

Carmustine (BCNU)

yes no

281

Total prescribed dose :282 mg/m2 mg/kg

Date started:283 __ __ __ __ - __ __- __ __

CCNU (Lomustine)

yes no

284

Total prescribed dose :285 mg/m2 mg/kg

Date started:286 __ __ __ __ - __ __- __ __

Other nitrosourea

yes no

287

Total prescribed dose :288 mg/m2 mg/kg

Date started:289 __ __ __ __ - __ __- __ __

Specify other nitrosourea:290

Paclitaxel (Taxol, Xyotax)

yes no

291

Total prescribed dose :292 mg/m2 mg/kg

Date started:293 __ __ __ __ - __ __- __ __

Teniposide (VM26)

yes no

294

Total prescribed dose :295 mg/m2 mg/kg

Date started:296 __ __ __ __ - __ __- __ __

Thiotepa

yes no

297

Total prescribed dose :298 mg/m2 mg/kg

Date started:299 __ __ __ __ - __ __- __ __

Treosulfan

yes no

300

Total prescribed dose :301 mg/m2 mg/kg

Date started:302 __ __ __ __ - __ __- __ __

Tyrosine kinase inhibitors

yes no

303

Dasatinib (Sprycel)

yes no

304

Total prescribed dose :305 mg/m2 mg/kg

Date started:306 __ __ __ __ - __ __- __ __

Imatinib mesylate (STI571, Gleevec)

yes no

307

Total prescribed dose :308 mg/m2 mg/kg

Date started:309 __ __ __ __ - __ __- __ __

Nilotinib

yes no

310

Total prescribed dose :311 mg/m2 mg/kg

Date started:312 __ __ __ __ - __ __- __ __

Other drug

yes no

313

Total prescribed dose :314 mg/m2 mg/kg

Date started:315 __ __ __ __ - __ __- __ __

Specify other drug:316

GVHD Prophylaxis Questions: 317 - 343

Was GVHD prophylaxis planned / given?

yes no

317

ALG, ALS, ATG, ATS

yes no

318

Total dose:319 mg/kg

Specify source320

ATGAM (horse)

ATG - Fresenius (rabbit)

Thymoglobulin (rabbit)

Other

Specify other source:321

Corticosteroids (systemic)

yes no

322

Cyclosporine (CSA, Neoral, Sandimmune)

yes no

323

Cyclophosphamide (Cytoxan)

yes no

324

Extra-corporeal photopheresis (ECP)

yes no

325

FK 506 (Tacrolimus, Prograf)

yes no

326

In vivo monoclonal antibody

yes no

327

Alemtuzumab (Campath)

yes no

328

Anti CD 25 (Zenapax, Daclizumab, AntiTAC)

yes no

329

Specify:330

Etanercept (Enbrel)

yes no

331

Infliximab (Remicade)

yes no

332

Other in vivo monoclonal antibody

yes no

333

Specify antibody:334

In vivo immunotoxin

yes no

335

Specify immunotoxin:336

Methotrexate (MTX) (Amethopterin)

yes no

337

Mycophenolate mofetil (MMF) (CellCept)

yes no

338

Sirolimus (Rapamycin, Rapamune)

yes no

339

Blinded randomized trial

yes no

340

Specify trial agent:341

Other agent

yes no

342

Specify other agent:343

Other Toxicity Modifying Regimen Questions: 344 - 344

Was KGF (palifermin, Kepivance) started or is there a plan to use it?

Yes No masked trial

344

Post-HCT Disease Therapy Planned as of Day 0 Questions: 345 - 357

Is this HCT part of a planned multiple (sequential) graft / HCT protocol?

yes no

345

Is additional post-HCT therapy planned?

yes no

346

Bortezomib (Velcade)

yes no

347

Cellular therapy (e.g. DCI, DLI)

yes no

348

Dexamethasone

yes no

349

Intrathecal therapy (chemotherapy)

yes no

350

Tyrosine kinase inhibitor (e.g. imatinib mesylate)

yes no

351

Lenalidomide (Revlimid)

yes no

352

Local radiotherapy

yes no

353

Rituximab (Rituxan, MabThera)

yes no

354

Thalidomide (Thalomid)

yes no

355

Other therapy

yes no

356

Specify other therapy:357

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

OMB No: 0915-0310

Expiration Date: 1/31/2020

Public Burden Statement:  An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control
number.  The OMB control number for this project is 0915-0310.  Public reporting burden for this collection of information is estimated to average 1.0 hours per response, including the
time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other
aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance Officer, 5600 Fishers Lane, Room 10-29, Rockville, Maryland, 20857.

Center Identification

Recipient Identification

Specify the HSC source(s) for all prior HCTs:

Specify the institution that performed the last HCT:

Specify product type: 

A series of collections should be considered a single product when they are all from the same donor and use the same collection method and technique (and mobilization, if
applicable), even if the collections are performed on different days.

Questions 53 – 60 are for autologous HCT recipients only.  If other than autologous skip to question 61

Specify all agents used in the mobilization events reported above:

Specify all methods used to manipulate the product:

Performance score prior to the preparative regimen:

Specify which malignancy(ies) occurred:

Indicate the total prescribed cumulative dose for the preparative regimen:

Specify radio labeled mAb:

This section is to be completed for allogeneic HCTs only; autologous HCTs continue with question 344.

Specify:

Specify in vivo monoclonal antibody:

Optional for non-U.S. Centers

Questions 347 – 357 are optional for non­U.S. centers

Center: CRID: 

Form 2400 R5.0: Pre-Transplant Essential Data

CIBMTR Form 2400 revision 5.0 last updated January 2017
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 11 / 12



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

EBMT Code (CIC):

Hospital:

Unit (check only one)

Adult Pediatric

CIBMTR Research ID:  (CRID)

Recipient Data Questions: 1 - 10

Date of birth:1 __ __ __ __ - __ __- __ __

Sex

male female

2

Ethnicity3

Hispanic or Latino

Not Hispanic or Latino

Not applicable (not a resident of the USA)

Unknown

Race (1) Questions: 4 - 4

Race4

Zip or postal code for place of recipient’s residence: (USA recipients only)5

Is the recipient participating in a clinical trial?

yes no

6

Clinical Trials (1) Questions: 7 - 10

Study Sponsor7

Specify other sponsor:8

Study ID Number9

Subject ID:10

Hematopoietic Cellular Transplant (HCT) Questions: 11 - 28

Date of this HCT:11 __ __ __ __ - __ __- __ __

Was this the first HCT for this recipient?

yes no

12

Is a subsequent HCT planned as part of the overall treatment protocol (not as a reaction to post-HCT disease assessment)? (For autologous HCTs only)

yes no

13

Specify subsequent HCT planned

Autologous Allogeneic

14

Specify the number of prior HCTs:15

Autologous

yes no

16

Allogeneic, unrelated

yes no

17

Allogeneic, related

yes no

18

Syngeneic

yes no

19

Date of the last HCT: (just before current HCT)20 __ __ __ __ - __ __- __ __

Was the last HCT performed at a different institution?

yes no

21

Name:22

City:

State:

Country:

What was the HSC source for the last HCT?23

Autologous

Allogeneic, unrelated donor

Allogeneic, related donor

Reason for current HCT24

Date of graft failure / rejection:25 __ __ __ __ - __ __- __ __

Date of relapse:26 __ __ __ __ - __ __- __ __

Date of secondary malignancy:27 __ __ __ __ - __ __- __ __

Specify other reason:28

Donor Information Questions: 29 - 63

Multiple donors?

yes no

29

Specify number of donors:30

Donor Information for this HCT (1) Questions: 31 - 63

Specify donor31

NMDP cord blood unit ID:32

NMDP donor ID:33

Non-NMDP unrelated donor ID: (not applicable for related donors)34

Non-NMDP cord blood unit ID: (include related and autologous CBUs)35

Is the CBU ID also the ISBT DIN number?

yes no

36

Specify the ISBT DIN number:37

Registry or UCB Bank ID38

Specify other Registry or UCB Bank:39

Specify the related donor type40

Syngeneic (monozygotic twin)

HLA-identical sibling (may include non-monozygotic twin)

HLA-matched other relative

HLA-mismatched relative

Date of birth (donor / infant)

Known Unknown

41

Date of birth: (donor / infant)42 __ __ __ __ - __ __- __ __

Age (donor / infant)

Known Unknown

43

Age: (donor / infant)44 Months (use only if less than 1 year old)

years

Sex (donor / infant)

male female

45

Bone marrow

yes no

46

PBSC

yes no

47

Single cord blood unit

yes no

48

Other product

yes no

49

Specify other product type:50

Specify number of products infused from this donor:51

Specify the number of these products intended to achieve hematopoietic engraftment:52

Did the recipient have more than one mobilization event to acquire cells for HCT?

yes no

53

Specify the total number of mobilization events performed for this HCT: (regardless of the number of collections or which collections were
used for this HCT)

54

G-CSF

yes no

55

GM-CSF

yes no

56

Pegylated G-CSF

yes no

57

Plerixafor (Mozobil)

yes no

58

Other CXCR4 inhibitor

yes no

59

Combined with chemotherapy

yes no

60

Was this donor used for any prior HCTs?

yes no

61

Donor CMV-antibodies (IgG or Total) (Allogeneic HCTs only)62

Reactive

Non-reactive

Not done

Not applicable (cord blood unit)

Was plerixafor (Mozobil) given at any time prior to the preparative regimen? (Related HCTs only)

yes no Unknown

63

Consent Questions: 64 - 71

Has the recipient signed an IRB-approved consent form for submitting research data to the NMDP / CIBMTR?64

Yes (patient consented)

No (patient declined)

Not approached

Date form was signed:65 __ __ __ __ - __ __- __ __

Did the recipient give permission to be directly contacted for future research?66

Yes (patient provided permission)

No (patient declined)

Not approached

Date form was signed:67 __ __ __ __ - __ __- __ __

Has the recipient signed an IRB-approved consent form to donate research blood samples to the NMDP / CIBMTR?68

Yes (patient consented)

No (patient declined)

Not approached

Not applicable (center not participating)

Date form was signed:69 __ __ __ __ - __ __- __ __

Has the donor signed an IRB-approved consent form to donate research blood samples to the NMDP / CIBMTR? (Allogeneic donors only)70

Yes (donor consented)

No (donor declined)

Not approached

Not applicable (center not participating)

Date form was signed:71 __ __ __ __ - __ __- __ __

Product Processing / Manipulation Questions: 72 - 90

Was the product manipulated prior to infusion?

yes no

72

Specify portion manipulated

entire product portion of product

73

Washed

yes no

74

Diluted

yes no

75

Buffy coat enriched (buffy coat preparation)

yes no

76

B-cell reduced

yes no

77

CD8 reduced

yes no

78

Plasma reduced (removal)

yes no

79

RBC reduced

yes no

80

Cultured (ex-vivo expansion)

yes no

81

Genetic manipulation (gene transfer / transduction)

yes no

82

PUVA treated

yes no

83

CD34 enriched (CD34+ selection)

yes no

84

CD133 enriched

yes no

85

Monocyte enriched

yes no

86

Mononuclear cells enriched

yes no

87

T-cell depletion

yes no

88

Other cell manipulation

yes no

89

Specify other cell manipulation:90

Clinical Status of Recipient Prior to the Preparative Regimen (Conditioning) Questions: 91 - 94

What scale was used to determine the recipient’s functional status?91

Karnofsky (recipient age ≥ 16 years)

Lansky (recipient age < 16 years) 

Karnofsky Scale (recipient age ≥ 16 years)92

Lansky Scale (recipient age < 16 years)93

Recipient CMV-antibodies (IgG or Total)

Reactive Non-reactive Not done

94

Comorbid Conditions Questions: 95 - 155

Is there a history of mechanical ventilation?

yes no

95

Is there a history of proven invasive fungal infection?

yes no

96

Were there clinically significant co-existing diseases or organ impairment at time of patient assessment prior to preparative regimen? Source: Blood, 2005 Oct 15;106(8):2912-2919

yes no

97

Arrhythmia - For example, any history of atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias requiring treatment

yes no Unknown

98

Cardiac - Any history of coronary artery disease (one or more vessel-coronary artery stenosis requiring medical treatment, stent, or bypass graft), congestive heart
failure, myocardial infarction, OR ejection fraction ≤ 50% on the most recent test

yes no Unknown

99

Cerebrovascular disease - Any history of transient ischemic attack, subarachnoid hemorrhage or cerebrovascular accident

yes no Unknown

100

Diabetes - Requiring treatment with insulin or oral hypoglycemics in the last 4 weeks but not diet alone

yes no Unknown

101

Heart valve disease - Except asymptomatic mitral valve prolapse

yes no Unknown

102

Hepatic, mild ­ Chronic hepatitis, bilirubin > upper limit of normal to 1.5 × upper limit of normal, or AST/ALT > upper limit of normal to 2.5 × upper limit of normal at the
time of transplant OR any history of hepatitis B or hepatitis C infection

yes no Unknown

103

Hepatic, moderate / severe ­ Liver cirrhosis, bilirubin > 1.5 × upper limit of normal, or AST/ALT > 2.5 × upper limit of normal

yes no Unknown

104

Infection - For example, documented infection, fever of unknown origin, or pulmonary nodules requiring continuation of antimicrobial treatment after day 0

yes no Unknown

105

Inflammatory bowel disease ­ Any history of Crohn’s disease or ulcerative colitis requiring treatment

yes no Unknown

106

Obesity - Patients with a body mass index > 35 kg/m2  prior to the start of conditioning

yes no Unknown

107

Peptic ulcer - Any history of peptic ulcer confirmed by endoscopy and requiring treatment

yes no Unknown

108

Psychiatric disturbance - For example, depression, anxiety, bipolar disorder or schizophrenia requiring psychiatric consult or treatment in the last 4 weeks

yes no Unknown

109

Pulmonary, moderate - Corrected diffusion capacity of carbon monoxide and/or FEV1 66-80% or dyspnea on slight activity at transplant

yes no Unknown

110

Pulmonary, severe - Corrected diffusion capacity of carbon monoxide and/or FEV1 ≤ 65% or dyspnea at rest or requiring oxygen at transplant

yes no Unknown

111

Renal, moderate / severe ­ Serum creatinine > 2 mg/dL or > 177 µmol/L or on dialysis at transplant, OR prior renal transplantation

yes no Unknown

112

Rheumatologic - For example, any history of systemic lupus erythmatosis, rheumatoid arthritis, polymyositis, mixed connective tissue disease, or polymyalgia
rheumatica requiring treatment (do NOT include degenerative joint disease, osteoarthritis)

yes no Unknown

113

Solid tumor, prior ­ Treated at any time point in the patient’s past history, excluding non­melanoma skin cancer, leukemia, lymphoma or multiple myeloma

yes no Unknown

114

Breast cancer

yes no

115

Year of diagnosis:116

Central nervous system (CNS) malignancy (glioblastoma, astrocytoma)

yes no

117

Year of diagnosis:118

Gastrointestinal malignancy (colon, rectum, stomach, pancreas, intestine)

yes no

119

Year of diagnosis:120

Genitourinary malignancy (kidney, bladder, ovary, testicle, genitalia, uterus, cervix)

yes no

121

Year of diagnosis:122

Lung cancer

yes no

123

Year of diagnosis:124

Melanoma

yes no

125

Year of diagnosis:126

Oropharyngeal cancer (tongue, buccal mucosa)

yes no

127

Year of diagnosis:128

Sarcoma

yes no

129

Year of diagnosis:130

Thyroid cancer

yes no

131

Year of diagnosis:132

Other co-morbid condition

yes no Unknown

133

Specify other co-morbid condition:134

Was there a history of malignancy (hematologic or non-melanoma skin cancer) other than the primary disease for which this HCT is being performed?

yes no

135

Acute myeloid leukemia (AML / ANLL)

yes no

136

Year of diagnosis:137

Other leukemia, including ALL

yes no

138

Year of diagnosis:139

Specify leukemia:140

Clonal cytogenetic abnormality without leukemia or MDS

yes no

141

Year of diagnosis:142

Hodgkin disease

yes no

143

Year of diagnosis:144

Lymphoma or lymphoproliferative disease

yes no

145

Year of diagnosis:146

Was the tumor EBV positive?

yes no

147

Other skin malignancy (basal cell, squamous)

yes no

148

Year of diagnosis:149

Specify other skin malignancy:150

Myelodysplasia (MDS) / myeloproliferative (MPN) disorder

yes no

151

Year of diagnosis:152

Other prior malignancy

yes no

153

Year of diagnosis:154

Specify other prior malignancy:155

Pre-HCT Preparative Regimen (Conditioning) Questions: 156 - 316

Height at initiation of pre-HCT preparative regimen:156 inches centimeters

Actual weight at initiation of pre-HCT preparative regimen:157 pounds kilograms

Was a pre-HCT preparative regimen prescribed?

yes no

158

Classify the recipient’s prescribed preparative regimen (Allogeneic HCTs only)159

Myeloablative

Non-myeloablative (NST)

Reduced intensity (RIC)

Date pre-HCT preparative regimen began: (irradiation or drugs)160 __ __ __ __ - __ __- __ __ (Use earliest date from question 164 radiation, or 169 - 316 chemotherapy)

Was irradiation planned as part of the pre-HCT preparative regimen?

yes no

161

What was the prescribed radiation field?162

Total body

Total body by intensity-modulated radiation therapy (IMRT)

Total lymphoid or nodal regions

Thoracoabdominal region

Total prescribed dose: (dose per fraction x total number of fractions) 163 Gy cGy

Date started:164 __ __ __ __ - __ __- __ __

Was the radiation fractionated?

yes no

165

Prescribed dose per fraction:166 Gy cGy

Number of days: (include "rest" days)167

Total number of fractions:168

ALG, ALS, ATG, ATS

yes no

169

Total prescribed dose:170 mg/kg

Date started:171 __ __ __ __ - __ __- __ __

Specify source172

ATGAM (horse)

ATG - Fresenius (rabbit)

Thymoglobulin (rabbit)

Other

Specify other source:173

Anthracycline

yes no

174

Daunorubicin

yes no

175

Total prescribed dose :176 mg/m2 mg/kg

Date started:177 __ __ __ __ - __ __- __ __

Doxorubicin (Adriamycin)

yes no

178

Total prescribed dose :179 mg/m2 mg/kg

Date started:180 __ __ __ __ - __ __- __ __

Idarubicin

yes no

181

Total prescribed dose :182 mg/m2 mg/kg

Date started:183 __ __ __ __ - __ __- __ __

Rubidazone

yes no

184

Total prescribed dose :185 mg/m2 mg/kg

Date started:186 __ __ __ __ - __ __- __ __

Other anthracycline

yes no

187

Total prescribed dose :188 mg/m2 mg/kg

Date started:189 __ __ __ __ - __ __- __ __

Specify other anthracycline:190

Bleomycin (BLM, Blenoxane)

yes no

191

Total prescribed dose :192 mg/m2 mg/kg

Date started:193 __ __ __ __ - __ __- __ __

Busulfan (Myleran)

yes no

194

Total prescribed dose :195 mg/m2

mg/kg

Target total AUC (µmol x min/L)

Date started:196 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

197

Carboplatin

yes no

198

Total prescribed dose :199 mg/m2 mg/kg

Date started:200 __ __ __ __ - __ __- __ __

Were pharmacokinetics performed to determine preparative regimen drug dosing?

yes no

201

Specify the target AUC:202 mg/mL/minute

Cisplatin (Platinol, CDDP)

yes no

203

Total prescribed dose :204 mg/m2 mg/kg

Date started:205 __ __ __ __ - __ __- __ __

Cladribine (2-CdA, Leustatin)

yes no

206

Total prescribed dose :207 mg/m2 mg/kg

Date started:208 __ __ __ __ - __ __- __ __

Corticosteroids (excluding anti-nausea medication)

yes no

209

Methylprednisolone (Solu-Medrol)

yes no

210

Total prescribed dose :211 mg/m2 mg/kg

Date started:212 __ __ __ __ - __ __- __ __

Prednisone

yes no

213

Total prescribed dose :214 mg/m2 mg/kg

Date started:215 __ __ __ __ - __ __- __ __

Dexamethasone

yes no

216

Total prescribed dose :217 mg/m2 mg/kg

Date started:218 __ __ __ __ - __ __- __ __

Other corticosteroid

yes no

219

Total prescribed dose :220 mg/m2 mg/kg

Date started:221 __ __ __ __ - __ __- __ __

Specify other corticosteroid:222

Cyclophosphamide (Cytoxan)

yes no

223

Total prescribed dose :224 mg/m2 mg/kg

Date started:225 __ __ __ __ - __ __- __ __

Cytarabine (Ara-C)

yes no

226

Total prescribed dose :227 mg/m2 mg/kg

Date started:228 __ __ __ __ - __ __- __ __

Etoposide (VP-16, VePesid)

yes no

229

Total prescribed dose :230 mg/m2 mg/kg

Date started:231 __ __ __ __ - __ __- __ __

Fludarabine

yes no

232

Total prescribed dose :233 mg/m2 mg/kg

Date started:234 __ __ __ __ - __ __- __ __

Ifosfamide

yes no

235

Total prescribed dose :236 mg/m2 mg/kg

Date started:237 __ __ __ __ - __ __- __ __

Intrathecal therapy (chemotherapy)

yes no

238

Intrathecal cytarabine (IT Ara-C)

yes no

239

Total prescribed dose :240 mg/m2 mg/kg

Date started:241 __ __ __ __ - __ __- __ __

Intrathecal methotrexate (IT MTX)

yes no

242

Total prescribed dose :243 mg/m2 mg/kg

Date started:244 __ __ __ __ - __ __- __ __

Intrathecal thiotepa

yes no

245

Total prescribed dose :246 mg/m2 mg/kg

Date started:247 __ __ __ __ - __ __- __ __

Other intrathecal drug

yes no

248

Total prescribed dose :249 mg/m2 mg/kg

Date started:250 __ __ __ __ - __ __- __ __

Specify other intrathecal drug:251

Melphalan (L-Pam)

yes no

252

Total prescribed dose :253 mg/m2 mg/kg

Date started:254 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

255

Mitoxantrone (Novantrone)

yes no

256

Total prescribed dose :257 mg/m2 mg/kg

Date started:258 __ __ __ __ - __ __- __ __

Monoclonal antibody

yes no

259

Radio labeled mAb

yes no

260

Total prescribed dose of radioactive component:261 mCi MBq

Date started:262 __ __ __ __ - __ __- __ __

Tositumomab (Bexxar)

yes no

263

Ibritumomab tiuxetan (Zevalin)

yes no

264

Other radio labeled mAb

yes no

265

Specify other radio labeled mAb:266

Alemtuzumab (Campath)

yes no

267

Total prescribed dose :268 mg/m2 mg/kg

Date started:269 __ __ __ __ - __ __- __ __

Rituximab (Rituxan, anti CD20)

yes no

270

Total prescribed dose :271 mg/m2 mg/kg

Date started:272 __ __ __ __ - __ __- __ __

Gemtuzumab (Mylotarg, anti CD33)

yes no

273

Total prescribed dose :274 mg/m2 mg/kg

Date started:275 __ __ __ __ - __ __- __ __

Other mAb

yes no

276

Total prescribed dose :277 mg/m2 mg/kg

Date started:278 __ __ __ __ - __ __- __ __

Specify other mAb:279

Nitrosourea

yes no

280

Carmustine (BCNU)

yes no

281

Total prescribed dose :282 mg/m2 mg/kg

Date started:283 __ __ __ __ - __ __- __ __

CCNU (Lomustine)

yes no

284

Total prescribed dose :285 mg/m2 mg/kg

Date started:286 __ __ __ __ - __ __- __ __

Other nitrosourea

yes no

287

Total prescribed dose :288 mg/m2 mg/kg

Date started:289 __ __ __ __ - __ __- __ __

Specify other nitrosourea:290

Paclitaxel (Taxol, Xyotax)

yes no

291

Total prescribed dose :292 mg/m2 mg/kg

Date started:293 __ __ __ __ - __ __- __ __

Teniposide (VM26)

yes no

294

Total prescribed dose :295 mg/m2 mg/kg

Date started:296 __ __ __ __ - __ __- __ __

Thiotepa

yes no

297

Total prescribed dose :298 mg/m2 mg/kg

Date started:299 __ __ __ __ - __ __- __ __

Treosulfan

yes no

300

Total prescribed dose :301 mg/m2 mg/kg

Date started:302 __ __ __ __ - __ __- __ __

Tyrosine kinase inhibitors

yes no

303

Dasatinib (Sprycel)

yes no

304

Total prescribed dose :305 mg/m2 mg/kg

Date started:306 __ __ __ __ - __ __- __ __

Imatinib mesylate (STI571, Gleevec)

yes no

307

Total prescribed dose :308 mg/m2 mg/kg

Date started:309 __ __ __ __ - __ __- __ __

Nilotinib

yes no

310

Total prescribed dose :311 mg/m2 mg/kg

Date started:312 __ __ __ __ - __ __- __ __

Other drug

yes no

313

Total prescribed dose :314 mg/m2 mg/kg

Date started:315 __ __ __ __ - __ __- __ __

Specify other drug:316

GVHD Prophylaxis Questions: 317 - 343

Was GVHD prophylaxis planned / given?

yes no

317

ALG, ALS, ATG, ATS

yes no

318

Total dose:319 mg/kg

Specify source320

ATGAM (horse)

ATG - Fresenius (rabbit)

Thymoglobulin (rabbit)

Other

Specify other source:321

Corticosteroids (systemic)

yes no

322

Cyclosporine (CSA, Neoral, Sandimmune)

yes no

323

Cyclophosphamide (Cytoxan)

yes no

324

Extra-corporeal photopheresis (ECP)

yes no

325

FK 506 (Tacrolimus, Prograf)

yes no

326

In vivo monoclonal antibody

yes no

327

Alemtuzumab (Campath)

yes no

328

Anti CD 25 (Zenapax, Daclizumab, AntiTAC)

yes no

329

Specify:330

Etanercept (Enbrel)

yes no

331

Infliximab (Remicade)

yes no

332

Other in vivo monoclonal antibody

yes no

333

Specify antibody:334

In vivo immunotoxin

yes no

335

Specify immunotoxin:336

Methotrexate (MTX) (Amethopterin)

yes no

337

Mycophenolate mofetil (MMF) (CellCept)

yes no

338

Sirolimus (Rapamycin, Rapamune)

yes no

339

Blinded randomized trial

yes no

340

Specify trial agent:341

Other agent

yes no

342

Specify other agent:343

Other Toxicity Modifying Regimen Questions: 344 - 344

Was KGF (palifermin, Kepivance) started or is there a plan to use it?

Yes No masked trial

344

Post-HCT Disease Therapy Planned as of Day 0 Questions: 345 - 357

Is this HCT part of a planned multiple (sequential) graft / HCT protocol?

yes no

345

Is additional post-HCT therapy planned?

yes no

346

Bortezomib (Velcade)

yes no

347

Cellular therapy (e.g. DCI, DLI)

yes no

348

Dexamethasone

yes no

349

Intrathecal therapy (chemotherapy)

yes no

350

Tyrosine kinase inhibitor (e.g. imatinib mesylate)

yes no

351

Lenalidomide (Revlimid)

yes no

352

Local radiotherapy

yes no

353

Rituximab (Rituxan, MabThera)

yes no

354

Thalidomide (Thalomid)

yes no

355

Other therapy

yes no

356

Specify other therapy:357

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

OMB No: 0915-0310

Expiration Date: 1/31/2020

Public Burden Statement:  An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control
number.  The OMB control number for this project is 0915-0310.  Public reporting burden for this collection of information is estimated to average 1.0 hours per response, including the
time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other
aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance Officer, 5600 Fishers Lane, Room 10-29, Rockville, Maryland, 20857.

Center Identification

Recipient Identification

Specify the HSC source(s) for all prior HCTs:

Specify the institution that performed the last HCT:

Specify product type: 

A series of collections should be considered a single product when they are all from the same donor and use the same collection method and technique (and mobilization, if
applicable), even if the collections are performed on different days.

Questions 53 – 60 are for autologous HCT recipients only.  If other than autologous skip to question 61

Specify all agents used in the mobilization events reported above:

Specify all methods used to manipulate the product:

Performance score prior to the preparative regimen:

Specify which malignancy(ies) occurred:

Indicate the total prescribed cumulative dose for the preparative regimen:

Specify radio labeled mAb:

This section is to be completed for allogeneic HCTs only; autologous HCTs continue with question 344.

Specify:

Specify in vivo monoclonal antibody:

Optional for non-U.S. Centers

Questions 347 – 357 are optional for non­U.S. centers

Center: CRID: 

Form 2400 R5.0: Pre-Transplant Essential Data

CIBMTR Form 2400 revision 5.0 last updated January 2017
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 12 / 12